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ABSTRACT
Regulation of Polymeric Immunoglobulin Receptor by Reovirus in
Intestinal Epithelial Cells

Kasturi Pal
Most pathogens invade the human body through mucosal surfaces. Enteric viruses are
one such group of pathogens that are of great public health significance because they
cause a number of serious diseases including gastroenteritis, hepatitis and poliomyelitis.
Gastrointestinal disease is the second most common cause of morbidity worldwide, with
diarrhea ranking first among infectious diseases in the categories of frequency and
mortality in children. The mucosal epithelium provides the first line of defense against
invading pathogens by serving as the first sensors of microbial infection and launching an
innate immune response that leads to the development of adaptive immunity. An
immunologic function of the mucosal epithelium is to mediate transcytosis of secretory
immunoglobulin A (sIgA) from the lamina propria into the intestinal lumen.
Transcytosis of IgA is dependent on the polymeric immunoglobulin receptor (pIgR)
expressed by mucosal and glandular epithelial cells because one molecule of pIgR must
be synthesized for each molecule of transported IgA. Thus, pIgR plays a role in mucosal
host defense, and factors that influence expression of pIgR could affect mucosal
immunity. This dissertation describes efforts to understand the role of intestinal
epithelial cells (IECs) as an active participant of mucosal immunity during enteric virus
infection. We used reovirus to demonstrate that a newly appreciated role of the IECs in
responding to infection is upregulation of pIgR expression, which appears to serve as an
innate host defense mechanism. Our studies demonstrate that reovirus upregulates pIgR
expression in the intestinal epithelial cell line HT-29 in a replication independent fashion,
and that binding of virus to cellular receptors and partial disassembly of virus inside
acidified endosomes are required steps for this innate immune response by IECs. In
addition, we demonstrate that activation of calpain and NFκB signaling and reovirus induced PIGR gene transcription in IECs upregulate pIgR expression during infection.
Signaling induced by virus-host interaction might serve to augment pIgR-mediated
transcytosis of IgA in vivo, thereby linking the innate and acquired immune responses to
enteric viruses. Our studies will contribute to improving human health by advancing
understanding of IEC biology and function, viral pathogenesis, and induction of innate
and adaptive immunity to viruses, particularly in the intestine.
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CHAPTER 1: GENERAL INTRODUCTION

Most of the pathogens, particularly viruses, invade the human body by the mucosal
epithelia. The mucosal surface is one of the first important interfaces between pathogens
and the host, and as such is critical in prevention of infectious disease. The
gastrointestinal mucosa comprised of a single layer of intestinal epithelial cells (IECs)
form a barrier between the body and a luminal environment, which not only contains
essential nutrients but also potentially harmful pathogens. Thus the major challenge
faced by IECs is to allow entry of nutrients from lumen for processing and absorption
while rigorously excluding passage of toxins and pathogens. In general, toxins and
microorganism that breach the epithelial barrier have unimpeded access to the systemic
circulation. Maintainance of an intact epithelium throughout the length of the digestive
system is essential for host defense and disruption of mucosal barrier leads to a number
of gastrointestinal diseases.

The gastrointestinal barrier has two specific components, (1) the intrinsic barrier and (2)
the extrinsic barrier. The intrinsic barrier comprises the epithelial cells lining the
digestive tract while the extrinsic barrier consists of secretions including mucus, trefoil
peptides and defensins, which modulate and maintain integrity of mucosal epithelial
cells.

1

The IECs are an important component in mucosal host defense and act at the interface
between the innate and acquired immune responses to pathogens in the gastrointestinal
tract. The innate immune arm of IECs and associated extrinsic barrier block the invading
pathogens non-specifically, while the adaptive immune responses triggered by initial
signaling through IECs provides pathogen specific immunity. IECs function as first
sensors of infection as direct contact with microbes or their metabolic products such as
lipopolysaccharide (LPS) and double stranded RNA (dsRNA) initiate innate responses
including production of antimicrobial substances that fight infection directly and
secretion of chemokines and cytokines that promote acquired adaptive immune
responses. A hallmark feature of adaptive mucosal immune responses is the production
and secretion of secretory immunoglobulin A (sIgA). Dimeric IgA produced by plasma
cells in lamina propria of the intestine is transported through adjacent secretory epithelia
by polymeric immunoglobulin receptor (pIgR) expressed by glandular and IECs into
intestinal secretions. Secretory antibodies including sIgA and secretory IgM (sIgM)
mediate immune exclusion at mucosal surfaces along with non-specific innate defenses to
restrict colonization of mucosal surfaces by microorganisms and inhibit potentially
dangerous soluble factors and antigens to breach the epithelial barrier. Thus, pIgR
synthesized by IECs and secretory antibodies are very important for maintaining the
integrity of the gut and factors that influence regulation of pIgR expression could affect
mucosal immunity. So it is of great interest to investigate modulation of pIgR and hence
secretory antibodies during pathogenic interactions.
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This dissertation is comprised of a series of studies examining the regulation of pIgR
expression in response to an enteric pathogen, reovirus in IECs. These studies showed
that reovirus induced expression of pIgR in IECs and characterized the various signaling
pathways including calpains and nuclear factor kappa B (NFκB) involved in virusmediated upregulation of pIgR. Signaling induced by microbes and their products that
augment pIgR-mediated transcytosis of IgA, links the innate and acquired immune
responses to viruses.

THE GENERAL ORGANIZATION, DEVELOPMENT AND MATURATION OF
GUT EPITHELIUM

Embryology of Gastrointestinal Tract. The human gastrointestinal tract (GI) can be
recognized early during ontogeny in the fourth week of gestation. During development
the GI tract can be divided into foregut, midgut and hindgut. The foregut develops into
esophagus, stomach, duodenum up to ampulla of Vater and associated organs including
liver and pancreas. The midgut gives rise to the distal 2/3 portions of duodenum,
jejunum, ileum and proximal transverse colon. The hindgut accounts for distal transverse
colon, remaining portion of large intestine up to the proximal anal canal (121).

Development and Maturation of Small and Large Intestines. In humans, the small
intestine and the colon develops around fifth week of gestation, which is relatively early
compared to other mammals including mice and rats. Simple cuboidal epithelial cells
initially line the small intestine and colon. At 8 weeks of gestation, the epithelium is
3

undifferentiated and stratified and and heparin sulphate, type IV collagen, and laminin,
produced by epithelial cells form a basement membrane before differentiation (25). At 9
week, the first important morphogenetic change is marked by development of the villi
first in the proximal intestine and successively in the distal portions of the intestine. At
this stage the villi is lined with a functional epithelium so that a typical adult –like
architechture is established in the small intestine. The four different cell types that
comprise the functional epithelium are absorptive columnar, goblet, enteroendocrine and
Paneth cells. In the following weeks of gestation the villi continues to develop in size
and number. At 14 – 16 weeks of gestation a second important morphogenetic event
occurs that results in invagination of the intervillous epithelium in the adjacent
mesenchyme to form crypts that harbors the majority of proliferative cells of the
epithelium. Thus, sequential morphogenesis leads to establishment of the crypt – villus
axis that serves as a typical intestinal renewing unit in the small intestine. The
morphogenesis of colon is similar to that of small intestine but the onset of development
is delayed by 2-3 weeks. Interestingly, the villi structures in the developing colon
eventually disappear after 30 weeks to form definitive adult –like glandular surface
epithelium (SE) axis, where proliferative cells are restricted to the lower third of the
glands (119,120,259).
Although not in humans, but in mice, some functional maturational changes of the small
intestine occur at the time of weaning, a process that begins in the third week after birth.
For example, in rodents development of many absorptive and enzymatic activities
coincide with weaning. During weaning the infant GI tract is exposed to a special diet of
‘maternal milk’ that is high in fat and low in carbohydrates. Increases in small intestine

4

weight, size and DNA or protein content have been reported in pigs, rabbits, rodents and
dogs when fed colostrums compared to conventional diet, suggests a role for maternal
milk in impacting intestinal maturation {787, 788}.

Basement Membrane of Intestine.
The intestinal epithelium lies on thin and continuous sheet of specialized extracellular
matrix (ECM) called the basement membrane, which separates the underying interstitial
connective tissue or stroma containing various cells types including the mesenchymal
cells from the epithelial cells (317). The basement membrane is composed of
glycoproteins and peptidoglycans including laminins, type IV collagens, nidogens and
heparan sulphate proteoglycans (294,295,317). The intestinal basement membrane
comprises of three layers and is considered a simple basement membrane (Fig. 1). It has
three distinct layers including the lamina densa (LD) adjacent to the intestinal epithelium,
the lamina lara (LR) that separates the LD from underlying stroma and the lamina
fibroreticularis (LFR), which connects the overlying basement membranes (LD and LR)
to the underlying extracellular matrix of the connective tissue (317). One of the primary
functions of basement membrane is to provide structural support for the intestinal cells
and offer compartmentalization. However, it has become evident over the past decade
that basement membrane composition dictates the necessary microenvironment and
influences a number of functions of the surrounding epithelial cells including growth,
migration, differentiation, tissue specific gene expression and apoptosis
(317,375,376,377,378). These cellular functions during development and maturation of
GI tract are regulated by various components of the basement membranes including
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fibronectins, tenascins and laminins and their interaction with cellular receptors such as
members of the integrin superfamily (115,116,372).

Epithelium
LR
LD
LFR

Connective Tissue Layer

Figure 1. Schematic Representation of Intestinal Basement Membrane.
Basement membrane is composed of three layers including a lamina rara (LR) adjacent to
epithelium, a lamina densa (LD) and a lamina fibroreticularis (LFR) that connects the
basement membrane (BM) the the underlying connective tissue. Diagram is adapted from
Quondamatteo et al. (2002) (317).
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Stem Cells of the Gastrointestinal Tract.
The regenerative property of the gut epithelium depends on the multipotent intestinal
stem cells that are stationary and anchored at specific locations along the entire length of
gut epithelium. Despite the lack of specific biomarkers for the intestinal stem cells, they
can be recognized morphologically by their undifferentiated, embryonic cell like features
such as a high nucleus-to-cytoplasm ratio, diffused chromatin, large reticulated nucleoli
and cytoplasm with few cellular organelles but abundant in free ribosomes. In addition,
intestinal stem cells are also distinct functionally as evident from their remarkable
capacity to proliferate to maintain their own renewal and produce all lineage precursors
of the gut epithelium (14,310,312). In the small intestine, these stem cells are arranged in
a ring like formation just above the Paneth cells in the crypt base, which marks the origin
of migration of epithelial cells to repopulate the differentiated, functional mature cells of
villi that are constantly shed in the intestinal lumen (14). The number of stem cells per
crypt is tightly regulated and each crypt comprised of approximately 250 epithelial cells
harbors 4-6 functional stem cells. Regulation of stem cell number is vital because one
additional stem cell might lead to an excess of 60-120 cells per crypt. Such regulation is
enforced by apoptosis in small intestine that removes excess but otherwise healthy stem
cells and / or stem cells with DNA damage and thereby checks replication errors despite
the rapid proliferation rate (238). Control of cell division in intestinal stem cell is an
active area of research and it has been proposed that a specific type of mitosis occurs in
the functional stem cell that is responsible for its self-renewal and maintainance.
Typically, normal stem cells undergo mitosis asymmetrically resulting in one daughter
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stem cell and one daughter cell that continue to divide, mature and differentiate.
Alternatively, there is a 5% chance of symmetric mitosis in the stem cells producing
either two stem cells or two maturing cells (223). The small intestinal stem cells gives
rise to three main precursors including pre-absorptive, pre-goblet and pre-Paneth cells
that ultimately evolve into absorptive, goblet and Paneth cell lineages respectively (176).
The entire gut epithelial cell types except the Paneth cells of small intestine migrate
upward from the base of the crypts as they mature and differentiate. It has been
speculated that since the small intestinal stem cells lies adjacent to Paneth cells always
localized at crypt base, the latter might contribute to control of stem cells (311)

Cell Differentiation in Crypt – Villus unit of Small Intestine.
The small intestine mucosa is composed of large finger-like projections called villi that
project into the intestinal lumen and the surrounding crypts of Lieberkuhn that extends
from base of villi and project away from the lumen (Fig. 2). A single layer of columnar
epithelial cell lines both the cypts and villi. The intestinal epithelium is a very dynamic
tissue and regenerates itself over a 3-5 day period in humans. Within the crypts
multipotent crypt stem cells divide through life, giving rise to the epithelial lineages. The
stem cells are localized at fixed positions in the middle to lower crypt cell region.
Columnar epithelial cells differentiate as they migrate from the crypt base to the villus tip
in 5 – 6 days in the proximal human small intestine and 3 days in the human ileum
(145,402,403). Migration continues until cells are lost from the tip of a villus and shed
into the intestinal lumen. The exceptions are the intestinal Paneth cells, which reside at
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the base of the crypts and turn over every 23.3 days being cleared from the crypt base by
phagocytosis (32,33).

Cell shedding
Differentiated Epithelial
Cell Compartment
Villus
transit
time
3-5 days

Enteroendocrine Cell

Villus
Goblet Cell

Absorptive Cell
Proliferative cell compartment

Transitory
Precursor cell
Stem cell
Paneth cell

Crypt-Villus
junction

Crypt

Stem cell
compartment

Figure 2. Anatomy of a crypt – villus unit of small intestine.
Stem cells lie in the base of the crypt above paneth cell cluster. Transitory progenitor cells derived
from stem cells migrate along the crypt-villus axis, rapidly dividing with an average cell –cycle time of
12h. Progenitor cells ultimately differentiate into goblet, enteroendocrine, and absorptive cells.
Migration of cells in completed in 3-5 days and finally they are shed into the lumen. Progenitors
destined to give rise to Paneth cells migrate downward towards crypt base. Diagram is adapted from
Fujita et al. (2004) (107).
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GUT EPITHELIUM AND INNATE DEFENSE FACTORS
Physical Barrier. The collective mechanisms by which the IECs controls the
commensal microflora and and actively responds to invading pathogens is referred to as
innate intestinal epithelial defense. The intestinal epithelium lining serves as a formidable
physical barrier to foreign antigens and microbes in the gut lumen and thus contributes in
host defense. The intestinal epithelium maintains its integrity by tight junctions between
IECs and thereby restricts uptake of noxious antigens while allowing passage of nutrients
by pinocytosis (331,392). The major function of the GI tract is digestion and absoption
of nutrients. To perform its primary function, the majority of the mucosal epithelium is
composed of absorptive epithelial cells (enterocytes). The apical surface of enterocytes
in tightly packed with microvilli that are covered with glycocalyx. The carbohydrate rich
glycocalyx coat contains various enzymes and nonenzymatic proteins including
disaccharidases, peptidases, receptors and transport proteins that help in digestion and
absorption of nutrients (106,112,151). In addition, the gut epithelium is bathed in
copious secretions of mucus that forms the outermost coat of the mucosal immune system
and acts as a selective permeable barrier like the cell membrane of epithelial cells.
Humans secrete a total of approximately 10 liters of mucus per day. Mucus is a sticky
slippery gel with viscoelastic properties and is composed of 1% mucin, 1% free protein,
1% dialyzable salts and more than 95% water. The viscoelastic property of mucus is
provided by the secreted mucins, which are, long fibrous peptides coated with a complex
and diverse array of oligosaccharides (237). Mucus protects the IEC surfaces as a
lubricant that protects against mechanical damage and serves as a shield by entrapping
10

harmful antigens and microorganisms before they can bind and interact with the cells
(104,232). Mucus prevents adherence of microorganisms including enteropathogenic
Escherichia coli, Entamoeba histolytica and Yerssinia enterolytica by trapping the
pathogens and covering their cellular binding sites with mucin and secretory IgA
(61,236,328). Recent studies have demonstrated that preformed mucus can be secreted
from goblet cells in response to stimulation by luminal pathogens to provide an additional
protective coat on the mucosal epithelial surface that restricts excessive uptake of
antigens and pathogens (105,296,331). However, mucus selects and support colonization
of gut by friendly and protective commensals and thus plays a role in establishing local
mucosal ecosystems that reduce or prevent colonization by pathogens (72,345).

Innate Defense Factors. The IECs are armed with an impressive set of constitutive
innate immune defense mechanisms including defensins, trefoil peptides, lactoferrin and
complement that protect the underlying biological compartments.
(a) Defensins: IECs express a class of antimicrobial peptides called defensins. Defensins
are the most abundant antimicrobial peptides released at the mucosal surfaces. They are
3 to 4 kDa cationic, arginine –rich β-sheet peptides with six cysteines that form three
disulphide bridges (172,211,288). Defensins are categorized as α –defensins and β defensins depending on their pattern of disulphide bonding (111). In the intestine, the
defensins were first identified in the mice Paneth cells located at the base of the crypts of
Lieburkuhn and hence this family of mouse α-defensins is called cyrptidins (289).
Secretion of defensins from Paneth cells might provide antimicrobial defense to the
intestinal stem cells lodged in crypts and thus provide a protective barrier for the highly
11

proliferative compartment of intestine. In newborn mice cryptidin mRNA expression is
not discernable but its expression gradually increase and reach adult levels by the fourth
postnatal week. The mechanisms controling cryptidin gene expression is not fully
understood (80,287,289,290). Interestingly, levels of cryptidin mRNA expression were
normal in nude and germ free mice suggesting that its expression is independent of both
T-cell mediated signals or colonization of gut by intestinal microflora (80,288).
Cryptidins exhibit antimicrobial activity by permeabilizing microbial cell membranes in a
number of virulent bacteria including Staphylococcus aureus, Listeria monocytogenes,
Salmonella typhimurium, Escherichia coli and fungi such as Candida albicans and
Aspergillus fumigatus (92,210,211,212). In humans, two intestinal α−defensins namely
human defensin 5 (HD-5) and HD-6 have been identified in the Paneth cell granules
(307). HD-5 and HD-6 mRNA expression can be detected by reverse transcriptase
polymerase chain reaction (RT-PCR) by 13.5 weeks of gestation that parallels with the
time when Paneth cells become morphologically distinguishable by electron microscopy
(EM). It has been demonstrated that recombinant HD-5 retained its antimicrobial activity
even after exposure to concentrations of trypsin that are physiologically present in the
intestinal lumen. HD-5 was effective against L. monocytogenes, E. coli and S.
typhimurium (307,308).

The first β-defensin isolated from cow is called tracheal antimicrobial peptide (TAP) and
its expression is restricted to the airway tissue (88,90). Later, another homologous
peptide was isolated from bovine tongue and named lingual antimicrobial peptide (LAP)
(340). Studies have shown that TAP and LAP mRNA expression is upregulated by LPS
12

and TNF-α suggesting that these bovine β-defensins provide an inducible mechanism of
host innate defense (89,90,357). In humans, members of β-defensins namely hBD-1 and
hBD-2 are more widely distributed within the GI tract. However, they are not under the
inducible control of cytokines such as TNF-α, IL-6 or IFN-γ (411). Human BD-2 has
been recently identified and not much is known about its regulation and induction by
cytokines or microbial components. Singh et al. reported that inflammatory cytokine IL1b induced hBD-2 in primary cultures of airway epithelial cells (350,351). In addition,
since hBD-2 was isolated exclusively from bronchoalveolar lavage (BAL) of cystic
fibrosis patients, it suggest that this β-defensin is only induced under inflammatory
conditions unlike hBD-1 which is present in BAL of all patients (17). However, future
studies will determine if the similar mechanisms of human β-defensin induction and
regulation applies to the intestinal tissues.

(b) Trefoil Peptides: Trefoil peptides or trefoil factors are a family of extracellular small
peptides that are synthesized and secreted by mucin secreting epithelial cells or goblet
cells in the gastrointestinal tract. The trefoil factor family (TFF) peptides are so named
because they assume a trifoliate pattern of chain folding tightly held together by three
pairs of disulphide bonds between cysteine residues (303,306). The distinct cysteine-rich
‘trefoil’ domains maintain stability of the molecule and render them resistant to
proteolytic degradation by gut proteinases (306,332). In humans, three trefoil factors
namely TFF1, TFF2 and TFF3 have been identified (65,379). All the three trefoil factors
are highly expressed in gastrointestinal tract: TFF1 is mainly expressed in stomach and
the antral mucosa; TFF2, in pancreas and stomach and TFF3 is expressed throughout the
13

small and large intestines (306,332). The trefoil factors play an important role in
maintaining integrity of the mucosal epithelium by coating the apical surface of the IECs
and thereby protecting them from direct assault by pathogens and toxins (192,305).
Recent studies have demonstrated that the trefoil factors act as motogens, which induces
cell migration without promoting cell division. The expressions of trefoil peptides are
upregulated in chronic inflammatory bowel disease (IBD) and peptic ulcers, suggesting a
role for these peptides in healing injured mucosal epithelium. Trefoil peptides are a
central player in the process of restitution, the initial phase of mucosal repair, which is
accomplished by rapid migration of the surviving epithelial cells from wound edge to
denuded areas ultimately re-establishing surface epithelial continuity and integrity.
Studies in mice with targeted deletions in trefoil genes exhibit susceptibility to epithelial
injury, impaired mucosal healing and death from extensive colitis, reinforcing the
contribution of trefoil peptides in epithelial restitution and maintainance of the intestinal
mucosa (100,240,371).

(c) Pattern Recognition Receptors: IECs are the first sensors of ‘non-self’ particles
including pathogens and their microbial products initiating an innate immune response.
IECs are decorated with an impressive arsenal of efficient sensing and defence molecules
called pattern recognition receptors (PRRs) that recognize pathogen-associatedmolecular-patterns (PAMPS), such as LPS, a glycolipid derived from the outermost
membrane of pathogenic gram –negative bacteria, peptidoglycan (PGN), bacterial DNA,
dsRNA and single stranded RNA (ssRNA) (139,304).

14

PRRs can be categorized into secreted, intracellular and cell surface forms (253). IECs
secrete soluble CD14 and also express a membrane bound form of CD14 (mCD14)
(56,110). CD14 facilitates binding of LPS to IEC, which is enhanced in presence of LPS
binding protein (LBP). It has been reported that low dose of LBP first recognizes
bacterial LPS and then transfers it to second receptor CD14, that directly transduces
signal in IECs and uncontrolled stimulation of host cells might result in septic shock
(207,208,341). However, high dose of LBP serves to inhibit LPS-mediated host cell
stimulation and subsequent cytokine release suggesting a protective effect against LPSmediated septic shock without imparing physiologic defense mechanism against infection
(205,414).

IECs express intracellular PRRs such as NOD (nucleotide-binding oligomerization
domain) proteins and Toll like receptor 3 (TLR3) (156,252,298). Members of the Nod
family include Apaf-1, Ced-4, Nod1, Nod2, and the cytosolic products of plant disease
resistance genes. Nod proteins function as cytosolic sensors for the innate recognition of
microorganisms, induction of apoptosis, and regulators of inflammatory responses
(157,158). The C-terminal domain of Nod proteins serve as the intracellular ligand
sensing domain while the N-terminal domains interact with downstream effector
molecules and subsequently activate various signaling pathways leading to various
immune responses and apoptosis (156). In IECs, Nod1 and Nod2 recognize intracellular
bacterial LPS; interact with downstream effector molecule Rip-2 via caspase activating
and recruitment domains (CARDs) and ultimately mediate activation of NFκB and JNK
(117,298,299). Nod proteins including mammalian Nod1 and Nod2 represent an
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evolutionarily conserved system of intracellular surveillance PRRs for recognizing
cytosolic LPS and pathogen components derived from invading bacteria.

In addition to soluble PRRs and intracellular Nod proteins, IECs are equipped with an
array of surface expressed and intracellular pathogen detection receptors called TLRs. In
insects and mammals, TLRs are type I transmembrane proteins that play a crucial role in
the recognition of invading pathogens and the activation of subsequent immune responses
against them. TLRs recognize pathogens through the PAMPs, which are conserved
structural moieties of pathogens essential for their viability and therefore serve as ideal
targets for detection (23,252,337,365). To date, 13 TLRs have been identified including
TLRs 1-9 are common to mouse and humans, while TLR 10 and TLRs 11-13 is unique to
human and mouse respectively (252,362,365). All TLRs are structurally similar in that
they are comprised of three major domains including an amino-terminal domain
containing a series of leucine rich repeat (LRRs) motifs, followed by a single putative
transmembrane domain and a carboxy-terminal toll/ IL-1 receptor (TIR) domain. The
LLR domain is important for pathogen recognition while the TIR domain interacts with
the downstream adaptor proteins including TRIF and MyD88 to transduce signaling
events leading to inflammatory and antimicrobial innate immune responses in host cells
(28,159,257,277,407).

TLRs are functionally expressed in a wide variety of cell types including macrophages,
neutrophils, dendritic cells and epithelial cells (252,286). Although, TLRs 1-9 is
expressed in the IEC, the GI tract exhibits a restricted and differential expression of
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TLRs. Selective expression of TLRs allow the enterocytes to maintain a state of
balanced responsiveness to microbes in normal healthy condition by mediating tolerance
to commensals while sensitively recognizing danger signals of potentially harmful
pathogens (55,286). The level of TLR2 and TLR4 expression decreases from the base of
intestinal crypt cells to the more mature IECs of the intestinal villus. Higher expression
of TLR2 and TLR4 in the crypt cells allows them to effectively sense and destroy
bacteria, maintain a sterile environment at the base of crypt-villus unit and thereby
protect the resident stem cells that are required for regeneration of epithelium (152,285).
The apical surfaces of IECs express minimal levels of TLR2 and TLR4, which traffic to
intracellular compartments upon activation by PGN and LPS respectively. Redistribution
of TLRs from apical surfaces to intracellular compartments allows IECs to detect
pathogens while limiting the extent of TLR –mediated signaling and subsequent
inflammation (53,152,153). In addition, TLR5 is expressed exclusively on the
basolateral surface of IECs, suggesting that signaling through TLR5 is triggered only in
response to flagellete invasive bacteria such as that breach the mucosal epithelial barrier
(114,135). Some recent studies have suggested the existence of an apical population of
TLR5 receptors but atleast in GI tract TLR5 is expressed basolaterally in IECs (184).

In addition to TLRs that sense bacteria, IECs express TLR3, TLR7 and TLR8 that
specialize in recognizing viral PAMPs (4,91,140). Various viral proteins and nucleic
acids either activate TLRs or inhibit their function and a complex interplay occurs in host
cells that ultimately leads to clearance of virus by activation of innate immune system or
leads to evasion of TLR surveillance by virus enabling it to replicate. TLR-3 is
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constitutively expressed in human intestinal epithelial cells (55), although the precise
intracellular location of TLR-3 has not yet been identified. In human dendritic cells
TLR-3 is expressed intracellularly in vesicles and possibly at a low level in late
endosomes (109,243,244). An intracellular localization on TLR3 is consistent with its
role of responding to viral nucleic acids likely available for interaction during partial viral
disassembly and / or during replication inside host cells (27). It has been implicated that
TLR 7 and 8 recognize viral PAMPs specifically ssRNA in endosomal or lysosomal
compartments. This is consistent with the possible route of naked virus nucleic acid
exposure to TLRs upon receptor-mediated uptake of virus particles inside endosomes
(91,140).

Stimulation of TLRs triggers activation of a common MyD88-dependent signaling
pathway as well as a MyD88-independent pathway mediated by several TIR domaincontaining adaptors proteins such as MyD88, TIRAP, and TRIF. Recruitment of
common adaptor MyD88 to TLR activates IL-1 receptor associated kinases (IRAKs),
which interact with TNF receptor associated factor 6 (TRAF6), ultimately leading to the
activation of MAP kinases and the transcription factor NFκB resulting in
proinflammatory cytokine production (404,407). The MyD88 –independent signaling
requires adaptor molecule TRIF for TLR3- and TLR4-mediated signaling pathways,
leading to activation of transcription factors NFκB and interferon regulatory factor 3
(IRF3) facilitating IFN-β production for mammalian antiviral host defense (404,405,406).
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The TLR- microbial interaction and signaling results in the secretion of anti-bacterial
peptides, defensins, and proinflammatory cytokines such as TNF-α and IL-6 which
initiate an inflammatory response to clear the invading pathogen and is essential for
initiation of the adaptive immune responses. Proinflammatory cytokines subsequently
recruit cells of adaptive immunity including neutrophils, macrophages and dendritic cells
(DCs). Neutrophils and macrophages play an active role in clearance of the pathogens
and contribute to host survival, while DCs primarily function as antigen presenting cells
(APCs) to both naïve and memory T cells and drive their differentiona into T helper (Th)effector cells (193,242,252,337). TLR-mediated recognition and microbial –epitheial
cross talk at mucosal surfaces bridges the immediate innate and subsequent adaptive
immune responses to invading mucosal pathogens.
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IMMUNOGLOBULIN A: SYNTHESIS, STRUCTURE AND FUNCTION
IgA synthesis. Immunoglobulin A (IgA) is the primary immunoglobulin induced at the
mucosal sites and it provides the first line of specific defense at mucosal surfaces
(46,201,202,204,246,248). One of the key effector functions of gut associated lymphoid
tissue (GALT) is the elaboration of B cells into an IgA producing plasma cell. Multiple
steps are involved in the priming and maturation of a naïve B cell to an IgA producing
cell (182,183). The major source of precursors of the IgA plasma cells in the intestine is
the organized lymphoid follicles of the PPs, where naïve B cells with surface IgM are
switched to IgA bearing cells with the help of T cells and cytokines (75,183). Protein
antigens including ovalbumin, bacterial proteins, and viruses are phagocytosed by APCs,
digested into peptides and reexpressed coupled with Major Histocompatibility Complex
(MHC) II molecules on surface of APCs. CD4+ T cells are activated upon interaction
between its T-cell receptor (TCR) and peptide/ MHC II on APCs. Activated T cells then
directly contact B cells via binding of specific cell surface molecules CD40 ligand on T
cell and CD40 on B cell, and such cognate interactions results in T- dependent B cell
activation (8,9,272). However, B cells can also be activated via a T independent
mechanism by T independent (TI) antigens including bacterial LPS, dextran sulphates
and capsular polysaccharides of bacteria such as Streptococcus pneumoniae, Neisseria
meningitidis (94). Macpherson et al. (233) reported a T independent pathway of B cell
differentiation to IgA producing plasma cells. Although, the conventional pathway of B
cell development requires membrane IgM or IgD heavy chain expression at an early stage
in B cell ontogeny, recent studies have shown that it is not an absolute requirement for
the generation of IgA+ B cells. Some murine IgA can be produced T cell independently
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by B1 cells originated from peritoneal cavity and likely represents an evolutionarily
primitive system for recognition of commensal bacteria by polyreactive antibodies. In
contrast, the B2 cells in the germinal centers of MALT produces the bulk of IgA by a T
cell dependent (TD) manner (233). At the inductive sites, TGF-β primarily drives class
switching of B cells to generate IgA+ B cells (39,60). These committed cells then migrate
from Peyer’s patches to the draining mesenteric lymph nodes, where they continue to
divide and differentiate. Finally they exit the lymph nodes and pass via the thoracic duct
into the blood and home to the lamina propria where they mature as IgA-secreting plasma
cells (203,297), and some B cells differentiate into memory cells (368).

Structure of IgA. IgA exists in both monomeric and polymeric forms. IgA present in
human serum or external secretions displays characteristic structural differences,
particularly in the relative proportions of monomeric and dimeric forms. In adults over
90% of the IgA in serum is monomeric, while in secretions IgA is primarily polymeric,
most often dimeric, in the form of sIgA (43,48,130). Monomeric IgA (mIgA) is
composed of two α (53-kDa) and two κ or λ (22.5-kDa) chains. Human α chains are
glycoproteins (6-10% carbohydrate) consisting of one variable and three constant
domains. Dimeric IgA consists of two monomers connected by disulphide bonds and
linked to an additional polypeptide called J chain (15-kDa; 8% carbohydrate) (discussed
in J chain). A distinguishing feature of polymeric IgA (pIgA), as well as IgM (which is
generally pentameric), is the presence of J chain, which is incorporated into pIgA and
IgM just prior to their secretion from plasma cells and plays a regulatory though not
indispensable role in the polymerization of these isotypes (45,130,254).
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IgA is the most heterogeneous immunoglobulin isotype. In addition to existing in a
variety of molecular forms, it exists in two distinct subclasses, IgA1 and IgA2. A major
difference between the two subclasses is found in the hinge region. IgA2 molecules lack
a 13 amino acid segment, which is present in the hinge region of IgA1 and consists
exclusively of prolyl, seryl, and threonyl residues. Four to five of the seryl and threonyl
residues carry O-linked glycans. Though the extended hinge region confer greater
segmental flexibility on IgA1 molecules, the O-glycosylation sites renders this isotype
susceptible to the activity of certain post-proline endopeptidases, called IgA1 proteases,
produced by bacterial pathogens and commensals colonizing the mucosa including
Neisseria meningitides, Streptococcus pneumoniae and Haemophilus influenzae type b
(187,190,191). The absence of hinge region in IgA2 molecules renders them resistant to
cleavage by IgA1-specific proteases, which is advantageous by IgA2 antibody function at
mucosal surfaces (186,189). The human IgA2 subclass exists in two allotypic forms
designated A2m (1) and A2m(2). The A2m(1) allotype is unconventional in that the
heavy (H) and light (L) chains are not covalently linked, and therefore can be separated
by non-reducing dissociating agents (122,393). Population studies of the IgA2 allotypes
have revealed a characteristic racial and ethnic distribution, where A2m(1) allotype is
highly predominant in caucasians and A2m(2) dominates in people of African origin
(388,393). The distribution of two IgA subclasses varies significantly in the different
parts of the immune system (251). In serum, 90% of the IgA is IgA1 which, is consistent
with a similar predominance of IgA1-producing cells in the bone marrow, where most
serum IgA is produced (86). However, in secretions IgA is produced by plasma cells at
effector sites. IgA1 also predominates in the salivary, upper respiratory and upper
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gastrointestinal tract secretions, while IgA2 is present in higher proportions in lower
gastrointestinal tract. The distribution of IgA subclasses depends on the nature of the
antigen such that proteins primarily induce IgA1 response, while immunization with
carbohydrates favor generation of IgA2 producing cells (369).

Role of J-chain. The joining (J) chain is a small polypeptide, expressed by mucosal and
glandular plasma cells, which regulates polymerization of IgA and IgM
(63,155,195,261). Incorporation of J- chain provides pIgA and IgM with a number of
unique advantageous features. First, it increases the valency of antigen-binding sites,
which make the antibodies suitable for agglutinating bacteria and viruses with little or no
complement-activating potential allowing them to operate in a non-inflammatory fashion.
Second and most importantly, only J-chain-containing polymers show high affinity for
the pIgR, also known as transmembrane secretory component (SC) (165,166,194). This
epithelial glycoprotein mediates active external transfer of pIgA and pentameric IgM to
exocrine secretions. Thus, secretory IgA (sIgA) and sIgM, as well as free SC (FSC), are
generated by endoproteolytic cleavage of the pIgR extracellular domain. IgA remains
covalently linked to the secretory piece forming sIgA by a single disulfide bond between
Cys 311 of one alpha-chain and Cys 467 of the secretory component (165,166). The
secretory antibodies form the first line of defense against inhaled, ingested and sexually
transmitted pathogens at mucosal sites. The J chain is critical for creating the binding
site for pIgR / SC in the Ig polymers, not only by driving their polymerization but also by
interacting directly with the receptor protein. Therefore, both the J chain and the pIgR /
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SC are key proteins in secretory immunity and factors that affect them could modulate
mucosal immunity.

IgA in mucosal immunity.
Polymeric Immunoglobulin Receptor (pIgR) and secretory IgA.
After secretion from plasma cells, IgA is transported from the lamina propria to the
intestinal across the adjacent mucosal epithelium by pIgR, which is a transmembrane
glycoprotein expressed on the basolateral surface of mucosal epithelial cells
(43,44,45,46,264)(discussed in details in pIgR section). Dimeric IgA binds to pIgR and
the whole complex is then endocytosed and transcytosed through vesicular compartments
to the apical surface (7,264,280,281). At the apical surface pIgR is cleaved between the
cytoplasmic and transmembrane domains by a leupeptin sensitive endopeptidase
releasing sIgA into the intestinal secretions (268). Polymeric IgA (pIgA) is covalently
linked by disulfide bonds to the extracellular portion of the receptor called secretory
component and this complex of pIgA and SC forms the molecular complex referred to as
sIgA (273).

Function of secretory IgA, pIgR and free secretory component.
SIgA is the first line of specific immunological defense at mucosal surfaces
(46,179,200). SIgA is an effective isotype at mucosa as it is very stable and resistant to
degrading enzymes. SIgA provides three tiers of immune protection at mucosal surfaces
(Fig. 3). First, sIgA blocks the interaction of bacterial or viral adhesins and their
receptors on the apical surface of mucosal epithelial cells, inhibits motility, or facilitates
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entrapment in mucus (169,248,267,273,367). Second, during transcytosis, IgA can also
neutralize intracellular microbial pathogens within epithelial cells
(36,169,246,247,248,248). Third, IgA can bind to soluble antigens in the mucosal lamina
propria and promote transcytosis of immune complexes by pIgR into the intestinal lumen;
thereby ridding the body of locally formed immune complexes (171,248). The SC
portion protects the binding site for Fc-α receptor in sIgA. Several studies have shown
that, receptor bound IgA and sIgA can trigger cellular functions including degranulation
and respiratory burst by binding to Fc-receptor for IgA on phagocytic cells (262,263).
Free secretory component protects sIgA from proteolytic degradation in vitro (221,318)
and in vivo in the GI tract and oral cavity (66,76). It also prevents binding of pathogens
including Escherichia coli, Streptococcus pneumoniae, and bacterial toxins to the
epithelium (79,81,118,133,134,169). Free SC can limit infection by binding of its
unusual N-glycans to bacterial components such as Clostridium difficile toxin A and
fimbriae of enterotoxigenic Escherichia coli (79,82).

Using pIgR knockout mice, Uren

et al. reinforced the importance of pIgR / sIgA for the protection of gastrointestinal
surfaces against secreted bacterial toxins including cholera toxin. However, pIgR / sIgA
was found to be dispensable for protection against infection with Salmonella
typhimurium or Citrobacter rodentium (231,386). Thus, pIgR / sIgA provides protection
against bacterial exotoxin but do not play a major role in controlling numbers of
pathogenic and commensal bacteria in the gut. Interestingly, pIgR knockout mice lack
secretory Igs and have 100-fold more serum IgA that normal mice. Also, pIgR knockout
mice have approximately thrice as many IgA-secreting plasma cells in lamina propria
compared to wild type mice, suggesting that pIgR might contribute to mucosal B-cell
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homeostasis in addition to transcytosis of pIgA (386). PIgR knockout mice also exhibit
reduced protection against infection with influenza A and B viruses following intranasal
immunization. Lack of intracellular neutralization of viruses during pIgR-mediated IgA
transcytosis and impaired immune exclusion in absence of pIgR likely contributes to
defective protection against influenza virus in pIgR knockout mice (11,12). Sun et al.
demonstrated the critical role of pIgR / sIgA in protection against nasal colonization by S.
pneumoniae in pIgR knockout mice (360). In addition, to antigen-specific functions,
sIgA and free SC contributes to regulation of innate, non-specific responses to pathogens.
Overall, sIgA/ pIgR contribute to maintaining the integrity of the mucosal barrier, and
regulation of receptor expression contributes to host defense.
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Figure 3. Three tiers of protection of mucosal epithelia by IgA.
First, sIgA blocks the interaction of bacterial or viral adhesins and their receptors on
mucosal epithelial cells. Second, sIgA neutralizes pathogens intracellularly. Third, immune
complexes are removed during pIgR-mediated IgA transcytosis. Diagram is adapted from
Mazanec et al. (1993) (248).
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Function of serum IgA.
Serum IgA is mainly monomeric. It is produced by B-lymphocytes in the bone marrow
and in some lymphoid organs. Humans produce as much serum IgA as they do IgG.
Serum IgA provides anti-inflammatory effects by inhibiting complement mediated IgG
and IgM responses (123,188,327). However, serum IgA may initiate complement
activation by the alternative (147,162) or by the mannan-binding lectin pathway (321).
In addition, IgA in the human amniotic fluid protects the fetus by binding to natural
maternal IgG autoantibodies (316).

IgG and other Ig at mucosa.
All the five classes of immunoglobulins including IgA, IgG, IgM, IgE and IgD are found
at mucosa. IgG in mucosal secretions is generally considered to originate from serum
either by diffusion or by hepatobiliary route specifically in humans (42,315). However,
IgG can be locally produced irrespective of the systemic immune system (30,41).
Interestingly, like IgA and IgM, a bi-directional transcytosis route exists for
transportation of IgG through mucosal epithelium. In human and mouse lung epithelium,
IgG can bind to a MHC class I-related Fc receptor, FcRn, which mediates transcytosis of
this immunoglobulin across the mucosal barrier to the apical side (355). In lungs,
protection provided by IgG has been found to be more effective against viral infections
than IgA (249,293). Thus, IgG response to mucosal antigens can complement that of
secretory IgA in the defense against some pathogens and suggests that both IgG and IgA
are important for mucosal immunity.
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Pentameric IgM is actively transported by pIgR through the mucosal epithelia into
secretions in a similar fashion as IgA (47). However, sIgM is not as resistant to
proteolytic enzymes as sIgA because of its non-covalent binding to the secretory
component portion of pIgR (41). Nevertheless, it contributes to mucosal defense and in
IgA deficient patients; higher concentrations of sIgM are produced to compensate for the
IgA deficiency (42).
Traces of IgE and IgD are found in mucosal secretions. IgE is believed to contribute to
protection against parasites and allergy, while IgD may play a role in maturation of
mucosal immune system but specific functions of IgD in secretions is still debatable
(269,270,342).
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POLYMERIC IMMUNOGLOBULIN RECEPTOR
Synthesis of pIgR
In polarized epithelial cells pIgR is synthesized as a 90-100 kDa precursor protein in the
rough endoplasmic reticulum and sent to the Golgi apparatus and then to the trans –Golgi
network. In the Golgi apparatus the precursor protein is glycosylated and it matures into a
100-120-kDa protein (43). The pathway of passage of pIgR through the polarized
epithelial cells has been extensively characterized (Fig. 4). In the trans –Golgi network,
newly synthesized pIgR is sorted into vesicles that deliver it to the basolateral surface of
epithelial cells where it may bind to its ligand, pIgA produced by plasma cells, most
commonly found in the lamina propria underlying the epithelium. With or without bound
pIgA, pIgR is endocytosed and targeted to basolateral early endosomes. The complex
then passage through a common endosomal compartment and are sorted into apical
recycling endosomes (ARE) and transcytosed to the apical membrane, where proteolytic
cleavage of the extracellular ligand-binding portion of pIgR results in the generation of
either free SC or secretory IgA (266,268). A fraction of pIgR at the apical surface may
be re-internalized into apical early endosomes (AEE), then redelivered to the apical
surface through the ARE (7,264,265,267). Studies have shown that phosphorylation of
Ser –664 in the cytoplasmic domain of the pIgR is a signal for transcytosis of the receptor
(58,149). Binding of dimeric IgA (dIgA) also stimulates pIgR transcytosis, which is
independent of the Ser –664 phosphorylation. It is speculated that dIgA binding may
cause pIgR dimerization or some conformational change that may serve as a signal for
transcytosis (354).
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Figure 4. Pathway of passage of pIgR through polarized epithelial cells.
BEE, basolateral early endosome; CE, common endosome; ARE, apical recycling endosome; AEE,
apical early endosome. 1. Expression of pIgR on basolateral surface of polarized epithelial cells. 2.
Ligand binding to pIgR. 3. Transcytosis of IgA and intracellular neutralization of pathogens. 4.
Proteolytic cleavage of pIgR to SC. 5. Immune function of free SC and sIgA (Kaetzel et al. 2005,
with permission).
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Structure of pIgR
pIgR is a transmembrane glycoprotein that is expressed on secretory epithelial cells. The
basic structure of pIgR comprises an extracellular domain, a transmembrane domain and
a cytoplasmic domain (Fig. 5). The N-terminal extracellular region consists of 560 amino
acids. The extracellular region of pIgR is the ligand-binding portion of the molecule and
is cleaved at the apical surface. It is comprised of five immunoglobulin-like domains and
a sixth non-immunoglobulin-like domain connecting it to the membrane-spanning piece.
Each of the five immunoglobulin-like extracellular domains contains an internal
disulphide bond, characteristic of immunoglobulin homology units, that is conserved in
all known species of pIgR. A second internal disulphide bond exists in all species in
domains 1 and 5, and in some species in domains 2, 3 and 4. A third highly conserved
disulphide bond in present in domain 5. In human sIgA, this extra disulphide bond in
domain 5 is rearranged to form a disulphide bond with the cysteine residues in one of the
alpha heavy chains of sIgA (96). Domain 1 of pIgR is critical and sufficient for binding
polymeric IgA and IgM. The crystal structure of domain 1 from human pIgR immensely
contributed to the understanding of ligand binding properties of pIgR (132). The overall
structure of domain 1 was very similar to the immunoglobulin variable domains,
including conservation of the five key residues that stabilize the β-pleated sheet structure
of the ‘immunoglobulin fold’. Though the domain 1 contained loop structures analogous
to the complementarity-determining regions (CDRs) of antibodies, some marked
differences existed. The relatively long CDR1 loop in the pIgR domain 1 containing a
single helical turn was crucial for pIgA binding, as mutations within the helix in CDR1 of
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rabbit pIgR abolished the ligand binding surface (74). The CDR2 loop comprised of only
two amino acids, with a highly divergent amino acid at position 53 (Glu in human pIgR)
followed by an invariant Gly at position 54. CDR2 plays an important role in binding of
human pIgR to pIgM. The CDR3 loop in human pIgR tilts away from the CDR1 and
CDR2 loops and this unique conformation increases the pIg-binding surface area (132).
In addition, the C-terminal domains of human IgA (Cα3) and IgM (Cμ4) are required for
J-chain binding, polymerization and association with pIgR (146). The presence of Jchain connecting the immunoglobulin subunits of pIgA and pIgM is essential for binding
pIgR. J –chain deficient mice have reduced IgA levels in external secretions
(143,144,165,230). The transmembrane region consists of 23 amino acids and is highly
conserved among different species (15,16). The transmembrane domain contains a kinkinducing proline (P) residue that is suggested to play a role in transmembrane signal
transduction (43). Proteolytic cleavage of pIgR in this domain releases IgA bound or
unbound secretory component into mucosal secretions (268). The C-terminal
cytoplasmic region consists of 103 amino acids and contains highly conserved signals for
basolateral targeting, intracellular sorting, endocytosis and transcytosis of pIgR
(10,57,58).
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Figure 5. Schematic structure of human polymeric immunoglobulin receptor. The pIgR is
a type I transmembrane protein, with an extracellular ligand binding comprising five domains
with homology to immunoglobulin variable regions. The three complementarity-determining
regions (CDRs) in domain 1 form a non-covalent binding surface for dimeric IgA (dIgA). During
transcytosis, a disulfide bridge is formed between domain 5 of pIgR and the Fcα region of
dimeric IgA. Peptide motifs in domains 3 and 4 cooperate to form a binding surface for the SpsA
protein of Streptococcus pneumoniae. A peptide of unknown structure links domain 5 to the
membrane-spanning region and contains site(s) for proteolytic cleavage of pIgR to secretory
component (SC). Seven N-glycan residues on domains 1, 2, 4, and 5 contribute to innate immune
functions of SC and may facilitate transcytosis of pIgR. The cytoplasmic domain of pIgR
contains highly conserved signals for intracellular sorting, endocytosis, and transcytosis.
(Kaetzel et al. 2005, with permission).
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Gene organization of pIgR

Figure 6. Organization of the polymeric immunoglobulin receptor (PIGR) gene locus
and regulatory elements. (A) Eleven exons comprise the PIGR gene, encoding the 5'untranslated region (UTR) (blue box), the coding region (red boxes), and the 3'-UTR (blue
box) of pIgR mRNA. The locations of potential binding sites for regulatory proteins are
designated. (B) Working model for regulation of PIGR gene transcription by cytokines and
microbial factors. AR, androgen receptor; AP, activator protein; αCP, cytoplasmic poly(C)binding protein α; IRF, interferon regulatory factor; HNF, hepatocyte nuclear factor; NF-κB,
nuclear factor-κB; STAT, signal transducer and activator of transcription; USF, upstream
stimulatory factor. (Kaetzel et al. 2005, with permission).
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Krajci et. al. determined the genomic organization of the human pIgR gene (24).
Human PIGR gene consists of 11 exons and 10 introns spanning 17944 base pairs on
chromosome 1 (Fig. 5) (169,196). The first exon is not translated while the open reading
frame is encoded by exons 2 –11. The extracellular region of pIgR includes five
immunoglobulin like domains. Domains 1,4 and 5 encoded by single separate exons are
always present in the pIgR mRNA but domains 2 and 3 encoded by the same exon are
sometimes deleted by alternative mRNA splicing in rabbit pIgR (85). The 5’ –flanking
region, exon 1 and intron 1 of the PIGR gene contain the binding sites for constitutively
expressed and induced transcription factors. The DNA element inverted repeat sequence
(IRS). An ‘E-box’ motif at position –71 of the human PIGR gene and –74 of the mouse
PIGR gene is essential for basal promoter activity (142,164,239,353). The E-box is the
binding site for transcription factors involved in pIgR synthesis. E-box motifs with the
sequence ‘CACG/ ATG’ bind transcriptions factors of the basic helix-loop-helix/ leucine
zipper family, including the Myc, upstream stimulatory factor (USF) family members
(164,185,229,352). Recently, Bruno et al. have demonstrated that USF-1 and USF-2 but
not c-Myc bind to the PIGR E-box in vitro and in vivo and enhance promoter activity
(52). Hempen et al. have shown that activator protein 2 (AP2) binds to a site adjacent to
USF site and cooperatively enhances PIGR promoter activity (142). The human pIgR
gene contains several regulatory DNA elements that serve as targets to cytokine
induction. The pIgR gene contains 3 interferon –stimulated response elements (ISREs),
two upstream of transcription start (centered around position –133 and –100) and one in
exon 1 (centered around position +13) that can be induced by proinflammatory cytokines
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including IFN-γ and TNF-α, which are produced in response to bacterial and viral
infections (302). Analyses of regulatory regions in the human PIGR gene have identified
an element in exon 1, that is perfectly conserved in the human, mouse, and rat, binds
members of interferon regulatory factor (IRF) family of cytokine-inducible transcription
factors (128,302).

Regulators of pIgR expression. A number of factors modulate expression of pIgR (169).
(a) Cytokines: A number of cytokines including IFN-γ, TNF-α, IL-1 and IL-4 has been
shown to upregulate pIgR expression in epithelial cells. Binding of IFN-γ to its cell
surface receptor activates the receptor associated Janus kinases (JAKs). JAKs in turn
phosphorylate the cytosolic proteins called signal transducers and activators of
transcription (STATs). Phosphorylated STATs form dimers, which then translocate to the
nucleus and increase transcription of IRF1 gene (34,170,301,302). In contrast, binding of
TNF and IL-1 to cell surface receptors induces activation of IRF1 gene by activating
nuclear factor kappa B (NFκB), which translocates to nucleus and binds to an element
adjacent to STAT1 site in the IRF-promoter (300). On the other hand, weak activation of
NFκB by IFN-γ could eventually increase PIGR gene transcription indirectly, by
synergizing with STAT1 to activate IRF1 gene transcription (34). Newly synthesized
IRF-1 protein is again translocated back from the cytosol to the nucleus where it can bind
to exon 1 of the pIgR promoter and enhance transcription (1,34). Two NFκB-binding
sites have been identified in the 5’ flanking region of human PIGR gene, mutation of
which resulted in a modest decrease in TNF-induced PIGR promoter activity (366).
Schjerven et al. have demonstrated that a novel NFκB site in intron 1 cooperates with the
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IRF-1 site in exon 1 to mediate TNF-induced transcription of human PIGR gene (335).
However, no cooperativity was found between the NFκB sites in intron 1 and 5’ flanking
region of the PIGR gene. TNF-induced PIGR gene transcription also requires de novo
synthesis of the RelB subunit of NFκB, which is consistent with the delayed kinetics of
transcriptional activation (336). Proinflammatory cytokines such as TNF and IL-1
typically activate the ‘classical’ NFκB pathway, characterized by rapid activation of
RelA/ p50 dimers and early transcription of genes involved in innate immunity and
inflammatory responses (38). The TNF-induced activation of classical NFκB pathway in
intestinal epithelial cells enhances transcription from RELB gene and indirectly increases
PIGR transcription by increasing steady state levels of RelB protein. Recently, Bruno et
al. demonstrated that long-term exposure of transformed human intestinal epithelial cells
HT-29 to TNF causes sustained upregulation of RelB and pIgR expression (51).

In

addition, certain members of the TNF cytokine family but not TNF-α itself could activate
NFκB by the fairly recently discovered ‘alternative pathway’ (38). It is possible that
TNF might induce synthesis of an as yet unidentified cytokine or signaling molecule that
eventually activates newly synthesized RelB via the ‘alternative’ NFκB pathway.
Induction of PIGR gene transcription through the alternative NFκB pathway that serve to
augment pIgR-mediated IgA transcytosis might provide a bridge between innate and
adaptive immune responses.

Interestingly, the Th-1 type cytokine IFN-γ and the Th-2 type cytokine IL-4, which are
usually antagonistic, regulate expression of pIgR in a cooperative fashion. IL-4 alone or
coupled with IFN-γ has been shown to upregulate pIgR mRNA and protein expression in
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human intestinal and respiratory epithelial cell lines (1). Studies by Schjerven et al. shed
some light on the paradigm of coordinate regulation of pIgR by IL-4 and IFN-γ.
Schjerven et al. discovered a novel IL-4 inducible STAT6 site in intron 1 of the human
PIGR gene. IL-4 activates PIGR transcription with delayed kinetics suggesting a
requirement for de novo protein synthesis. But, STAT6 translocates to nucleus within
minutes of IL-4 activation. However, these contradictory observations was explained
when Schjerven et al. postulated the existence of an unidentified IL-4 induced protein
that cooperates with STAT6 to form an IL-4 responsive enhancer element (334).
Alternatively, since the NFκB/ RelB and STAT6 site in intron 1 are very close, it is
possible that de novo synthesized RelB might synergize with STAT6 to activate the IL-4
dependent enhancer element (169). But this alternate hypothesis has not yet been tested
and future studies with provide more insight into the mechanism of cooperative
regulation of PIGR gene by IFN-γ and IL-4.

Overall, proinflammatory cytokines

including IFN-γ, TNF-α, IL-1 and IL-4 increase pIgR expression in epithelial cells.

(b) Hormones. A number of polypeptide and steroid hormones including estrogen,
progesterone, androgens, glucocorticoids and prolactin regulate expression of pIgR in a
cell type specific manner. The antagonistic effects of estrogen and progesterone
modulate expression of pIgR during the estrous cycle (31,181). However, the binding
sites for estrogen and progesterone receptors on PIGR have not yet been identified and
the mechanisms by which the regulate pIgR expression is still unknown. Androgens
upregulate pIgR expression in the reproductive tissues of males and females. Two
important androgen receptor binding sites have been identified on PIGR gene (67). In
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addition, pIgR mRNA and protein expression is upregulated in mammary epithelial cells
in sheep in response to glucocorticoid treatment and this effect could be mediated
through an IFN-γ-linked mechanism (319,320). Also, prolactin likely plays a role in
regulation of pIgR expression in lactating mammary glands through upregulation of IRF1 expression following activation of a JAK/ STAT pathway (62,409).

(c) Microbial Factors. Signaling induced by a variety of microbes and their products
have been shown to regulate expression of pIgR. Butyrate, a bacterial fermentation
product and important energy source in colon upregulates pIgR expression (198,199).
Bacteroides thetaiotaomicron, increased pIgR expression by 2-4 fold when the gut of
germ free mice was colonized with this commensal bacterium (150). Bruno et al.
(unpublished communication) have found that pIgR mRNA levels were 8-10 fold higher
in the colon than in the small intestine of mice. In addition, antibiotic metronidazole
treatment in mice that selectively ablates anaerobic bacteria including Bacteroides
thetaiotaomicron, resulted in a 50% decrease in pIgR mRNA levels, suggesting a role for
commensal bacteria in the maintenance of pIgR expression in gut.

Signaling induced by microbes and their products may serve to augment pIgR-mediated
transcytosis of polymeric immunoglobulins including IgA and IgM, linking the innate
and acquired immune responses. Host cells mediate innate immune responses to
pathogen through TLR signaling (23,365). Interestingly, intestinal epithelial cells
express a variety of TLRs and inflammatory responses upregulate expression of these
pattern recognition receptors (PRRs) (55,56). Recently, Schneeman et al. have
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discovered that a bacterial lipopolysaccharide LPS, a ligand for TLR4 and a chemical
analog of viral dsRNA, poly I: C, a ligand for TLR3 upregulates pIgR expression in HT29 cells (338). Both these ligands, induce de novo synthesis of RelB and activation of
PIGR gene transcription depends on the NFκB element in intron 1. In addition, poly I: C
also activates IRF-1 and thereby mediates pIgR upregulation. IRF-3, a related
transcription factor that binds to the same consensus element as IRF-1 on PIGR gene is
also activated through TLR3 and TLR4 signaling pathways (407). It is likely that IRF-3
might cooperatively interact with NFκB and upregulate pIgR expression, but such
mechanism is yet to be established by future studies. Recently, it has been demonstrated
that during pIgR –mediated transport dIgA intracellularly neutralizes LPS within
epithelial cells, suggesting that LPS induced upregulation of pIgR, which serve to
augment IgA transcytosis might be an important mechanism in controlling intestinal
inflammation induced by proinflammatory PRRs such as LPS (102).

Function of pIgR
A hallmark feature of adaptive mucosal immune responses is the production and
generation of sIgA and free SC, which is entirely dependent upon the sacrificial receptor
pIgR expressed by mucosal and glandular epithelial cells (Fig. 7). PIgR is responsible for
transport of polymeric immunoglobulins, primarily pIgA from lamina propria to the
intestinal lumen, where the receptor is cleaved releasing sIgA or the free secretory
component in the luminal secretions (43,380). In average adults, approximately 3 grams
of sIgA is transported daily into intestinal lumen. The magnitude of pIgR –mediated
epithelial transcytosis of pIgA is impressive, since the daily production of IgA exceeds
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the production of all other immunoglobulin classes combined (255,258). Because one
molecule of pIgR is required for every molecule of transported polymeric
immunoglobulin, synthesis of pIgR by epithelial cells is a rate-limiting step for
generation of secretory pIg (267,273,367). Thus, pIgR plays a role in mucosal host
defense, and factors that influence expression of pIgR could affect mucosal immunity.
The respective roles of sIgA and free SC have been discussed previously under ‘function
of secretory IgA and free secretory component’.
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Figure 7. Transcytosis of empty receptor and dimeric IgA leading to generation of free
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produced by the plasma cells in lamina propria. 2) dIgA binds to pIgR via its J-chain. 3) The
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Diagram is adapted from Kantele (1992) (175).41
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REOVIRUS AS A MODEL PATHOGEN
Mammalian Orthoreoviruses (reovirus) is a model pathogen for studying immune
responses and pathogenesis to enteric virus infection. Respiratory enteric orphan virus
(reovirus) serves as an excellent probe to study different aspects of immunity against
enteric virus infection because it is well characterized at molecular level, naturally infects
a wide variety of mammalian species including mice and humans and is of low
pathogenecity in immunocompetent hosts (214,323). In experimental models of mice,
reovirus has been shown to induce gastroenteritis, hepatitis, myocarditis,
meningoencephalitis, biliary atresia and autoimmune syndromes
(22,78,113,138,278,283,284,326,346,347,356,384). Though, reovirus is ubiquitous in
nature and infects a wide range of mammalian hosts, it is typically non-pathogenic in
immunocompetent hosts. Approximately 85% of human adults are seropositive for antireovirus antibodies suggesting previous exposure to reovirus (343). Although attempts
to correlate reovirus infections in humans with disease have been inconclusive, prenatal
and perinatal reovirus infections have been associated with a rare pediatric liver disease,
extrahepatic biliary atresia (173,382). In addition, reovirus can be pathogenic or lethal
and might induce diseases including hydrocephalus, encephalitis, and lethal hepatitis in
neonatal and severe combined immunodeficient (SCID) mice (113,129,391). In adult
mice an oral (OR) or intravenous (IV) dose of 1010 plaque forming units is lethal, killing
the mice by 48 hrs post infection and autopsy revealed pneumonitis, inflammation and
hemorrhagic areas of the intestines (325). Reovirus (Fig. 8) is a lytic, non-enveloped,
icosohedral, 10-segmented dsRNA genome containing virus. The viral genome
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comprises 10 unique segments, three large (L), three medium (M), and four small (S)
fragments, each of which encodes a single protein, except the bicistronic S1 gene from
which two proteins are synthesized (284,344). Reoviruses were originally classified into
3 serotypes designated T1, T2, and T3 based on expression of the viral haemagglutinin,
which serves as the viral ligand for cellular receptors (383). Of the 3 serotypes, T1 and
T3 have been extensively used to investigate different aspects of viral pathogenesis and
mucosal immunity, while T2 has been utilized to study immunological mechanisms of
diabetes in neonatal mice (136,137,235,390). Although both T1 and T3 infect hosts via
the intestine, significant differences exist in the capacity of the serotypes to bind to
intestinal epithelial cells and replicate in the intestine (396). Differences among
serotypes have been atttributed to the S1 gene, σ1 protein that is responsible for cellular
tropism and diseases characteristic of the different serotypes (180,322,325,381,397).
Neurovirulence studies utilizing viral reassortants demonstrated that the σ1 of type 1
reovirus was responsible for the development of hydrocephalus and the destruction of the
ependymal cells, whereas, the σ1 of type 3 caused necrotizing encephalitis in newborn
mice (397). Interestingly, the σ1 protein, which is a long trimeric fiber that extends 40
nm from the viral capsid serves as the reovirus cell attachment protein in all three
serotypes (37,209).
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Figure 8. Structure of reovirus virion and ISVP after proteolytic digestion of outer
capsid proteins. The virus has an intact outer capsid and σ1 protein in an un-extended
conformation. After proteolytic cleavage of the outer capsid the σ1 protein is fully extended
and capable of binding cell surface receptors. Core contains ten dsRNA segments: 3 Large
(L), 3 Medium (M) and 3 Small (S) .
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Reovirus Infection.
When reovirus enters a host through the oral route, proteases including pancreatic
chymotrypsin in luminal secretions activate the virus by cleaving the outer capsid
proteins of virions to form the intermediate subviral particles (ISVPs) (Fig. 8) resulting in
a conformational change of the cell binding protein σ1 (45,46,47). The exposed σ1 of
ISVPs bind Microfold (M) cells, which are a specific cell type in the intestinal epithelium
overlying lymphoid follicles called Peyer’s patches (PPs) that endocytose a variety of
protein and peptide antigens (5,24,35). Wolf et al. demonstrated that both T1 and T3
bind to M cells and this specific binding and uptake by PP exposes the virus to innate and
adaptive immune cells in the intestine (271,399,400,401). Although, both T1 and T3
infect hosts through gastrointestinal tract and induce robust mucosal and systemic
immune responses, significant differences exist in the capacity of the serotypes to bind
IECs and replicate in intestine. Reoviruses use the cell surface molecule, junctional
adhesion molecule (JAM) expressed basolaterally on the epithelial cell to gain entry and
for infecting and spreading to the adjacent epithelial cells (21,141). In addition to JAM,
T3 but not T1 binds to sialic acid residues on as yet unidentified cellular proteins (20).
However, the long held notion the T1 does not bind sialic acid is debatable because
Helander et al. demonstrated that T1 is capable of binding on sialic acid residues
expressed on M cells (141). Reovirus T3, but not T1, also binds to the apical surfaces of
absorptive IECs and are endocytosed (180). It is unclear whether this is a ‘dead-end’
path for T3 virus. Endocytosed viruses appear to become trapped in lysosomes in IEC
and basolateral transport has not been uniformly observed (180). On the other hand, at
least in young animals, T3 infection induces villus shortening and mild mononuclear
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infiltration in the lamina propria. Alterations in IEC from T3-infected neonates include
reduction in lactase and enterokinase activities, and increased maltase and leucine
aminopeptidase activities (50). Together these results indicate that reovirus T3 can bind
to and be taken up by IECs and affect IEC function, even though replication and viral
shedding is limited. Although T3 enters absorptive epithelial cells from the lumenal
surface, replication of infectious T1 virus in the intestine appears to be more efficient
than T3 because infectious virus is shed longer and at higher levels following T1
infection than T3. Reovirus T1 causes enteric disease primarily in the ileal crypts of
Lieberkuhn. During T1 infection, viral entry into IECs occurs through the basolateral
surfaces (326); most likely as a result of T1 binding to cellular JAM. Productive
infection is limited to immature crypt enterocytes, likely due to a requirement for factors
available only in replicating host cells to support replication of virus. One such critical
host factor is an activated Ras signaling pathway that exhibits an active epidermal growth
factor receptor-Ras/RalGEG/p38 pathway. Either Ras or another downstream component
of activated Ras pathway inhibits the activation of protein kinase R (PKR), a dsRNAactivated eIF2α kinase (Fig. 10). Reovirus replication proceeds unimpeded in the Raspositive crypt enterocytes in absence of anti-viral host protein synthesis through the PKR
pathway (71,358). In cells lacking an activated Ras signaling pathway, active
(phosphorylated) PKR phosphorylates eIF2α, halting translation initiation, which inhibits
blocks viral protein synthesis. However, activated PKR does not prevent entry of
reovirus and induction of early mRNA transcription (358).
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Reovirus Replication.
Reovirus enters host cell by receptor –mediated endocytosis. Inside the endosomes the
outer shell of the virus particle is modified by removal of two proteins and cleavage of
another by lysosomal enzymes. This uncoating process activates the viral RNAdependent RNA Polymerase and hence initiates the virus replication. Reoviruses contain
within their virions all the enzymes required for replication and RNA synthesis including
RNA-dependent RNA Polymerase, nucleotide phosphohydrolase and enzymes that
participate in the capping of messenger RNA, RNA methyltransferase and guanyl
transferase. Replication of reovirus RNA occurs exclusively in the cytoplasm of the host
(Fig. 9). However, replication seems to proceed within an intracellular equivalent of the
viral core, called the subviral particle, which remains intact in the cytoplasm. Replication
of reovirus genome occurs by a conservative and asychronous method. First, one strand
of parental RNA is used as a template, and then the single stranded product serves as a
template to form the progeny double helix (213,339). The dsRNA is inactive as mRNA,
and the first step in reovirus replication is transcription, using the minus strand as a
template to make mRNA. Replication of reovirus starts within the viral core with the
RNA-dependent RNA polymerase (the product of the L1 gene), forming a capped plusstrand mRNA, which is the exact size and a perfect complement of the parental minus
strand dsRNA genome (2,213,329,339,394,395). The completed capped plus-strand
mRNAs are ejected from the viral core through the λ2 spike into the host cytoplasm
where they are utilized as templates for translation of structural and nonstructural proteins
using the host’s ribosomes (168,213). After protein synthesis, the capped single-stranded
plus RNA act as templates for the synthesis of the progeny minus-strand genomic RNAs,
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yielding progeny double stranded viral RNAs (213,330). Interestingly, the fact that only
the plus-strand mRNA is found free in the infected host cell during the course of reovirus
infection has become an important factor for designing and development of reovirus RTPCR reactions.
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Figure 9. Illustration of Life Cycle of Reovirus. Reovirus binds to the host cell surface receptors and
undergoes receptor-mediated endocytosis. Inside the host endosome, reovirus is partially uncoated by the
action of endosomal proteases, which initiates viral replication. The replication of the reovirus genome is
conservative and occurs in an asynchronous manner forming progeny virions with dsRNA. Newly
synthesiszed viral proteins assemble to form core and outer capsids of progeny virus and finally virus is
released from host cells by lysis.
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Immune responses to enteric reovirus infection.
Intestinal immune responses to reovirus include production and secretion of virusspecific IgA (226), development of virus-specific precursor CD8+ cytotoxic T-cells in the
PP, lamina propria and epithelium (77,225,226), and production of T-helper (Th) cell
responses characterized by robust Th1 responses that produce IFN-γ (97,235). Both
innate and adaptive immune responses are induced following reovirus infection (113).

Innate immunity.
In SCID mice, reovirus infection activates and increases the number of natural killer
(NK) cells in liver, suggesting that the influx of NK cells into the liver helps to slow
down the viral infection and subsequent death of the mice (370). In immunocompetent
mice, reovirus infection induces interleukin-15 (IL-15), an innate cytokine that activates a
number of immune cells including NK cells, DCs and macrophages, mediating innate
responses such as cytotoxic killing by NK cells, production of IL-12 and IFN-γ from DCs
and macrophages and synthesis of nitric oxide (NO) from macrophages (101,245,279).
In addition, proinflammatory cytokines including TNF-α and IL-1β are also induced
following reovirus infections. TNF-α and IL-1β are secreted by epithelial cells in a p38
MAPK-dependent manner and by peritoneal macrophages following exposure to reovirus
(99,256). Thus, the innate immune arm comprises epithelial cells, NK cells,
macrophages, and DCs all of which orchestrate and participate to provide protection
following reovirus infection.
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Adaptive immunity.
Reovirus infection results in the stimulation of both humoral and cellular immune
responses. Reovirus infection induces humoral immune responses characterized by the
production of antibodies of the IgG and IgA isotypes {521, 732, 733, 496,734,735, 498}
and the development of T-cell responses including cytokine producing T-helper (Th) 1
and Th2 cells (97,234,241,373). Antibody responses following either oral or systemic
infection are directed mainly against structural proteins (234). IgA is important for
protection of mice against reovirus infection. Following oral infection reovirus clearance
was delayed in the intestine in B cell-deficient mice (18). Studies with IgA-deficient
mice have demonstrated a crucial role for IgA in protection against reovirus entry into
murine Peyer’s patches (349). Hutchings et al. demonstrated that mice bearing IgA
hybridomas specific for the σ1 outer capsid protein of reovirus, such that the monoclonal
IgA is transported into intestinal secretions by pIgR-mediated transcytosis, were
protected against infection (154). In adult mice, reovirus σ1-specific IgA antibodies
protect the PPs from being re-infected upon secondary oral reovirus infections suggesting
that IgA neutralizes reovirus in the lumen of the intestines and prevents it from binding to
the M-cells of the PPs (154,349). In addition, mouse pups suckled on reovirus-immune
dams acquire IgA-mediated passive immunity and thus protected against lethal reovirus
infection (78). In neonatal mice (10 days old), enteric reovirus infection leads to
significant changes in the mucosal immune system, characterized by the induction of PP
germinal centers and production and secretion of IgA. Most of this IgA is not specific for
reovirus, but appears to be directed against environmental antigens (197).
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In addition, following exposure to reovirus by oral route, reovirus –specific IgG
antibodies of the IgG2a and IgG2b subclasses, appear in the serum and mesenteric lymph
nodes (MLNs) (234). In response to systemic reovirus exposure, the majority of the
antigen-specific spleen and lymph node B cells secrete IgG antibodies (226,234). Like
gut, reovirus infection of respiratory tract induces production of IgA and IgG antibodies
(374,412). Following oral reovirus infection, placental transfer of IgG can prevent
neonatal pups from dying, with no evidence of meningoencephalitis (78). However, the
reovirus σ1-specific IgG did not prevent reovirus infection of the PPs as confirmed by
detection of reovirus within the PPs and intestines (154,391). In addition, in SCID mice
transfer of reovirus-specific IgG (18) did not clear reovirus infection of PPs. Taken
together, it appears that IgA antibodies neutralize reovirus in the lumen of the intestines
and prevent reovirus from infecting the mucosa, while IgG antibodies prevent the
systemic spread of reovirus following oral infections.
Th cells respond as a result of uptake and presentation of viral antigens by APCs (103).
Although the contribution of various cells types as APCs in infection has not yet been
defined, it is likely that dendritic cells are the most important antigen-presenting cell for
priming reovirus-specific naïve T-cells in the intestine and periphery.
In addition to humoral immune responses, reovirus induces potent effector CD8+ T-cells
that mediate cytokine production and cellular cytotoxicity (108,225,226,413). Virusspecific cytotoxic T-lymphocytes (CTLs) are induced within the PP following intestinal
infection (226). CTLs migrate via efferent lymphatic vessels to the mesenteric lymph
nodes, then through the thoracic duct lymph and the systemic circulation to the spleen
(226) or to intestinal mucosal sites such as the intestinal epithelium where virus-specific
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cells can be found among the intraepithelial lymphocytes (IELs) (64,77,224). Parenteral
infection with reovirus induces virus-specific CTLs in the draining peripheral lymph
nodes and spleen (215,390).

Effects on Cell Signaling by Reovirus.
Interaction of virus with host cells in vitro initiates a number of signaling cascades
including increased activation of calpains (83,84), activation of c-Jun N-terminal kinase
(JNK), and extracellular signal-related kinase (ERK) (70). These signaling cascades
result in up-regulation of NFκB activation (68,69,73) and phosphorylation of c-Jun (70),
which increases transcription of regulated genes (275). While these signaling pathways
are involved in inducing apoptosis in infected cells, particularly during infection with T3
(383), their roles in other reovirus-induced cellular changes have not been extensively
characterized, although one report (131) has linked increased NFκB activation with
production of chemokines and cytokines during virus exposure. Significantly, most or all
of these changes in cell signaling in vitro occur independently of viral replication.
Rather, other steps during infection such as binding to specific receptors, endocytosis and
uncoating, and cellular exposure to viral RNA appear to be sufficient to affect the host
cell biology (19,131).

Reovirus as potential anticancer therapeutic.
Reovirus possesses the distinctive ablility to replicate in transformed cells and so reovirus
infection in vivo is limited to cells with an activated Ras signaling pathway. In adults,
reovirus infection is usually subclinical because most adults have reovirus specific
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antibodies and normal untransformed cells are unable to support reovirus replication. In
normal cells, double stranded RNA structures in reovirus transcripts activate PKR, which
subsequently phosphorylates eIF-2α ultimately inhibiting translational initiation of viral
genes. Studies with chemical analog of dsRNA, poly I:C have shown that PKR mediates
activation of NFκB inducing kinase (NIK) and I kappa B kinase (IKK), leading to IκB
degradation and subsequent NFκB activation (415). However, in transformed cells with
an activated Ras signaling pathway either Ras itself or another unidentified component
downstream in the signaling pathway blocks PKR phosphorylation, which allows viral
translation to proceed. Ras pathways are activated in approximately 30% of all human
cancers including adenocarcinomas of the pancreas, colon, and lung; in addition to
thyroid tumors and in myeloid leukemia and mutations in other elements in the Ras
pathway also contributes to cancer development (40). So implications for the use of
reovirus as an anticancer therapeutic agent are obvious as has been reported for reovirusmediated killing of oncogenic cell lines including breast, colon and ovarian cancers and
in vivo murine cancer models (3,71,148,274). Recently, Dr. Matthew C. Coffey has been
instrumental in developing reovirus as a human cancer therapeutic named as
REOLYSIN®, which is a proprietary formulation of the human reovirus of Oncolytics
technologies and has been demonstrated to replicate specifically in tumour cells bearing
an activated Ras pathway. REOLYSIN® is a potential therapeutic for upto two thirds of
all human cancers, including, but not limited to, malignant glioma, pancreatic, colon and
some lung cancers and is undergoing Phase I and Phase II clinical trials in Canada and
United States. REOLYSIN® appears to be promising tool to combat cancer as it utilizes
naturally occurring reovirus without genetic modification to cancer cells, while other
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current anti-viral therapies have potentially harmful side effects, and must be genetically
modified to remove those detrimental. Therefore, reovirus appears to be a great tool to
probe the mucosal immune system and holds promise as an anti-cancer therapeutic.
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Figure 10. Usurpation of the Ras signaling pathway by reovirus. In untransformed, reovirus-resistant
cells such as mature iecs double-stranded RNA structures in reovirus transcripts activate PKR, which
subsequently phosphorylates eIF-2 , inhibiting translation initiation of viral genes. However, in cells with
an activated Ras signaling pathway such as rapidly developing crypt cells of intestine, PKR
phosphorylation in response to viral transcripts is inhibited either by Ras or an unidentified upstream
element in the ras signaling pathway and viral translation proceeds unimpeded. Diagram is adapted from
Strong et al. (1998) (358).
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OVERVIEW OF EXPERIMENTS
The second chapter of the dissertation is dedicated to examining the regulation IgAreceptor namely pIgR in reovirus infection and demonstrates that a newly appreciated
effect of reovirus on mucosal epithelial cells is upregulation of pIgR expression.
Upregulation of pIgR expression directly contributes to host defense by enhancing
transcytosis of IgA from mucosal lamina propria into intestinal secretions where
secretory IgA and free SC neutralize pathogens and inhibit binding of invading mucosal
pathogens including virus and bacteria and prevent them from breaching the mucosal
barrier. In chapter 2, a series of experiements have been reported that aimed to
characterize the virus-host cell interactions that result in pIgR upregulation and the cell
signaling pathways that are affected.

The third chapter in this dissertation is dedicated to examining downstream signal
transduction pathways triggered by reovirus that likely contributes to upregulation of
pIgR expression in intestinal epithelial cells. The main pathways examined include
NFκB and IRF-1 and it has been demonstrated that activation of both these transcription
factors contribute to upregulation of pIgR following reovirus infection, suggesting a coordinate regulation of pIgR gene transcription in response to virus.

Chapter four comprises of preliminary experiments that aimed to understand
contribution of virus components in upregulation of pIgR. Preliminary experiments have
been conducted to understand the importance of virus dsRNA in virus-mediated
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upregulation of pIgR. Though these studies have not fully answered the important of
RNA genome of virus in upregulation pIgR expression, it also has not ruled out its
contribution. Continuation of these studies with either engineered virus lacking a RNA
genome will provide valuable insights in future.

Chapter five comprises of preliminary experiments that aimed to understand the
biological relevance of virus-mediated pIgR upregulation in an in vivo model.
Experiments have been conducted in conventional and germ free mice to determine levels
of pIgR expression in mice following reovirus infection and to compare if levels of pIgR
are modulated in response to virus. In addition, the preliminary in vivo studies indicated
an increase in pIgR expression following virus treatment, suggesting that
immunologically competent but naïve intestinal epithelium can respond to enteric
infection with virus.
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SUMMARY
Polymeric immunoglobulin receptor (pIgR) transcytoses dimeric IgA and IgA-coated
immune complexes from the lamina propria across epithelia and into secretions. The
effect of reovirus infection on regulation of pIgR expression in the human intestinal
epithelial cell line HT-29 is characterized in this report. Both replication-competent and
UV-inactivated reovirus at multiplicities of infection equivalent of 1-100 up-regulated
pIgR mRNA by 24 hour post infection, and intracellular pIgR protein was increased at 48
hour following exposure to UV-inactivated virus. Binding of virus to HT-29 cells was
required because pre-incubating virus with specific antiserum, but not non-immune
serum, inhibited reovirus –mediated pIgR up-regulation. Endosomal acidification
leading to uncoating of virus is a required step for pIgR up-regulation because
ammonium chloride or bafilomycin-A1 pre-treatment inhibited virus-induced pIgR upregulation. Inhibition experiments using the calpain inhibitor N-acetyl-leucyl-leucylnorleucinal suggest that calpains are involved in reovirus –mediated pIgR up-regulation.
Up-regulation of pIgR following virus infection appears to be an innate immune response
against invading pathogens that could help the host effectively clear infection. Signaling
induced by microbes and their products may serve to augment pIgR-mediated
transcytosis of IgA, linking the innate and acquired immune responses to viruses.
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INTRODUCTION
A hallmark feature of adaptive mucosal immune responses is the production and
secretion of secretory immunoglobulin A (sIgA) (Lamm, 1997; Brandtzaeg et al., 1997;
Kato et al., 2001). In the intestine, polymeric IgA produced by plasma cells in the lamina
propria is transported across the adjacent mucosal epithelium into the lumen by the
polymeric immunoglobulin receptor (pIgR) expressed on the basolateral surface of
intestinal epithelial cells (Brandtzaeg, 1978; Brandtzaeg, 1985; Brandtzaeg et al., 1997).
At the apical surface, pIgR is cleaved by an endopeptidase, releasing sIgA into luminal
secretions (Musil & Baenziger, 1987). The rate of IgA transcytosis depends on the level
of pIgR expression because one molecule of pIgR must be synthesized for each molecule
of transported IgA (Mostov & Deitcher, 1986; Tamer et al., 1995; Song et al., 1995;
Norderhaug et al., 1999). Thus, pIgR plays a role in mucosal host defense, and factors
that influence expression of pIgR could affect mucosal immunity. A number of cytokines
including gamma interferon (IFN-γ) (Denning, 1996; Ackermann et al., 1999; Schjerven
et al., 2000), tumor necrosis factor alpha, interleukin 1b (Blanch et al., 1999), and
interleukin 4 (Denning, 1996; Ackermann et al., 1999; Schjerven et al., 2000) increase
pIgR expression in epithelial cells. However, little is known about regulation of pIgR
during enteric virus infection.
Mammalian orthoreovirus (reovirus) are classified into 3 serotypes designated T1, T2,
and T3 based on expression of the viral haemagglutinin, which serves as the viral ligand
for cellular receptors (Weiner & Fields, 1977). Reovirus infects the gastrointestinal tract
in a wide range of mammalian species including mice and humans (Organ & Rubin,
1998). Although both T1 and T3 infect hosts via the intestine, significant differences

59

exist in the capacity of the serotypes to bind to intestinal epithelial cells and replicate in
the intestine. Wolf et al. (Wolf et al., 1981; Wolf et al., 1983; Wolf et al., 1987)
demonstrated that both T1 and T3 bind to microfold (M)-cells that overlie Peyer’s
patches (PP) in the small intestine. This specific binding and uptake by PP exposes the
virus to innate and adaptive immune cells in the intestine (Weltzin et al., 1989).
Reovirus T3, but not T1, also binds to the apical surfaces of absorptive intestinal
epithelial cells (IECs) and are endocytosed (Kauffman et al., 1983). It is unclear whether
this is a ‘dead-end’ path for T3 virus. Endocytosed viruses appear to become trapped in
lysosomes in IEC and basolateral transport has not been uniformly observed (Kauffman
et al., 1983). On the other hand, at least in young animals, T3 infection induces villus
shortening and mild mononuclear infiltration in the lamina propria (Branski et al., 1980).
Alterations in IEC from T3-infected neonates include reduction in lactase and
enterokinase activities, and increased maltase and leucine aminopeptidase activities
(Branski et al., 1980). Together these results indicate that reovirus T3 can bind to and be
taken up by IECs and affect IEC function, even though replication and viral shedding is
limited.
Reoviruses induce robust mucosal and systemic mucosal immune responses (London et
al., 1987; Cuff et al., 1993; Fan et al., 1998; Major et al., 1998). The intestinal cellular
immune response is dominated by T-helper (Th) type 1 responses resulting in local
production of IFN-γ (Fan et al., 1998; Mathers & Cuff, 2004) and development of virusspecific CTL responses in the intestine and periphery (London et al., 1987; London et al.,
1989; London et al., 1990; Fulton et al., 2004).
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Rubin et al. (Rubin et al., 1985) reported that reovirus grows best in the rapidly
developing cells of the crypts. In this model, virus is released from cells deep in the
intestinal crypts and interacts with adjacent epithelial cells or is shed in the feces.
Productive infection is limited to immature crypt enterocytes, perhaps due to a
requirement for an activated Ras signaling pathway (Coffey et al., 1998; Strong et al.,
1998).
Virus infection induces a number of changes in host cell biology that could influence cell
function. Interaction of reovirus cell attachment protein σ1 with its respective cell
surface receptors including sialic acid and Junctional Adhesion Molecule (JAM) triggers
a number of signaling cascades including increased activation of calpains (Debiasi et al.,
1999; Debiasi et al., 2001), activation of c-Jun N-terminal kinase (JNK), and extracellular
signal-related kinase (ERK) (Clarke et al., 2001). These signaling cascades result in upregulation of NF-κB activation (Tyler et al., 1995; Connolly et al., 2000; Hamamdzic et
al., 2001) and phosphorylation of c-Jun (Clarke et al., 2001). While these signaling
pathways are involved in inducing apoptosis in infected cells, particularly during
infection with T3 (Tyler et al., 1995), their roles in other reovirus-induced cellular
changes have not been characterized extensively, although one report (Hamamdzic et al.,
2001) has linked increased NF-κB activation with production of chemokines and
cytokines during reovirus exposure. Significantly, most or all of these changes in cell
signaling in vitro occur independently of viral replication in as much as UV-inactivated
virus mediates the observed effects (Tyler et al., 1995; Debiasi et al., 1999; Hamamdzic
et al., 2001). These studies indicate that at least in vitro, replication incompetent virus
can have many effects on cellular processes.
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Virus-host cell interactions and some of the possible cell signaling pathways involved in
reovirus-mediated pIgR up-regulation are characterized in this report. Reovirus upregulated pIgR expression in the transformed human intestinal epithelial cell line, HT-29,
and this up-regulation is independent of virus replication. Binding of the virus to its
cellular receptors is required for reovirus-mediated pIgR up-regulation because treatment
of virus with reovirus specific serum abolished the increase in pIgR expression.
Endosomal acidification leading to uncoating of virus is necessary for virus-mediated
pIgR up-regulation because ammonium chloride blocked the process. Furthermore,
treatment of HT-29 cells with a specific inhibitor of calpain abrogated reovirus –mediated
pIgR up-regulation. These observations support the hypothesis that IECs upregulate
pIgR expression following exposure to enteric virus, possibly by altering cell-signaling
pathways that control pIgR expression.

METHODS
Cells. HT-29 (ATCC HTB38) cells were cultured in McCoy’s 5A Modified Medium
(ATCC, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) and 1 %
penicillin-streptomycin. Calu-3 (ATCC 55-HTB) cells were cultured in Eagle’s
Minimum Essential Medium (ATCC) supplemented with 10 % FBS and 1 % penicillinstreptomycin. Cells were plated in T-25 flasks or 12-well plates and incubated at 37 °C
for 24 hours to allow the formation adherent monolayers and then exposed to virus, UVinactivated virus, and/or inhibitors.
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Virus and antibodies. Third passage stocks of reovirus serotype 3, strain Dearing
(T3/D, originally obtained from ATCC) were prepared in L929 cells and purified by
1,1,2-trichloro-1, 2,2-trifluoroethane (freon) extraction and CsCl gradient centrifugation
(Smith et al., 1969). The concentration of virions in purified preparations was
determined by spectrophotometry where 1 absorbance unit at 260 nm = 2.1×1012 particles
ml-1 (Smith et al., 1969) and by plaque assays (Cuff et al., 1990). T3/D was exposed to
UV light at 100 μJ cm2 -1 for 2 minutes at a distance of 15 cm at room temperature.
UV-inactivation reduced infectivity by approximately 1000-fold as determined by a
single cycle infection assay. Polyclonal anti-T3/D antiserum was obtained from mice
infected with 3 × 107 p.f.u. of purified T3/D virions 1 month previously. One ml of
serum completely neutralized a minimum of 1 × 1010 p.f.u. of virus as assessed by in
vitro neutralization (Cuff et al., 1990). In some experiments, UV-irradiated, virus-free
L929 cell lysates or wheat germ agglutinin (Biomeda Corporation, Foster City, CA) were
used to treat HT-29 cells.

RNA extraction and quantitative RT-PCR for pIgR mRNA. Total cellular RNA
was extracted from HT-29 cells using RNeasy® mini kits (Qiagen, Valencia, CA) and
RNA was reverse transcribed into cDNA using Superscript TM RNase H- Reverse
Transcriptase (Invitrogen Life Technologies, Carlsbad, CA) according to manufacturers’
protocols. Real-time PCR was performed using a Lightcycler (Roche Molecular
Biochemicals, Indianapolis, IN). Taqman® primers and probes for human pIgR (from
Applied Biosystems, Foster City, CA) were produced using published sequences (Blanch
et al., 1999) and human b-actin was obtained from Biosource International Inc.
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(Camarillo, CA). Reactions were carried out in a total volume of 20 ml, and 2.5 mg of
bovine serum albumin (BSA) was added to each sample. PCR conditions were optimized
for human pIgR and human β-actin primer pair as follows: denaturation for 1 cycle at 95
°C for 15 seconds; enzyme activation for 1 cycle at 50 °C for 2 minutes followed by 95
°C for 10 minutes; amplification for 55 cycles at 94 °C for 30 s followed by 60 °C for 1
minute; cool down for 1 cycle at 40 °C for 1 minute. Data were analyzed by determining
‘crossing points’ or the cycle number at which newly synthesized PCR product is first
detected. Samples were analyzed in duplicate. PIgR expression was normalized with
respect to b-actin expression by subtracting the β-actin crossing point from the pIgR
crossing point for each sample. Preliminary experiments demonstrated that mRNA could
be quantitatively reverse transcribed to cDNA and amplified by PCR over at least a 64fold range of concentrations (See Supplementary Figure in JGV Online). The fold
induction of pIgR in virus-treated cells compared to the control was determined using the
equation: Fold change = KgeneΔCp, where Kgene is the amplification coefficient for the
pIgR gene and ΔCp is the difference in crossing point between the normalized nontreated and virus-treated HT-29 cells (Schjerven et al., 2000). The theoretical value of
Kgene is 2, and preliminary experiments indicated that the Kgene value for this system
ranged from 1.9 to 2.0 (See Supplementary Figure in JGV Online). Therefore, the Kgene
value of 2 was used for data analysis.

ELISA for cell –associated pIgR. Concentrations of pIgR protein in cell lysates were
determined by ELISA as described (Chintalacharuvu et al., 1991). Briefly, 96-well
EIA/RIA (Costar, Acton, MA) flat-bottom plates were coated with guinea pig anti-human
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secretory component (SC). Human SC purified from colostrum (Kobayashi, 1971) was
used to generate standard curves. Purified SC was diluted in cell lysis buffer (1X PBS, 1
% Nonidet P-40, 0.5 % sodium deoxycholate, 0.1 % SDS and protease inhibitors 1mM
phenylmethylsulfonyl fluoride (PMSF) and 5 mg ml-1 aprotinin). Bound SC was
detected with rabbit anti-human SC, followed by horseradish peroxidase-conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA)
and 100 ml of substrate, 2,2´ -azinobis-3-ethylbenzthiazoline-6-sulfonic acid substrate
(ABTS) (Sigma, St. Louis, MO) (0.3 mg ml-1 in 0.1 M citric acid, pH 4.35)
supplemented with 10 ml of 30 % H2O2 per 10 ml of ABTS. Color development was
assessed at 405 nm. Total protein concentration in cell lysates was determined using the
bicinchoninic acid protein assay reagent kit (Pierce Biotechnology, Rockford, IL)
according to the manufacturer’s protocol. Data were expressed as ng pIgR mg-1 total
protein.

Inhibition of endosomal acidification. Ammonium chloride (Sigma) is an inhibitor of
endosomal acidification that reduces intracellular digestion of reovirus outer capsid
proteins and blocks reovirus induced apoptosis (Canning & Fields, 1983; Sturzenbecker
et al., 1987; Connolly & Dermody, 2002). Bafilomycin –A1 (Sigma) is a specific
inhibitor of vacuolar proton ATPase (Bowman et al., 1988; Yoshimori et al., 1991;
Hacker et al., 1998) and blocks reovirus replication (Martinez et al., 1996). Adherent
monolayers of HT-29 cells grown at 37 °C in 12 well plates were pre-treated for 1.5
hours with various doses of ammonium chloride, or 1 hour with bafilomycin-A1 or
DMSO (vehicle control). Inhibitor-containing medium was then removed and the cells
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were cultured in the presence or absence of UV-inactivated reovirus at a multiplicity of
infection (MOI) equivalent of 50 pfu/cell for 1 hour. The MOI equivalent was calculated
based on the concentration of replication competent virus prior to UV-inactivation.
Virus-exposed cells were then incubated in medium that contained inhibitor. mRNA was
isolated 24 hours post exposure to virus. Inhibitors used at the doses indicated were not
visibly toxic to the cells.

Inhibition of calpains. Calpain inhibitor I (N-acetyl-leucyl-leucyl-norleucinal [aLLN];
Calbiochem, La Jolla, CA.) is a modified peptide that competes for the active site of
calpain (Wang & Yuen, 1994) and it was prepared as a 25 mM stock in DMSO.
Adherent monolayers of HT-29 cells were pre-treated with the indicated doses of aLLN
or DMSO for 1 hour. Inhibitor-containing medium was then removed and cells were
exposed to UV-inactivated reovirus at an MOI-equivalent of 50. After 1 hour incubation,
inhibitors were added back to each culture (Debiasi et al., 1999) and mRNA was isolated
at 24 hours after exposure to virus. Intracellular pIgR protein was isolated at 48 hours
post exposure to virus. The inhibitor aLLN used at the doses indicated was not visibly
toxic to the cells.

Immunofluorescence Analysis. HT-29 cells were grown on coverslips or T-25 flasks
overnight and treated with 50 mM NH4Cl or 10 μM aLLN for 1 hour at 37°C. Cells were
pulsed with virus at a particle to cell ratio of approximately 105, or rendered non-adherent
with trypsin-EDTA solution and then exposed to virus. For virus binding assays, viruspulsed cells were incubated on ice for 30 minutes and kept cold during subsequent
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staining. Additionally, all stains and washes were performed in solutions containing
0.04% (w/v) sodium azide to inhibit endocytosis. Cells were analyzed using a BectonDickinson FACScalibur and Cell Quest Pro software (BD Biosciences, San Jose, CA)
For intracellular staining experiments, virus-infected cells were incubated for 1-2 hours at
37°C. Cells on coverslips were fixed for 15 minutes in PBS supplemented with 4%
paraformaldehyde and 1% Triton X-100 and then stained for 30 minutes with a 1:500
dilution of rabbit anti-reovirus antiserum diluted in PBS/1%Triton X-100. The rabbit
antiserum was previously raised in this laboratory. Coverslips were then washed in
PBS/1% Triton X-100 and stained for 15 minutes with a 1:100 dilution of Alexa 488-anti
rabbit IgG (Molecular Probes, Eugene, OR) diluted in PBS /1% Triton X-100.
Coverslips were dried, mounted and analyzed with a laser scanning confocal microscope
(Zeiss LSM 510).

Statistical analysis. Data from multiple experiments were expressed as the mean ±
SEM. The statistical significance of differences between mean values was assessed by
either two-way-analysis of variance (ANOVA) followed by Tukey’s test or one-way
ANOVA followed by Orthogonal Contrast to test for both a trend in dose response and
the threshold at which the effect appears. A P value of <0.05 was considered significant.
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RESULTS
Reovirus upregulates pIgR mRNA and protein in HT-29 cells. To determine whether
reovirus is capable of modulating pIgR expression in epithelial cells, infectious reovirus
T3/D or UV-inactivated virus was adsorbed to confluent monolayers of HT-29 cells at an
MOI or equivalent of 1, 10, and 100 and pIgR mRNA was measured 24 hours post virus
exposure by RT-PCR. No cytopathic effect was observed in cultures of cells exposed to
replication competent or UV-inactivated virus for up to 48 hours of culture. Cytopathic
effect was observed at 72 hours post-infection with replicating virus; no CPE was
observed with UV-irradiated virus. Infectious virus increased pIgR mRNA 2-8 fold over
several experiments. However, UV-inactivated virus was substantially more effective in
up-regulating pIgR mRNA expression at equivalent amounts of virus (Fig. 1). No
significant increase in pIgR mRNA was detected in cells treated with UV-irradiated Lcell lysates (4 × 104 cells/ml), or wheat germ agglutinin (50 mg/ml) (Fig. 2); a ligand for
sialic acid that serves as one of the cellular receptors for reovirus.
To determine whether the increased mRNA levels resulted in increased pIgR protein
production, HT-29 cells were cultured in the presence or absence of infectious virus or
UV-inactivated virus at an MOI equivalent of 50, and intracellular pIgR protein was
measured from cell lysates by ELISA (Fig. 3). Increased levels of intracellular pIgR
were detected by 48 hours of reovirus exposure. Thus, the elevation in protein levels
followed the increased mRNA levels by 24 hours. As with the mRNA, UV-inactivated
virus had a more pronounced effect than replicating virus. Immunoblot analysis
additionally demonstrated upregulation of pIgR protein by UV-treated reovirus or IFNγ (See Supplementary Fig. S2 in JGV Online ).

68

Virus-specific antiserum blocks the effect of reovirus on pIgR up-regulation. To
ascertain whether increased pIgR mRNA requires virus binding to the host cells, UVinactivated T3/D was pre-incubated with T3/D-immune or non-immune mouse serum
prior to use on HT-29 cells. T3/D-immune but not non-immune serum blocked the
virus-induced up-regulation of pIgR, indicating that virus binding to HT-29 cells is
required to upregulate pIgR (Fig. 4).

Inhibition of endosomal acidification blocks reovirus mediated pIgR up-regulation.
Reovirus is endocytosed following binding to its cellular ligands, sialic acid and JAM
(Borsa et al., 1979; Borsa et al., 1981; Sturzenbecker et al., 1987; Rubin et al., 1992;
Barton et al., 2001b; Prota et al., 2003; Forrest et al., 2003). Acidification leads to partial
uncoating of the virus inside endosomes, resulting in production of intermediate subviral
particles that translocate to the cytoplasm and initiate transcription of viral genes (Borsa
et al., 1979; Borsa et al., 1981; Sturzenbecker et al., 1987). To examine whether
endosomal acidification is required for reovirus –mediated pIgR up-regulation, HT-29
cells were pre-treated for 90 minutes with various doses of ammonium chloride.
Inhibitor-containing medium (or control) was then removed, and the cells were cultured
in the presence or absence of UV-inactivated reovirus at an MOI equivalent of 50 for 1
hour. Ammonium chloride was then added back to each well and pIgR mRNA was
measured 24 hours post exposure to virus. Ammonium chloride blocked virus mediated
pIgR mRNA up-regulation in a dose dependent manner (Fig. 5), suggesting that
endosomal acidification leading to uncoating of virus plays a role in pIgR up-regulation.
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Bafilomycin-A1, another inhibitor of endosomal acidification that acts through inhibition
of vacuolar proton ATPase (Bowman et al., 1988; Yoshimori et al., 1991; Martinez et al.,
1996; Hacker et al., 1998), also blocked reovirus-induced pIgR upregulation (Fig. 6).

Calpain inhibition abrogates reovirus –mediated pIgR up-regulation. Calpains,
calcium-dependent cysteine proteases, induce nuclear factor kappa B (NFκB) activation
through the degradation of its cytosolic repressor inhibitory kappa B alpha (IκBa).
Debiasi et al. demonstrated that calpain inhibitors reduced reovirus-mediated calpain
acitivation in vitro (Debiasi et al., 1999) and in vivo (Debiasi et al., 2001). To determine
whether calpains play a role in reovirus-mediated up-regulation of pIgR, HT-29 cells
were pre-treated for 1 hour with the calpain I inhibitor aLLN at doses of 0.001 to 10 μM,
or vehicle control DMSO. Medium containing inhibitor (or control) was then removed,
and the cells were cultured in the presence or absence of UV-inactivated reovirus at an
MOI equivalent of 50. After 1hour incubation, inhibitors were added back to each well
and pIgR mRNA was measured 24 hours after exposure to virus. Virus-mediated upregulation of pIgR mRNA was inhibited by aLLN in a dose-dependent manner,
suggesting that calpains play a role in virus-induced pIgR up-regulation (Fig. 7A). Under
similar culture conditions, UV-inactivated T3/D failed to upregulate intracellular pIgR
protein in cells treated for 48 hours with 1-10 μM aLLN (Fig. 7B and supplemental data
in JGV Online), suggesting a role for calpain activation in pIgR up-regulation.
Neither NH4Cl nor aLLN affected binding of virus to cellular receptors as determined by
flow cytometric analysis of cells pulsed with virus at 4°C in the presence of sodium
azide. Additionally, when inhibitor-treated, virus-infected cells were incubated at 37°C
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to allow endocytosis, bright intracellular perinuclear staining of reovirus was observed
(Fig. 8).

DISCUSSION

pIgR contributes to host defense of mucosal surfaces by mediating efficient transport and
secretion of IgA. How mucosal pathogens affect pIgR expression to the advantage of
either the host or the pathogen is not clear. These studies are the first to show that
reovirus increases pIgR mRNA and protein in mucosal epithelial cells. The results
indicate that virus binding to cellular ligands and uncoating in acidified endosomes are
required steps for virus-mediated pIgR up-regulation through a calpain-mediated
pathway.

UV-inactivated T3/D reovirus induced higher levels of pIgR expression than

infectious virus, possibly because replicating virus usurps or inhibits normal host cell
mRNA and protein synthesis to produce infectious virions (Kudo & Graham, 1966;
Ensminger & Tamm, 1969; Zweerink & Joklik, 1970; Sharpe & Fields, 1981; Sharpe &
Fields, 1982).
Preliminary studies indicated that both replication competent and UV-inactivated T1
(strain Lang) was less efficient than T3/D in inducing pIgR up-regulation (data not
shown). It has long been thought that during T1 infection, viral entry into IECs occurs
through the basolateral surface (Rubin et al., 1985), most likely as a result of T1 binding
to cellular JAM (Barton et al., 2001b; Prota et al., 2003; Forrest et al., 2003) and not
through sialic acid (Wolf et al., 1981; Wolf et al., 1983; Wolf et al., 1987). Together
these observations imply that perhaps sialic acid –mediated binding and entry is critical
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for pIgR upregulation. However, it has been recently reported that T1 can also bind to
glycoconjugates containing alpha 2-3-linked sialic acid on M-cell apical surfaces
(Helander et al., 2003). Therefore the role of sialic acid binding in mediating pIgR
upregulation remains to be determined. Approaches to assessing the role of sialic acid
include using reoviruses deficient in the ability to bind sialic acid, and pre-treating HT-29
cells with sialidase. Replication of virus in host cells is not required for reovirusmediated pIgR up-regulation, implying that this innate immune response can occur in the
absence of significant virus replication.
Reovirus infection of the respiratory tract induces various types of pathology including
acute pneumonia in juvenile mice (Morin et al., 1994; Morin et al., 1996). Reovirus also
up-regulated pIgR mRNA expression by 15-fold in the transformed human airway
epithelium cell line Calu-3, while UV-inactivated virus up-regulated pIgR mRNA
expression by as much as 25-fold under similar conditions (See Supplementary Figure in
JGV Online) suggesting that pIgR up-regulation in epithelial cells from both the
respiratory tract and the intestine could clear infection more effectively by increasing
transport of pIgA in the mucosal secretions.
Virus infection of host cells involves multiple steps including binding, uptake, and
replication. The requirements of receptor engagement and uptake for virus-mediated
pIgR up-regulation were also investigated. T3/D-immune but not non-immune serum
blocked the up-regulation of pIgR, indicating that specific virus binding to HT-29 cells is
required to induce pIgR up-regulation. Whether virus binding through JAM (Barton et
al., 2001b; Prota et al., 2003; Forrest et al., 2003), sialic acid (Chappell et al., 1997;
Chappell et al., 2000; Connolly et al., 2001; Barton et al., 2001a; Connolly & Dermody,
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2002; Helander et al., 2003), or both, is required for pIgR up-regulation is under
investigation. After binding, the virus undergoes receptor-mediated endocytosis (Borsa
et al., 1979; Borsa et al., 1981; Sturzenbecker et al., 1987; Rubin et al., 1992) and
subsequent endosomal acidification leads to partial uncoating of virus inside the
endosomes (Borsa et al., 1981; Sturzenbecker et al., 1987). Ammonium chloride blocked
virus-mediated pIgR up-regulation, indicating that endosomal acidification leading to
viral disassembly is necessary for pIgR up-regulation. Ammonium chloride-mediated
inhibition of viral disassembly has been previously shown to block reovirus-induced
apoptosis (Connolly & Dermody, 2002) without affecting binding or uptake of virus
(Sturzenbecker et al., 1987), which was confirmed in this study. Bafilomycin-A, an
inhibitor of vacuolar proton ATPases, was previously shown to block reovirus replication
in cells infected with whole virions but not in cells infected with intermediate subviral
particles (Martinez et al., 1996). Like NH4Cl, bafilomycin-A1 inhibited reovirusinduced pIgR upregulation, further supporting the idea that viral uncoating is required for
pIgR upregulation. It is possible that following degradation in the endosomes, liberated
viral dsRNA interacts with intracellular Toll like receptor –3 (TLR-3) to induce
intracellular signals that lead to pIgR up-regulation. TLR-3 is constitutively expressed in
human intestinal epithelial cells (Cario & Podolsky, 2000), although the precise
intracellular location of TLR-3 has not yet been identified. In human dendritic cells
TLR-3 is expressed intracellularly in vesicles and possibly at a low level in late
endosomes (Matsumoto et al., 2003; Funami et al., 2004). Thus, TLR-3 signaling in
response to reovirus dsRNA might be initiated following fusion of endosomes containing
reovirus dsRNA from degraded virions with cellular vesicles containing TLR-3.
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However during virus replication it is possible that dsRNA synthesized inside newly
formed capsids is shielded from intracellular TLR-3. Therefore an alternative activation
pathway such as through TLR-7 in mice or TLR-8 in human, which recognize viral
ssRNA (Diebold et al., 2004; Heil et al., 2004) might be responsible for the observed
effects.
Alternatively, reovirus dsRNA may trigger cellular responses via a TLR –independent
mechanism. Double stranded RNA may bind to the cellular RNA helicase, retinoic acidinducible gene-1 (RIG-1) (Li et al., 2005; Sumpter, Jr. et al., 2005), or melanoma
differentiation-associated gene 5 (mda-5) (Kang et al., 2002; Andrejeva et al., 2004) and
subsequently activate latent transcription factors including IFN regulatory factor 3 and
NFκB. Activation of NFκB results in transcription of the pIgR gene (Ackermann et al.,
1999; Schjerven et al., 2001; Ackermann & Denning, 2004) Because RIG-1 and mda-5
activate NFκB, and reovirus upregulates NFκB activation, it is possible that one or both
of these intracellular pathogen receptor/signaling molecules mediate the effect of reovirus
on pIgR levels. These hypotheses are currently being investigated. UV inactivation of
reovirus damages the dsRNA genome by bonding the pyrimidine molecules, which
impairs replication and blocks transcription of early and late genes (Strong et al., 1998).
However, it is not known whether there is residual transcription of viral mRNA in the
UV-inactivated virus used in the experiments reported here.
The calpain inhibitor aLLN abolished virus-mediated pIgR up-regulation, suggesting an
essential role for calpain activation in this process. Calpains are calcium dependent
cysteine proteases widely distributed throughout the cytosol of many cell types (Murachi,
1989). Calpains exists in the cytosol as an inactive proenzyme bound to its endogenous
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inhibitor calpastatin (Croall & DeMartino, 1991). Upon activation, calpains degrade a
variety of substrates including proto-oncogenes, steroid hormone receptors, protein
kinases, and cytoskeletal elements (Croall & DeMartino, 1991). Calpains also regulate a
number of cellular transcription factors, including activation of NFκB, by mediating
degradation of its inhibitor IκB (Liu et al., 1996; Chen et al., 1997). It seems reasonable
to speculate that reovirus-induced pIgR up-regulation is mediated through NFκB
activation via a calpain-mediated pathway, and this hypothesis is also under
investigation. It has been speculated that aLLN can transiently affect endocytosis (Kamal
et al., 1998), but no evidence was found to support that mechanism of action in the
experiments reported here.
Enteroinvasive bacteria including Salmonella dublin, enteroinvasive Escherichia coli and
Yersinia enterocolitica can increase NFkB activity in human intestinal epithelial cell
lines, HT-29, Caco-2 and T84. NFkB activation leads to enhanced transcription of an
array of downstream inflammatory genes including interleukin 8, tumor necrosis factor
alpha, and monocyte chemoattractant protein-1 (Elewaut et al., 1999). Thus, NFkB
serves as a central regulator of the intestinal epithelial cell innate immune responses to
infection with enteroinvasive bacteria, and perhaps enteric viruses as well.
Although not yet demonstrated, it is reasonable to speculate that reovirus infection leads
to pIgR up-regulation in vivo. Reovirus replicates in the rapidly dividing cells of the
intestinal crypts (Rubin et al., 1985), and viral replication appears to be restricted to host
cells with an activated ras pathway (Strong et al., 1998). If only replicating virus induced
pIgR upregulation, then the effect in vivo would be limited to crypt cells. However,
reovirus replication is not necessary for up-regulating pIgR expression, so reovirus could
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potentially modulate pIgR levels in differentiated IECs lacking an activated ras pathway.
At least in vitro, reovirus infection results in the production of replication competent and
replication incompetent virus (Smith et al., 1969). This phenomenon likely occurs in
vivo as well, and could result in production of particles that would efficiently induce
pIgR expression in IECs independent of viral replication. Although it could be
questioned whether UV-inactivated virus is equivalent to normally occurring, replication
incompetent virus, UV-inactivated virus has been used as a surrogate for replication
incompetent virus in in vitro (Farone et al., 1993; Tyler et al., 1995; Debiasi et al., 1999;
Hamamdzic et al., 2001; Labrada et al., 2002) and in vivo (Rubin et al., 1981) studies.
Up-regulation of intestinal pIgR mRNA expression has been reported in formerly germfree mice colonized with Bacteroides thetaiotaomicron (Hooper et al., 2001). In
addition, pIgR mRNA and protein expression is upregulated in mammary epithelial cells
in sheep in response to exogenous hormones and glucocorticoid treatment (RinchevalArnold et al., 2002b), and this effect could be mediated through an IFN-γ-linked
mechanism (Rincheval-Arnold et al., 2002a). Lamina propria mononuclear cell-derived
IFN-g has been shown to upregulate pIgR expression in HT-29 cells (Youngman et al.,
1994). Thus, along with the direct effects of the virus, reovirus infection induced IFN-g
expression in the intestine (Fan et al., 1998; Mathers & Cuff, 2004), so cytokinemediated up-regulation of pIgR might be operative in vivo. Virus-induced up-regulation
of pIgR that augments IgA transcytosis could be an innate host defense mechanism
against mucosal pathogens.
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Fig. 1. Reovirus upregulates pIgR mRNA expression in HT-29 cells. Confluent monolayers of HT-29
cells were cultured at 37°C for 24 hours in the presence or absence of reovirus serotype 3, strain Dearing
(T3/D), (closed bars) or UV inactivated T3/D, (open bars) at multiplicities of infection (MOI) equivalents
of 1, 10 and 100. Following incubation pIgR mRNA levels were quantified by real-time RT-PCR and
normalized to β-actin mRNA. Samples were analyzed in duplicate. Data are expressed as fold-increases in
pIgR mRNA in response to reovirus (mean ± SEM). Data are compiled from three independent
experiments. Asterisks indicate that the mean is significantly different from that of control cells (no virus)
as determined by two-way ANOVA followed by Tukey’s test (p< 0.050).
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Fig. 2. UV-irradiated L-cell lysates (4×104 cells/ml) or wheat germ agglutinin (WGA) (50 μg/ml) does
not upregulate pIgR mRNA expression in HT-29 cells. Confluent monolayers of HT-29 cells were
cultured at 37°C for 24 h in the presence or absence of UV inactivated T3/D at MOI equivalents of 50 or
UV-irradiated L-cell lysate or WGA. Following incubation pIgR mRNA levels were quantified by realtime RT-PCR and normalized to β-actin mRNA. Samples were analyzed in duplicate. Data are expressed
as fold-increases in pIgR mRNA in response to reovirus or lysate or WGA. Data are from two separate
independent experiments.
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Fig. 3. UV-inactivated reovirus increases pIgR protein levels in HT-29 cells. Confluent monolayers of
HT-29 cells were cultured at 37°C for 48 hours in the presence or absence of reovirus T3/D or UVinactivated T3/D at an MOI equivalent of 50. Cells were collected at 24, 48 and 72 hours post –infection
and lysed. Intracellular pIgR protein in cell lysates was measured by ELISA. Total protein concentration
in lysates was determined by BCA protein assay. The results are expressed as ng pIgR mg-1 total protein
(mean ± SEM). Data are representative of three independent experiments. Asterisks indicate that the mean
is significantly different from that of control cells (no virus) as determined by two-way ANOVA followed
by Tukey’s test (p< 0.050).
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Fig. 4. Reovirus specific antibody abolishes up-regulation of pIgR mRNA in HT-29 cells. HT-29
cells were cultured in the presence or absence of UV- irradiated T3/D (MOI equivalent of 10) that had been
pre-incubated for 30 minutes on ice with saline (no serum), mouse T3-immune serum (αT3) or mouse nonimmune serum (NI). pIgR mRNA levels were quantified 24 hour post exposure. Data are expressed as
fold-increases in pIgR mRNA in response to reovirus (mean ± SEM). Data are representative of three
independent experiments. Asterisks indicate that the mean is significantly different from that of only virus
(no serum) treated cells as determined by two-way ANOVA followed by Tukey’s test (p< 0.050).
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Fig. 5. Ammonium chloride blocks reovirus-mediated pIgR up-regulation in HT-29 cells. HT-29
cells were pre-treated for 90 minutes with indicated doses of ammonium chloride. Medium was then
removed and cells were cultured in the presence or absence of UV-inactivated reovirus at an MOI
equivalent of 50. Inhibitors were added back to each well after 1-hour incubation. pIgR mRNA levels
were quantified 24 hour post exposure. Data are expressed as fold-increases in pIgR mRNA in response to
virus compared to cells receiving no virus at each dose of ammonium chloride (mean ± SEM). Data are
compiled from three independent experiments. Asterisks indicate that the mean is significantly different
from that of control cells (no pre-treatment with ammonium chloride) as determined by one-way ANOVA
followed by Orthogonal Contrast (p< 0.050).
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Fig. 6. Bafilomycin -A1 blocks reovirus-mediated pIgR up-regulation in HT-29 cells. HT-29 cells were pre-treated
for 60 minutes with indicated doses of bafilomycin-A1. Medium containing inhibitor or (control DMSO) was then
removed and cells were cultured in the presence or absence of UV-inactivated reovirus at an MOI equivalent of 50.
Inhibitors were added back to each well after 1-hour incubation. Following incubation pIgR mRNA levels were
quantified by real-time RT-PCR and normalized to β-actin mRNA. Samples were analyzed in duplicate. Data are
expressed as fold- increases in pIgR mRNA in response to virus compared to cells receiving no virus at each dose of
bafilomycin-A1. Data are from two separate independent experiments.
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Fig. 7. Calpain inhibition abrogates reovirus-mediated pIgR up-regulation in HT-29 cells. (A) HT29 cells were pre-treated for 60 minutes with indicated doses of calpain inhibitor aLLN. Medium
containing inhibitor (or control DMSO) was then removed, and the cells were cultured in the presence or
absence of UV-inactivated reovirus at an MOI equivalent of 50. After 1 hour incubation, inhibitors were
added back to each well and pIgR mRNA was quantified at 24h post exposure. Data are expressed as foldincreases in pIgR mRNA in response to virus compared to cells receiving no virus at each dose of aLLN
(mean ± SEM). Data from Panel A are compiled from 3 independent experiments. Asterisks indicate that
the mean is significantly different from that of control cells (no pre-treatment with aLLN) as determined by
one-way ANOVA followed by Orthogonal Contrast (p< 0.050). (B) Under identical culture conditions,
cells were lysed at 48 hours post exposure to virus and pIgR protein levels were determined by ELISA.
Data are from a single experiment. Data from an additional similar experiment can be found as a
Supplementary Figure in JGV Online).
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Fig. 8. Neither NH4Cl nor aLLN affect endocytosis of reovirus by HT-29 cells. (A) HT-29 cells grown on cover
slips were pre-incubated for 1 hour in the presence or absence of 50 mM NH4Cl or 10 μM ALLN at 37oC followed by
exposure to reovirus for 30 minutes at a dose of 105 particles /cell. Unbound virus was washed free and cells were
incubated for an additional 90 minutes at 37oC. Following incubation cells were fixed with 4% paraformaldehyde and
stained with rabbit anti-reovirus followed by Alexa488-anti rabbit IgG. Intracellular staining was visualized using laser
scanning confocal microscopy through multiple z planes. Images shown are taken through central planes on the cells
and demonstrate perinuclear staining of virus. Each panel is approximately 60 μm wide. (B) In a separate similar
experiment, HT-29 cells were pre-treated with inhibitors in T-25 flasks, stripped from the flask with trypsin-EDTA,
pulsed with reovirus and incubated at 37o C for 1 hour. Cells were then fixed, permeabilized, stained for reovirus
antigen and analyzed by flow cytometry. Dashed lines indicate non-infected cells, solid line indicate reovirus-infected
cells.
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FIG S1. Linearity of RT-PCR reaction for pIgR using total mRNA and efficiency calculation of PCR
reactions. (A) Total mRNA from a reovirus-stimulated HT-29 cells that contained high levels of pIgR mRNA
were serially diluted in mRNA from human Jurkat cells (pIgR mRNA negative). Samples were reverse transcribed
and resulting pIgR cDNA was amplified and quantitated using pIgR-specific primers. PCR products were detected
with a pIgR-specific fluorescent probe as described in Methods. The cycle number that product is detected is
graphed against the dilution of mRNA. Linearity of the response over a 64-fold concentration demonstrates that
the reaction is quantitative and linear over a broad range of pIgR mRNA concentrations. (B) pIgR cDNA was
serially diluted and amplified by PCR as described in Schjerven et al., 2000. Cycle thresholds for each sample
were used to determined PCR efficiency as described in Schjerven et al.,2000.
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Fig S2. Immunoblot analysis of pIgR protein in stimulated cells. Cells were cultured in 6-well plates
and treated under the indicated conditions. Cells were treated with trypsin-EDTA, transferred to a
microfuge tube, and pelleted by centrifuging at 1200 rpm for 5 min at 4ºC. The cells were incubated in cell
lysis buffer (1X PBS, 1 % Nonidet P-40, 0.5 % sodium deoxycholate, 0.1 % SDS and protease inhibitors
1mM phenylmethylsulfonyl fluoride (PMSF) and 5 µg ml-1 aprotinin) for 20 min on ice, centrifuged at
12000 g for 15 min at 4°C, and the supernatant fraction was transferred to a new microfuge tube. Total
protein concentration in cell lysates was determined using the bicinchoninic acid protein assay reagent kit
(Pierce Biotechnology, IL) according to the manufacturer’s protocol. Equal amounts of protein (140 µg)
were separated on 7·5% SDS polyacrylamide gels, transferred to nitrocellulose, and subjected to Western
blot analysis using the indicated antibody. Briefly, non-specific binding was blocked by incubating the
blots for 1 hr at room temperature with non-fat dry milk (NFDM), 5% NFDM in PBS with 0·05% Tween
20. After each step the blots were washed four to five times for 10 min each with 1X PBS/ 0·05% Tween
20. The blots were incubated overnight at 4°C with monoclonal anti-human secretory component (1: 2500,
Sigma). Blots were then incubated for 1 hr at room temperature with horseradish peroxidase (HRP)conjugated sheep anti-mouse (1:5000, Amersham Biosciences). Antibody binding was visualized using the
ECL western blotting detection reagents (Amersham Biosciences, Piscataway, NJ) and film was developed
in All-Pro 100 Plus X-ray Film Developer (All Pro Imaging). RT-PCR analysis from RNA samples
collected 24 hours earlier indicated a 30-fold and 8-fold increase in pIgR message in IFN-γ and reovirus
treated cells over control levels.
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FIG. S3. Calpain inhibition ameliorates reovirus-mediated pIgR protein up-regulation in HT-29
cells. HT-29 cells were pre-treated for 60 minutes with indicated doses of calpain inhibitor aLLN.
Medium containing inhibitor (or control) was then removed and the cells were cultured in the presence or
absence of UV-inactivated reovirus at an MOI equivalent of 50. After 1 hour incubation, inhibitors were
added back to each flask. Cells were lysed at 48 hours post exposure to virus and pIgR protein levels were
determined by ELISA.
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FIG. S4. Reovirus upregulates pIgR mRNA expression in Calu-3 cells. Confluent monolayers of
Calu-3 cells were cultured at 37 °C for 24 hours in the presence or absence of reovirus serotype 3, strain
Dearing (T3), UV inactivated T3, or IFN-γ for 24 h. Following incubation pIgR mRNA levels were
quantified by real-time RT-PCR and normalized to β-actin mRNA.
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SUMMARY

The role of nuclear factor kappa B (NFκB) in reovirus -induced polymeric
immunoglobulin receptor (pIgR) upregulation in HT-29 intestinal epithelial cells was
examined. Helenalin, a chemical inhibitor of NFκB activation, inhibited reovirusmediated pIgR mRNA and protein upregulation. Expression of dominant negative
IκBα blocked the ability of reovirus to upregulate pIgR mRNA. Reovirus increased
transcriptional activity by reporter plasmids that contained a functional NFκB and
interferon regulatory factor-1 (IRF-1) binding site from intron 1 and exon 1 of the PIGR
gene respectively, but not by plasmids containing either one or both mutations. Together,
these findings suggest that reovirus activates PIGR gene transcription by binding
activated NFκB and IRF-1 to their respective cognate sites of the pIgR promoter.
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Secretory immunoglobulin A (sIgA) is the first line of specific immunological defense at
mucosal surfaces (Lamm, 1997; Brandtzaeg et al., 1997; Kato et al., 2001). Dimeric IgA
and larger polymers of IgA and IgM bind to polymeric immunoglobulin (pIg) receptor
(pIgR) basolaterally on mucosal epithelial cells, and are transcytosed through the
epithelium (Brandtzaeg, 1978; Brandtzaeg, 1985; Apodaca et al., 1994; Brandtzaeg et al.,
1997; Kaetzel, 2005). At the apical surface, the pIgR –pIg complex or the empty receptor
is proteolytically cleaved close to its transmembrane domain, releasing secretory IgA or
the free secretory component into luminal secretions (Musil & Baenziger, 1987).
Because one molecule of pIgR is required for every molecule of transported polymeric
immunoglobulin, synthesis of pIgR by epithelial cells is a rate-limiting step for
generation of secretory pIg. In addition to transporting IgA, free secretory component
protects sIgA from proteolytic degradation and can inhibit binding of pathogens
including Escherichia coli, Streptococcus pneumoniae, and bacterial toxins to the
epithelium (Giugliano et al., 1995; Hammerschmidt et al., 1997; Dallas & Rolfe, 1998;
Hammerschmidt et al., 2000; de Araujo & Giugliano, 2001; Kaetzel, 2005). Using pIgR
knockout mice, Uren et al. reinforced the importance of pIgR / sIgA for the protection of
gastrointestinal surfaces against secreted bacterial toxins including cholera toxin.
However, pIgR / sIgA was found to be dispensable for protection against infection with
Salmonella typhimurium or Citrobacter rodentium (Uren et al., 2005). Sun et al.
demonstrated the critical role of pIgR / sIgA in protection against nasal colonization by S.
pneumoniae in pIgR knockout mice (Sun et al., 2004).
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Expression of pIgR can be modulated by a variety of environmental stimuli including
proinflammatory cytokines, hormones and commensal bacteria. Cytokines including
gamma interferon (IFN-γ), tumour necrosis factor-alpha (TNF-α), interleukin (IL)- 4, and
IL-1 upregulate pIgR expression in epithelial cells (Schjerven et al., 2001; Ackermann &
Denning, 2004; Schjerven et al., 2004). Several hormones including estrogen,
progesterone, androgens, glucocorticoids and prolactin also regulate pIgR expression
(Bjercke & Brandtzaeg, 1993; Kaushic et al., 1995; Chapman et al., 2000; Claessens et
al., 2001; Yu-Lee, 2001; Rincheval-Arnold et al., 2002a; Rincheval-Arnold et al.,
2002b). PIgR expression was increased in germfree mice following colonization with
commensal Bacteroides thetaiotaomicron (Hooper et al., 2001) and following weaning, a
time in which normal bacterial flora is established in mice (Jenkins et al., 2003).
Microbial products such as bacterial lipopolysaccharide (LPS) and poly I:C, a chemical
analog of viral double stranded RNA, also induced pIgR upregulation in HT-29 cells
(Schneeman et al., 2005). In addition, chronic mucosal disorders including celiac
disease, Helicobacter pylori gastritis, and Sjogren’s syndrome increase pIgR synthesis
(Brandtzaeg et al., 1992). Taken together, these studies suggest that pIgR contributes to
maintaining the integrity of the mucosal barrier and regulation of receptor expression is a
developmental response by epithelial cells that contributes to host defense.

Mammalian orthoreovirus (reovirus) infects the mucosa in a wide variety of mammalian
species including mice and humans. Reovirus infection initiates a number of signaling
cascades in host cells including increased activation of calpains (Debiasi et al., 1999;
Debiasi et al., 2001), activation of c-Jun N-terminal kinase (JNK), and extracellular
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signal-related kinase (ERK) (Clarke et al., 2001). These signaling cascades result in
upregulation of NFκB activation (Tyler et al., 1995; Connolly et al., 2000; Hamamdzic et
al., 2001) and phosphorylation of c-Jun (Clarke et al., 2001). Significantly, most or all of
these changes in cell signaling in vitro occur independently of viral replication in as much
as UV-inactivated virus mediates the observed effects (Rubin et al., 1981; Tyler et al.,
1995; Debiasi et al., 1999; Hamamdzic et al., 2001; Pal et al., 2005). Other steps during
infection such as binding to specific receptors, endocytosis and uncoating, and cellular
exposure to viral RNA also appear to affect host cell biology (Barton et al., 2001;
Hamamdzic et al., 2001; Pal et al., 2005).

Reovirus upregulates pIgR mRNA and protein in transformed human intestinal epithelial
HT-29 cells (Pal et al., 2005). This report examines the role of NFκB in reovirus –
induced pIgR upregulation. To determine whether NFκB activation is necessary for
reovirus-mediated upregulation of pIgR, HT-29 cells were pre-treated for 1 hour with the
NFκB inhibitor helenalin (Sigma, St. Louis, MO) at doses of 0.001 to 10 μM, or vehicle
control DMSO. Helenalin specifically alkylates the p65 subunit of NFκB, rendering it
incapable of binding to DNA. Inhibitor containing media was then removed and cells
were cultured for 1 hour in the presence or absence of UV-inactivated reovirus serotype
3, strain Dearing (T3/D). Following incubation, inhibitors were added back to each well
and pIgR mRNA was measured by real time reverse transcriptase (RT) PCR 24 hours
after exposure to virus. Virus-mediated upregulation of pIgR mRNA was inhibited by
helenalin in a dose-dependent manner (Fig. 1A). Under similar culture conditions, 1-10
μM helenalin blocked virus-mediated increase in intracellular pIgR protein as determined
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by ELISA (Fig. 1B). To further test the hypothesis that NFκB is involved in virusmediated pIgR upregulation, HT-29 cells were infected with recombinant adenovirus that
over-expresses a dominant negative form of IκBα ( IκBdn) that lacks two serine residues
and cannot be phosphorylated. As a control for transfection efficiency cells were infected
with an adenovirus vector expressing β-galactosidase (AdLacZ) (University of Iowa
Gene Therapy Vector Core Facility, Iowa). 24 h later, confluent monolayers of HT-29
cells were cultured at 37°C for 24 h in the presence or absence of UV-inactivated T3/D.
The dominant negative construct has been previously shown to block cytokine-induced
upregulation of pIgR (Ackermann & Denning, 2004). The dominant negative mutant
blocked the ability of UV-inactivated reovirus to upregulate pIgR mRNA when compared
to cells transfected with a control adenovirus vector (AdLacZ), which also accounts for
transfection efficiency (Fig. 2). To further examine whether reovirus can upregulate
PIGR gene expression through NFκB or interferon regulatory factor –1 (IRF-1) mediated
transcriptional activation, HT-29 cells were transfected for 2 hours with 1μg of wild type
(WT), mutant plasmids or promoter-less (control) as indicated. 24 hours posttransfection, cells were cultured at 37°C in the presence or absence of UV-inactivated
T3/D for another 24 hours. In these plasmids, transcription of the firefly luciferase
reporter gene is driven by an 8.6 kb fragment of the human PIGR gene, including 2684
bp of 5’ –flanking sequence, exon 1 (132 bp), intron 1 (5751 bp), and the first 56 bp of
exon 2, up to and including the translation start site (Schneeman et al., 2005). The ‘NFκB
mutant’ plasmid contains a mutation that abolishes an NFκB –binding site in intron 1; the
‘IRF-1 mutant’ plasmid contains a mutation that abolishes an IRF-1 binding site in exon
1, and the ‘double mutant’ plasmid contains both mutation. These mutations have been
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previously shown to inhibit TNF-α (Schjerven et al., 2001) and poly I: C (Schneeman et
al., 2005)-induced activation of PIGR gene transcription. As a control for transfection
efficiency, cells were co-transfected with 5 ng of pRL-CMV (Promega, Madison, WI,
USA), in which the CMV promoter drives transcription of the Renilla luciferase gene.
Cell lysates were analyzed for firefly and Renilla activities using the ‘Dual- Luciferase
Reporter Assay System’ according to the manufacturer’s protocol (Promega, Madison,
WI, USA). Reovirus increased transcriptional activity from WT plasmid, but not from
the mutant NFκB, mutant IRF-1 and double mutant plasmids (Fig. 3). Taken together,
studies with the chemical inhibitor helenalin, the dominant negative mutant for IκBα, and
reporter gene promoter analysis suggest that reovirus activates PIGR gene transcription
by binding of activated NFκB to its cognate site in intron 1 of pIgR promoter. Also,
results using IRF-1 mutant and double negative mutant plasmids suggest that
upregulation of PIGR gene transcription by reovirus involves co-operativity between
IRF-1 and NFκB.

Activation of NFκB in the cytoplasm involves the inducible phosphorylation of its
repressor IκB in response to stimuli, which then undergoes ubiquitin-mediated
proteolysis, releasing NFκB dimers to translocate to nucleus and bind target genes
(DiDonato et al., 1995; Barnes & Karin, 1997; May & Ghosh, 1998). Studies with
enteroinvasive bacteria have shown that signal transduction through NFκB is a central
regulator of innate immune responses triggered by the epithelium (Seydel et al., 1998;
Elewaut et al., 1999). Reovirus could activate NFκB either directly or by a calpainmediated pathway (Debiasi et al., 1999; Connolly et al., 2000; Hamamdzic et al., 2001),
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and calpains have been shown to be critical for reovirus –mediated pIgR upregulation
(Pal et al., 2005). However, it is possible that NFκB can be activated by other signals
during reovirus infection of host cells including virus dsRNA and/or interferon-β (IFNβ). Future studies may reveal the role of IRF-3, dsRNA-Toll like receptor-3 (TLR3)dependent, or TLR3-independent pathways including RNA helicases retinoic acidinducible gene-1 (RIG-1) (Li et al., 2005; Sumpter, Jr. et al., 2005) or melanoma
differentiation-associated gene 5 (mda-5)(Kang et al., 2002; Andrejeva et al., 2004) in
virus-mediated pIgR upregulation. The present study suggests a phenomenon of IRFNFκB synergy in reovirus-induced transcriptional activation. It is reasonable to speculate
that the two sites act cooperatively such that an NFκB family member interacts with an
IRF family member, perhaps IRF-3, to activate transcription of the pIgR gene as has been
reported for the activation of the beta interferon (IFN-β) gene (Maniatis et al., 1998).
Hempen et al. have suggested a complex model for the basal transcriptional regulation of
human PIGR gene that involves cooperative binding among multiple transcription
factors, including upstream stimulatory factor (USF) and AP2 (Hempen et al., 2002).
Interestingly, during immune or inflammatory responses, basal regulatory factors may
interact with various other inducible factors including NFκB, IRF-1 and STAT-6 to
upregulate PIGR gene transcription. This study corroborates the importance of a central
NFκB pathway in modulating immune responses by demonstrating its role in the
upregulation of pIgR from epithelial cells against reovirus using three experimental
approaches. Other pathways may also be involved.
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Fig. 1. Helenalin inhibits reovirus-mediated pIgR up-regulation in HT-29 cells. (A) HT-29 cells were
pre-treated with indicated doses of NFκB inhibitor helenalin and then cultured in the presence or absence
of UV-inactivated reovirus at a multiplicity of infection (MOI) equivalent of 50. 24 h post exposure, pIgR
mRNA levels were quantified by real-time RT-PCR and normalized to β-actin mRNA. Samples were
analyzed in duplicate. Data are combined from 3 independent experiments and expressed as fold-increase
in pIgR mRNA in response to reovirus compared to cells receiving no virus at each dose of helenalin (mean
± SEM). Asterisks indicate that the mean is significantly different from that of control cells (no pretreatment with helenalin) as determined by one-way ANOVA followed by Tukey’s test (p< 0.050). (B)
Under similar culture conditions, cells were lysed at 48 hours post exposure to virus and pIgR protein
levels were determined by ELISA. Data in panel B are from a single experiment.
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Fig. 2. Dominant negative mutant of IκBα blocks reovirus-mediated pIgR mRNA upregulation in
HT-29 cells. HT-29 cells were transfected with adenovirus vector expressing β-galactosidase (AdLacZ) or
IκBα - serine mutant (IκBdn) and then cultured for 24 h in the presence or absence of UV-inactivated T3/D
at an MOI equivalent of 50. Data are compiled from three independent experiments and expressed as fold
increase in pIgR mRNA in response to reovirus (mean ± SEM) compared to cells receiving no virus at each
of indicated treatments. Upregulation of pIgR mRNA in the non-transfected cells was approximately 18
fold. Asterisks indicate that the mean is significantly different from that of control cells (Ad-LacZ) as
determined by one-way ANOVA followed by Tukey’s test (p< 0.050).
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Fig. 3. Reovirus enhances transcription of wild-type PIGR gene reporter plasmids. HT-29 cells were
co-transfected with promoterless control or indicated PIGR reporter plasmids and a Renilla luciferase
plasmid and then cultured in the presence or absence of UV-inactivated T3/D at an MOI equivalent of 200.
Data are compiled from two independent experiments, and are expressed as luciferase activity (normalized
for co-transfected Renilla luciferase) of the same plasmid in response to reovirus treatment or mock
treatment (mean ± SEM, n=6). Asterisks indicate significant difference between experimental and controls
(no virus) by one-way ANOVA followed by Tukey’s test (p< 0.050).
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INTRODUCTION
Studies reported in Chapter 2 of this dissertation demonstrated that UV-inactivated
reovirus up-regulates pIgR mRNA and protein. This observation suggests that specific
virus-host interactions, and not viral replication, initiate signaling pathways that regulate
pIgR expression. Reovirus is a 10-segmented dsRNA-containing virus that infects a wide
variety of mammalian species including mice and humans (12,14). Reovirus enters host
cells by receptor-mediated endocytosis, and inside the acidified endosomes it undergoes
partial disassembly resulting in intermediate subviral particles (ISVPs) and / or liberation
of viral dsRNA genome from degraded virions (3,4,15). Viral dsRNA is a wellcharacterized PAMP that is recognized by TLR3 (1,8,9,13). TLR-3 is constitutively
expressed in human intestinal epithelial cells (5), although the precise intracellular
location of TLR-3 has not yet been identified. However, in human dendritic cells TLR-3
is expressed intracellularly in vesicles and possibly at a low level in late endosomes
(7,9,10). An intracellular localization on TLR3 is consistent with its role of responding
to viral nucleic acids likely available for interaction during partial viral disassembly and /
or during replication inside host cells (2). Recently, Schneeman et al. reported that cell
surface expression of TLR3 by transformed human intestinal epithelial cell line HT-29 is
enhanced following prolonged stimulation with chemical analog of viral dsRNA, poly I:C
(13). Taken, together it appears that IECs including HT-29 cell line express TLR3 and a
TLR-mediated recognition of viral dsRNA exists in them.
The working hypothesis of this project is that viral dsRNA released during endosomal
processing is sufficient to trigger signaling cascades resulting in pIgR up-regulation.
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This is important globally because it demonstrates that viruses (and not only chemical
analogs of dsRNA) can trigger innate immune responses in cells that do not support virus
replication. To examine if TLR3-mediated recognition of dsRNA leads to upregulation
of pIgR in IECs, first the role of poly I: C in modulating pIgR expression in HT-29 cells
was assessed. Second, the ability of purified reovirus dsRNA to modulate pIgR
expression in HT-29 cells was also examined.

METHODS
Cells. HT-29 (ATCC HTB38) cells were cultured in McCoy’s 5A Modified Medium
(ATCC, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) and 1 %
penicillin-streptomycin. Cells were plated in 12-well plates and incubated at 37 °C for 24
hours to allow the formation adherent monolayers and then exposed to UV-inactivated
reovirus, poly I:C (Sigma, St. Louis, MO) and/or purified reovirus dsRNA.

RNA extraction and quantitative RT-PCR for pIgR mRNA. Total cellular RNA was
extracted from HT-29 cells using RNeasy® mini kits (Qiagen, Valencia, CA) and RNA
was reverse transcribed into cDNA using Superscript TM RNase H- Reverse
Transcriptase (Invitrogen Life Technologies, Carlsbad, CA) according to manufacturers’
protocols. Real-time PCR was performed using a Lightcycler (Roche Molecular
Biochemicals, Indianapolis, IN) as described previously in Chapter 2.
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Double Stranded reovirus RNA extraction. L929 cells were grown in T-75 flask and
then infected with reovirus T3/D at an MOI of 10. Infected L-cell cultures were
incubated at 37°C for about 36 hours until CPE was well advanced (>70%). 36 hours
post infection, cells were trypsinized and centrifuged at 1200 rpm for 5 mins at 4°C.
Supernatant was discarded and cells were resuspended in TRI reagent (Molecular
Research Center) at a concentration of 5× 106 - 1×107 cells / ml, and dsRNA was
extracted by the acid-phenol/guanidinium thiocyanate procedure, according to the
manufacturer’s instructions. The cell lysate was passed several times through pipette and
then transferred to a new eppendorf tube and incubated for 5 mins at room temperature to
allow complete dissociation of nucleoprotein complexes. 100 μl of BCP per 1ml of
TRIreagent was added to lysates, and shaken vigorously for 15 secs. The resulting
mixture was incubated at room temperature for 10 mins and then centrifuged at 12000g
for 15 mins at 4°C. Following centrifugation, the mixture separates into a lower red
phenol-chloroform phase, interphase and the colorless upper aqueous phase. RNA
remains exclusively in the aqueous phase whereas DNA and proteins are in the interphase
and organic phase. The volume of the aqueous phase is about 60% of the volume of
TRIreagent used for homogenization. The aqueous phase was transferred to a new tube.
500 μl of isopropanol (500 μl per 1ml of TRI reagent) was added to the aqueous phase.
RNA was precipitated from the aqueous phase by mixing with an equal volume of
isopropanol. Lysate was stored at room temperature for 10 mins and centrifuged at
12000g for 8 mins at 4°C. RNA, which was often invisible before centrifugation, was
precipitated at this step and appeared as a gel-like or white pellet on the side and bottom
of the tube. The supernatant was removed very carefully and the RNA pellet was washed
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(by vortexing) with 1ml of 75% ethanol and then centrifuged at 7500g for 5mins at 4°C.
The ethanol wash was removed and RNA pellet was briefly air -dried for 3-5min. It is
important not to completely dry the RNA pellet as this greatly decreases its solubility in
water. The RNA pellet was dissolved in 120 μl of RNAse free water. This was followed
by precipitation with 2M LiCl to remove single-stranded RNA as follows:
(1) Add 8M LiCl (Sigma) to a final concentration of 2M LiCl, that is add 40ul of
LiCl to 120μl total RNA. Leave in an ice-water slurry for 2 hours. Centrifuge at
14000-16000 g for 30 mins. The dsRNA is purified from the supernatant using a
column from a Gel Extraction Kit (Qiagen).
(2) Transfer the supernatant to a new tube (note the precipate formed after addition of
LiCl is ss RNA). To the supernatant (which is 120+40 =160μl), add 480μl (3
volumes) of Buffer QG and 160μl (1 volume) of isopropanol and mix well.
(3) Place a QIAquick spin column in a provided 2ml collection tube. Add the sample
mixture to the QIAquick column and centrifuge for 1min. (Maximum volume of
column is 800μl).
(4) Discard flow-through and place the QIAquick column back in the same collection
tube.
(5) To wash add 750μl of Buffer PE to QIAquick column and centrifuge for 1min.
(6) Discard flow-through and centrifuge the QIAquick column for an additional 1min
at >10000g (~13000 rpm).
(7) Place QIAquick column into a clean 1.5ml microcentrifuge tube. To elute DNA,
add 50μl of Buffer EB or Nuclease free water to the center of the QIAquick
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membrane and centrifuge the column for 1min at maximum speed. Store the DNA
at –80°C.

RESULTS
TLR3 mediated signaling upregulates pIgR mRNA expression in HT-29 cells.
To determine whether TLR3 signaling regulated pIgR expression in human IEC, HT29
colon carcinoma cells were treated with indicated doses of chemical analog of viral
dsRNA (poly I: C) or exposed to UV-inactivated reovirus at an MOI of 50 for 24 hours.
The concentration of the virus was 148 ng/μl. Preliminary experiments demonstrated that
poly I: C upregulates pIgR mRNA expression in HT-29 cells in a dose-dependent
manner, suggesting that TLR3 mediated signaling in IECs play a role in pIgR upregulation. A dose of 100-µg/ml poly I: C was optimal and pIgR was induced by as much
as 20 fold (Fig. 1).

Extracellular reovirus dsRNA does not upregulate pIgR expression in HT-29 cells.
Although poly I: C is an almost universally accepted analog for viral dsRNA, there are
few studies that test the role of TLR3-mediated activation in response to actual viral
dsRNA. Confluent monolayers of HT-29 cells were incubated at 37°C in presence or
absence of intact UV-inactivated reovirus at an MOI of 50 (764 ng of RNA) or equivalent
amounts of purified dsRNA from reovirus or UV-irradiated purified reovirus dsRNA
under cell culture conditions that ensured that the RNA was not degraded (Fig. 2). 24
hours post exposure to intact virus or naked dsRNA, pIgR mRNA was measured by real
time quantitative RT-PCR as described previously. Although intact virus increased pIgR
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mRNA expression by 20 fold, the purified reovirus dsRNA did not induce pIgR mRNA,
suggesting that extracellular dsRNA does not trigger TLR3 signaling in IECs (Fig. 3).

DISCUSSION
The first line of specific defense against invading mucosal pathogens is provided by
sIgA. The pIgR-mediated transport of IgA by IECs is very impressive resulting in the
daily delivery of 3 g of sIgA into the intestinal secretions of the average adult (11). A
number of factors including proinflammatory cytokines and microbial interaction
including reovirus modulates pIgR expression and thereby impact mucosal immunity.
This report describes efforts to understand the importance of dsRNA signature of reovirus
to enhance pIgR expression in HT-29 cells.

Several mechanisms could facilitate association of reovirus dsRNA with intracellular
PRRs including TLR3. Delivery of reovirus into acidified endosomes leads to viral
uncoating and formation of intermediate sub-viral particles (ISVP), which are
subsequently delivered to the cytoplasm. Although the dsRNA genome should be
protected within ISVP, it is possible that some dsRNA might be released within the
endosomal/lysosomal pathway. If TLR3 is present in endosomal vesicles, dsRNA
binding and signal transduction could be initiated following endosome-lysosome fusion
and acid activation (6). The intracellular distribution of TLR3 has not been examined in
detail, but immunofluorescence images of normal human IEC and dendritic cells suggest
that TLR3 is present intracellularly in endosomes (5,6,9) as well as possibly on the cell
surface (5,13). Alternatively, “naked” dsRNA from partially disassembled virions might
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be released from dying cells, providing an early warning system to adjacent uninfected
cells. The dsRNA can signal through TLR3 to activate IRF-3 and NFκB ultimately
leading to pIgR upregulation.

These studies were inconclusive for a role of viral dsRNA as an activator of pIgR
expression during virus infection and might suggest alternative mechanisms of activation.
Two apparently contradictory observations have been reported in this study. Poly I:C
induced pIgR mRNA expression in HT-29 cells suggesting a role for TLR3 mediated
viral dsRNA recognition in pIgR upregulation. However, purified reovirus dsRNA added
extracellularly to HT-29 cells failed to induce pIgR mRNA expression. Our data
demonstrated that reovirus dsRNA when incubated with HT-29 cells was not degraded.
Why extracellular reovirus dsRNA did not induce pIgR expression could be explained in
the following ways. First, extracellular reovirus dsRNA may not get access to cell
surface TLR3. Second, even if reovirus dsRNA binds to TLR3 on surface, we do not
know if extracellular TLR is functional and capable of signaling. Third, there are no cell
surface-expressed TLR3 on HT-29 cells with which reovirus dsRNA can interact and
tranduce signals. Although prolonged stimulation with poly I:C leads to cell surface
expression of TLR3 (13), it is possible that under our experimental conditions in the
absence of pre-stimulation with poly I:C, HT-29 cells did not express extracellular TLR3
. Fourth, extracellular ‘naked’ reovirus dsRNA is not endocytosed by HT-29 cells in
which case it may interact with intracellular TLR3. It is likely that both poIy I:C and
purified dsRNA exerts its effect in inducing pIgR expression via interaction with
intracellular TLR3. Although poly I:C is added extracellularly, it might diffuse non-
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specifically through cell membrane and thus excites intracellular TLR3 but extracellular
‘naked’ dsRNA fails to enter cell. Thus, the results with poly I:C support an important
role for dsRNA-TLR3 signaling in virus-mediated pIgR upregulation and negative
findings with extracellular reovirus dsRNA does not rule out the importance of viral
genome in the process. Future experiments will be required to test the hypothesis that
reovirus mediated up-regulation of pIgR expression occurs through TLR3 signaling. It is
possible to transfect the dsRNA or modify it for endocytic uptake and assess pIgR
upregulation in HT-29 cells. In addition cells can be transfected with TIR-deleted TLR3
or dominant negative TRIF or si RNA to TLR3 to examine the involvement of TLR3 and
its downstream adaptor molecules in pIgR upregulation.
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Fig. 1. Poly I:C upregulates pIgR mRNA expression in HT-29 cells. Confluent monolayers of HT-29
cells were cultured at 37°C for 24 h in the presence or absence of UV inactivated T3/D or poly I:C. 24h
post treatment pIgR mRNA levels were quantified by real-time RT-PCR and normalized to β-actin mRNA.
Samples were analyzed in duplicate to minimize error. Data are combined from 3 independent experiments
and expressed as fold-increase in pIgR mRNA in response to reovirus or poly I:C compared to cells
receiving no treatment (mean ± SEM). Asterisks indicate that the mean is significantly different from that
of control cells (no treatment with virus or poly I:C) as determined by one-way ANOVA followed by
Tukey’s test (p< 0.050).
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Fig. 3. Extracellular reovirus dsRNA does not upregulate pIgR mRNA expression in HT-29 cells.
Confluent monolayers of HT-29 cells were cultured at 37°C for 24 h in the presence or absence of UV
inactivated T3/D or reovirus dsRNA (148μg/ml) or UV-inactivated dsRNA (148μg/ml). Culture conditions
were optimized so that dsRNA was not degraded after 1 hour of initial addition to media. Following
incubation pIgR mRNA levels were quantified by real-time RT-PCR and normalized to β-actin mRNA.
Samples were analyzed in duplicate to minimize error. Data are expressed as fold increases in pIgR mRNA
in response to reovirus. Data are representative of two independent experiments.
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INTRODUCTION

In the previous studies we demonstrated that reovirus upregulates pIgR expression in
transformed lung and intestinal epithelial cell lines and characterized a number of
underlying signal transduction mechanisms involved in reovirus-mediated pIgR
upregulation. But the important biological question is whether reovirus upregulates pIgR
in vivo because it leads to an understanding of how non-lymphoid cells mount innate
immune responses that amplify or synergize with the adaptive response. Hooper et al. (4)
demonstrated that pIgR expression was increased in germfree mice following
colonization with commensal bacteria. Other studies demonstrated that pIgR expression
is upregulated following weaning, and is under partial control of adaptive immunity (5).
A number of cytokines including IFN-γ (1,2), TNF-α, IL-1β (3) and IL-4 (1,2,7) have
been shown to increase pIgR expression in epithelial cells but the contribution in vivo of
specific cytokines versus the pathogen itself to pIgR expression is not known. So it is
reasonable to hypothesize that reovirus infection and the subsequent production of Th1
cytokines such as IFN-γ and TNF-α upregulates pIgR in vivo, which can increase IgA
production in secretions and contribute to host defense. The first step to further these
studies includes comparison of pIgR expression levels in intestine of naïve and reovirus
infected mice as reported in Chapter 5.
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METHODS

Animals and infections. Male Balb/c mice were purchased from Charles River
Laboratories, Inc. (Wilmington, MA). Mice were housed under specific-pathogen-free
conditions in micro-isolater cages and used between the ages of 3 and 4 weeks. Mice
were treated in accordance with West Virginia University laboratory animal guidelines.
Germ free mice were raised in special germ free facility in University of Pennsylvania,
PA and infection of mice and subsequent collection of intestinal tissues were conducted
in Late Dr. John Cebra’s laboratory at U. Penn. Reovirus serotype 3, strain Dearing
(T3/D) was purified according to previous protocols (6). Mice were infected orally with
reovirus T3/D at doses of 107-108 plaque forming units (pfu) diluted in 50 μl boratebuffered gelatin, using 20-gauge feeding needles.

Collection of mouse intestine. Small intestines were removed from mice and intestine
was cut longitudinally and then approximately 2 cm segments were cut from duodenum,
jejunum and ileum. Intestinal contents were removed by thoroughly washing in HBSS
supplemented with 10 mM HEPES and 0.35 g/L NaHCO3. Each intestinal segment was
transferred to tubes containing 0.5 ml of RNALater™ (Ambion, Inc Austin, TX) to
stabilize RNA in tissues and held on ice till RNA isolation or stored at –80 °C.

RNA extraction and quantitative RT-PCR for mouse pIgR mRNA. Approximately
35 μg pieces of intestinal tissues in RNALater™ were homogenized sequentially by
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mechanical disruption in Buffer RLT (Qiagen, Valencia, CA) followed by
homogenization using Qiashredders™ (Qiagen). Total RNA isolation was performed
using RNeasy® mini /RNase-free DNase set (Qiagen) following manufactures protocols.
RNA was quantified by spectrophotometry at 260/280 nm. RNA was reverse transcribed
into cDNA using Superscript TM RNase H- Reverse Transcriptase (Invitrogen Life
Technologies, Carlsbad, CA) in a Genius thermocycler (Techne, Inc, Princeton, NJ)
according to manufacturer’s protocols. Real-time PCR was performed using a
Lightcycler (Roche Molecular Biochemicals, Indianapolis, IN). Taqman® primers and
probes for mice pIgR (from Applied Biosystems, Foster City, CA) were produced using
published sequences (Blanch et al., 1999) and mouse GAPDH was obtained from
Biosource International Inc. (Camarillo, CA). Reactions were carried out in a total
volume of 20 μl. PCR conditions were optimized for mouse pIgR primer pair as follows:
enzyme activation for 1 cycle at 50 °C for 2 minutes followed by 95 °C for 10 minutes;
amplification for 45 cycles at 94 °C for 45 s followed by 61 °C for 45 s and then 72°C for
110 s; cool down for 1 cycle at 40 °C for 1 minute. PCR conditions were optimized for
mouse GAPDH primer pair as follows: enzyme activation for 1 cycle at 50 °C for 2
minutes followed by 95 °C for 10 minutes; amplification for 45 cycles at 94 °C for 30 s
followed by 60 °C for 1 minute; cool down for 1 cycle at 40 °C for 1 minute. Data were
analyzed by determining ‘crossing points’ or the cycle number at which newly
synthesized PCR product is first detected. Samples were analyzed in duplicate. pIgR
expression was normalized with respect to β-actin expression by subtracting the β-actin
crossing point from the pIgR crossing point for each sample. The fold induction of pIgR
in virus-treated mice compared to the control was determined using the equation: Fold
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change = KgeneΔCp, where Kgene is the amplification coefficient for the pIgR gene and
ΔCp is the difference in crossing point between the normalized non-treated and virustreated mice (Schjerven et al., 2000). The theoretical value of Kgene = 2 was used for data
analysis.

RESULTS AND DISCUSSION
To determine if reovirus modulates expression of pIgR in intestine following oral
infection, mRNA levels for pIgR in different segments of intestine was assessed by
quantitative RT-PCR. In adult mice, no apparent difference in pIgR mRNA expression
was detected 48 hours post infection (Table 1). In germ free mice, no difference in pIgR
levels was observed in any region of intestine including duodenum, jejunum and ileum 3day post infection. Interestingly, pIgR mRNA was upregulated approximately 3-fold by
7 days after infection in the ilea from infected mice compared to non-infected age
matched mice while a 2 fold decrease was observed in the ilea 4 days post infection (Fig.
1). These preliminary data suggest that immunologically competent but naïve intestinal
epithelium can respond to enteric infection with reovirus.

The gut of conventional mice harbors a plethora of commensal microbes that are well
tolerated by mucosal immune system. It is reasonable to speculate that in response to the
presence of microbes and their metabolic products, the IECs in conventional mice
express high level of pIgR and so it becomes a challenge to measure any further increase
in pIgR expression when another pathogen such as reovirus is introduced in these mice.
However, if pIgR expression in IECs is modulated by microbial interactions, then it is
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possible to measure such change in pIgR expression in germ free mice that have a naïve
quiescent gut environment. Hooper et al. reported a 2-4-fold increase in the pIgR mRNA
expression when the gut of germ free mice is colonized with commensal bacterial
Bacteroides thetaiotaomicron (4), which is consistent with the observation made in this
study.

Table 1: Expression of pIgR and GAPDH mRNA in mouse intestine 48 hours post infection with
reovirus.

SAMPLES

MOUSE PIGR C.P.

GAPDH C.P.

FOLD CHANGE

Control / D

24.8 *

21.8

Control / J

27.1

21.8

Control / I

24.5

22.1

Reovirus / D

24.6

21.1

Reovirus / J

25.8

20.8

1.2

Reovirus / I

24.2

20.6

-2.3

-1.4 **

*Data are represented as average of crossing points (C.P.) from 2 control mice and 3 infected mice.
D= Duodenum, J= Jejunum, I= Ileum.
** The fold induction of pIgR in virus-treated mice compared to the control was determined using the
equation: Fold change = KgeneΔCp, where Kgene is the amplification coefficient for the pIgR gene and
ΔCp is the difference in crossing point between the normalized non-treated and virus-treated mice
(Schjerven et al., 2000).
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Fig. 1. Expression of pIgR mRNA in germfree mice. Germfree mice were mock infected or infected
with reovirus T3/D and duodenum, jejunum, and ileum was analyzed for pIgR mRNA expression by real
time quantitative RT-PCR. Samples were analyzed in duplicate to minimize error. Data are expressed as
fold change in pIgR mRNA in response to reovirus. Data is from a single experiment.
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CHAPTER 6: GENERAL DISCUSSION

Enteric viruses including rotavirus, calicivirus (including noroviruses and sapporovirus),
astrovirus, and adenovirus are the major cause of gastrointestinal diseases in humans
(260,282). Gastrointestinal disease is the second most common cause of morbidity
throughout the world after acute upper respiratory tract (URT) infections. Diarrhea is not
as dramatic an illness as Acquired Immunodeficiency Syndrome (AIDS) but it continues
to be a major cause of morbidity and mortality worldwide resulting in an estimated 1000
deaths among children each day (125,126). An estimate of the number of diarrheal
episodes in children below 5 years of age in Africa, Latin America and Asia for a 1 year
period indicated more than 450 million cases of diarrhea occurred and that 1-4% were
fatal, ranking diarrhea first among infectious diseases in the categories of both frequency
and mortality in children (98,206,219).

Human enteric viruses represent a diverse group. However, most of them are nonenveloped RNA viruses. Rotavirus and Norovirus are the two common agents that cause
acute gastroenteritis (389). Rotaviruses are the most common cause of severe diarrhea
worldwide (282). In addition, Centers for Disease Control (CDC) estimates that 23
million cases of acute gastroenteritis are due to norovirus infection, and at least 50% of
all food borne outbreaks of gastroenteritis can be attributed to highly contagious
noroviruses. Symptoms range from gastroenteritis to more life threatening diseases such
as myocarditis and aseptic meningitis (228). The burden of diarrheal disease caused by
these enteric viruses are of great economic importance, causing millions of lost working
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days each year to mini-epidemics in families, hospital wards and rural villages in
developing countries. Enteric viruses contribute to massive mortality caused by infantile
diarrhea in developing countries where infections may be exacerbated by malnutrition,
unsanitary conditions and / or be favored by co-infection with other enteropathogens
(124,127,218). Transmission of these enteric viruses occurs primarily through the oralfecal route. However, other routes including foodborne and waterborne transmission
potentially via contaminated water exist. The proportion that is directly food borne or
waterborne is unclear, but it is likely to be substantial. One well-documented source of
food-borne infection is consumption of shellfish polluted by sewage (13).

Relatively little is known about different aspects of enteric virus infection, in part because
many enteric viruses are difficult to grow in cell culture and few animal models of
infection exist for elucidating mechanisms of anti-viral host defense in the intestine.
However it is transparent that these enteric human pathogens dramatically affect public
health and significantly impact economy worldwide. Thus, eliminating enteric infection
in children is a desirable goal. On the other hand, there have been dramatic increases in
allergic diseases in children living in developed countries where there are reduced
episodes of severe gastrointestinal infections by pathogens including viruses. This
association has contributed to the ‘Hygiene Hypothesis’, which suggests that the
decreased incidences of mucosal infection early in life reduce the ability of the immune
system to mature properly and increases the susceptibility to allergic responses (313,314).
Therefore, there is a need for intensive research to understand virus-host interactions and
the ensuing immune responses following infection with enteric viruses, particularly in
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immunologically immature individuals. Such work will contribute to better management
of chronic diarrhea, which is a persistent threat in developing countries and of great
economic significance in developed countries. In addition, research in this area hold the
promise of development of novel therapies including designing of efficacious vaccines
for infantile diarrhea and utilizing reovirus to ‘mature’ the mucosal immune system to
improve the efficacy of enteric virus targeted vaccines that are given early in life.

Reovirus infection in mice is an excellent model to study host-pathogen interactions, in
part because experimental reovirus infection induces a spectrum of pathologies
resembling diseases caused by enteric viruses and thus serves as a probe to understand
mucosal immunity. Rotavirus belongs to the virus family Reoviridae, which also include
Orthoreovirus (commonly called reovirus) that infect the human gastrointestinal and
respiratory tracts.

The intestinal immune system has evolved under the contradictory pressures of protecting
the host epithelium from potential pathogenic threats and tolerating the co-existence of
myriad commensal organisms in lumen. The IECs are an integral component of the
intestinal immune system and the power to recognize and discriminate between nefarious
pathogens and friendly commensals hold the key to maintaining a state of controlled
inflammation in the gut (139,333). IECs act at the interface between the innate and
acquired immune responses to microorganisms in the gastrointestinal tract. IECs mount
innate responses upon direct contact with microbes or their metabolic products resulting
in production of antimicrobial substances that fight infection directly, and secretion of
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chemokines and cytokines that enhance acquired, antigen-specific immune responses. A
hallmark feature of adaptive mucosal immune responses is production and secretion of
sIgA. During the response, pIgA antibodies or the empty receptor is transcytosed across
secretory epithelia by the pIgR expressed on the basolateral surface of IECs producing
sIgA and FSC in intestinal secretions. The rate of IgA transcytosis depends on the level
of pIgR expression because one molecule of pIgR must be synthesized for each molecule
of transported IgA. Thus, pIgR plays a role in mucosal host defense, and factors that
influence expression of pIgR affect mucosal immunity. Expression of the PIGR gene is a
significant developmental response by epithelial cells that appears to be under the control
of multiple environmental factors including infection. Signaling induced by microbes
and their products may serve to augment pIgR-mediated transcytosis of IgA, linking the
innate and acquired immune responses to viruses and bacteria. Both FSC and sIgA
contribute to clearance of infection and thus maintain integrity of the mucosal barrier.
Therefore it was very logical to conduct research to further the understanding of
regulation of pIgR expression by IECs during enteric virus infection and evaluate how
IECs respond to assault by reovirus. The experiments reported in this dissertation
confirm that a newly appreciated role of the IECs in sensing the mucosal pathogen
reovirus is upregulation of pIgR expression by IECs, which serves as an innate host
defense mechanism that subsequently affect the development of antigen-specific adaptive
immune responses.

The work reported in this dissertation demonstrated that reovirus upregulates pIgR
mRNA and protein expression in IECs in a replication independent fashion and that
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binding of virus to cellular receptors and partial disassembly of virus inside acidified
endosomes are required steps for this innate immune response by IECs. How the host
cells respond to reovirus at a molecular level and upregulate expression of pIgR was a
very intriguing question. So, we sought to delineate the possible signaling events that are
triggered following interaction of reovirus with IECs that ultimately lead to upregulation
of pIgR expression by the host cells.

Reovirus infection triggers a number of signaling cascades including increased activation
of calpains, JNKand ERK (70,73,83). These signaling cascades result in activation of
NFκB and phosphorylation of c-Jun (69,70,73,131,383). In addition, extensive studies
have demonstrated that NFκB is a central regulator of the IEC response to infection with
enteric microbial pathogens and to proinflammatory cytokines including TNF-α and IL1. Although enteric microbial pathogens utilize a number of different strategies to
interact with or invade the IECs, they trigger signaling events in IECs that activate NFκB
and upregulate the expression of an array of NFκB responsive genes and their products
including proinflammatory cytokines, antimicrobial peptides and chemotactic cytokines
(29,93,160,276). We conducted a series of studies to investigate whether epithelial cell
NFκB signaling mediate upregulation of pIgR expression during reovirus infection. The
major pathway leading to NFκB activation comprises inducible degradation of its
cytosolic repressor IκB, which releases NFκB and allows it to shuttle to nucleus (87,177).
The findings reported in this dissertation suggest that reovirus activates NFκB either
directly or via a calpain-mediated pathway that ultimately degrades IκB. In addition,
promoter analysis studies suggested that reovirus enhances PIGR gene transcription by
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binding activated NFκB and IRF-1 to their respective cognate sites of the pIgR promoter
resulting in increased expression of pIgR by IECs.

NFκB is known to regulate the transcription of genes that are proinflammatory and
required for host innate immunity and defense and those that are anti-apoptotic
(93,177,178,217). The anti-apoptotic role of NFκB is evident from the ability of this
transcription factor to prevent TNF-α induced apoptosis in several experimental models
and IECs (26,222,250,309,387). Cellular transcription factors are often targeted by viral
pathogens to modulate host cell signaling events and influence cell fate. Multiple family
of viruses including human immunodeficiency virus type 1 (HIV-1) (324), human T-cell
lymphotropic virus (361), hepatitis B virus, hepatitis C virus (363,364,408), rotavirus
(59), and influenza virus (291,292) activate NFκB to promote viral replication and
prevent virus-induced apoptosis. However, NFκB activation also induces immune
responses to infecting virus. NFκB can also be activated by the chemical analog of viral
dsRNA, poly I:C, suggesting that dsRNA viruses or viruses that generate dsRNA
intermediates can exploit various aspects of NFκB biology. Recently, it has been shown
that dsRNA-activated serine threonine protein kinase, PKR is involved in dsRNAinduced NFκB activation. PKR is an important mediator of poly I:C induced NFκB
signaling that involved sequential activation of NIK and IKK leading to degradation of
IκB (415). This dsRNA-PKR mediated activation of NFκB can be particularly important
in reovirus-induced pIgR upregulation in IECs because PKR is activated in response to
dsRNA signature in reovirus infected cells. It makes perfect sense that reovirus
replication in vivo is restricted to the immature Ras positive cells of intestinal crypts as
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Ras or a downstream component of Ras signaling pathway blocks activation of PKR and
thus permits viral replication and translation. Now, we know that viruses by blocking
PKR activation inhibit NFκB activation that could trigger inflammatory and immune
responses including upregulation of pIgR expression by host against invading pathogens.

Clarke et al. reported that reovirus infection induces two distinct phases of NFκB
regulation, which are required to efficiently activate virus-induced apoptosis in host cells.
In the first phase, 2-4 hours post infection; NFκB is activated followed by inhibition of
NFκB activation at later times post infection (69). This dual phase of NFκB regulation
has serious consequences for the reovirus and host epithelial cells. NFκB activation has
an anti-apoptotic effect on host cells that provides reovirus enough time to establish
infection. In addition, the ability of reovirus to block NFκB activation at later times post
infection promotes virus-induced apoptosis in host cells that might serve to increase virus
spread. Some viruses including Sindbis virus and Dengue virus are known to activate
NFκB and utilize NFκB induced apoptosis of host cell to spread infection (161,220). On
the other hand, our studies have demonstrated that reovirus upregulates pIgR expression
via an NFκB mediated pathway, suggesting that activation of this transcription factor
promotes host immune responses to reovirus. So the paradoxical question is whether
NFκB activation is beneficial to the host or does it favor the virus? It can be reasoned
that the anti-apoptotic effects of NFκB activation is important for both the virus and the
host because a delay in the onset of apoptosis by host cells allows the virus to adapt to
cellular environment and establish infection while providing sufficient time for the
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epithelial cells to generate signals leading to induction of immune responses including
upregulation of pIgR, against the invading pathogen.

Although, reovirus mediated upregulation of pIgR occurs primarily via NFκB activation,
it is possible that other signaling pathways including TLRs and RNA helicases might be
involved. Since reovirus is a dsRNA-containing virus, analysis of additional signal
transduction pathways in IECs that recognize dsRNA as pathogen-associated signatures
might be relevant. The finding that endocytosis of reovirus and subsequent acidification
of endosomes in intestinal epithelial cell line HT-29 was a required step in pIgR
upregulation suggests a role for viral disassembly in the process. It is possible that
following degradation in the endosomes, liberated viral dsRNA interacts with
intracellular TLR-3 to induce intracellular signals that lead to pIgR up-regulation. TLR-3
is constitutively expressed in human IECs, although the precise intracellular location of
TLR-3 has not yet been identified (54,55,56,338). Thus, TLR-3 signaling in response to
reovirus dsRNA might be initiated following fusion of endosomes containing reovirus
dsRNA from degraded virions with cellular vesicles containing TLR-3.

Experiments reported in Chapter 4 of this dissertation demonstrated upregulation of pIgR
expression by poly I:C, chemical analog of viral dsRNA and not by extracellular dsRNA
purified from reovirus. These contradictory results could be explained by the fact that
poly I:C diffuses non-specifically inside cells and exert its effect in upregulating pIgR
expression by stimulating intracellular TLR3. However, extracellular dsRNA incubated
with cells under conditions where the RNA was intact still failed to elicit similar response
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because of the inability of cells to endocytose ‘naked’ dsRNA or lack of interaction with
surface expressed TLR3. Overall these studies indicate responsiveness of IECs to poly
I:C and imply that the viral dsRNA - TLR3 pathway might be involved in pIgR
upregulation. In addition, during virus replication it is possible that dsRNA synthesized
inside newly formed capsids is shielded from intracellular TLR-3. Therefore an
alternative activation pathway such as through TLR-8, which recognizes viral ssRNA
might be responsible for the observed effects (91,140). Alternatively, reovirus dsRNA
may trigger cellular responses via a TLR –independent mechanism. Double stranded
RNA may bind to the cellular RNA helicase, retinoic acid-inducible gene-1 (RIG-1) or
melanoma differentiation-associated gene 5 (mda-5) and subsequently activate latent
transcription factors including IRF 3 and NFκB (6,174,216,359). However, further
experimentation will be required to test these hypotheses and gain a full understanding of
spectrum of pathways involved in modulation of pIgR expression by IECs in response to
pathogenic interactions.

Knowing that reovirus upregulates pIgR expression in transformed lung and intestinal
epithelial cell lines, we addressed the important biological question and this is whether
reovirus upregulates pIgR expression in vivo. This is an important question because it
leads to an understanding of how non –lymphoid cells initiate immune responses that
amplify or synergize with the antigen-specific adaptive response. Studies by Hooper et
al. suggest that commensal bacteria can induce pIgR expression in vivo (150). Other
studies demonstrated that pIgR expression is upregulated during weaning, and is under
partial control of adaptive immunity (163). Although a number of cytokines have been
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well documented to increase pIgR expression in vitro, the contribution of specific
cytokines versus reovirus itself in pIgR upregulation in vivo is not known. In addition,
enteric reovirus infection in germfree and neonatal mice stimulate the development of
germinal centers and induces virus –specific and ‘bystander’ IgA responses, suggesting
that the pathogen stimulate immunologically competent but naïve mucosal tissues, which
respond by initiating innate immune responses in IECs that shape the nature of
subsequent adaptive immunity (197,398). The preliminary in vivo experiments reported
in Chapter 5 of this dissertation indicates that pIgR mRNA expression is upregulated in
germfree but not conventionally reared adult mice following oral reovirus infection.
Why a change in pIgR expression could be measured in germ free mice but not in
conventional mice has been discussed in details in Chapter 5. Overall, it seems that
commensal and pathogenic microorganisms can upregulate pIgR expression by signaling
through IECs, which serves to bridge the innate and adaptive immune responses at
mucosal surfaces. Future work on pIgR expression during virus infection in vivo will
advance our understanding of the way that innate responses are regulated by adaptive
responses in the intestine, and will provide much needed in vivo correlates to
observations initially made in vitro using transformed intestinal epithelial cell lines.
Future in vivo studies in germfree and neonatal mice should aim to understand the
contribution of the virus itself or cytokines induced in mucosal virus infection to
upregulate intestinal pIgR expression.

Studies with the pIgR knockout mice model have demonstrated the specific requirement
of sIgA in mucosal homeostasis and protection at mucosal surfaces (167,348). Although
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pIgR knockout mice lack mucosal Igs, they accumulate pIgA in circulation at levels of
100-fold higher than wild type mice (385). However, pIgR knockout mice demonstrated
the importance of pIgR / sIgA for the protection of gastrointestinal surfaces against
secreted bacterial toxins including cholera toxin (386). Sun et al. demonstrated the
critical role of pIgR / sIgA in protection against nasal colonization by S. pneumoniae in
pIgR knockout mice (360). In addition, chronic inflammatory mucosal disorders
including celiac disease, Helicobacter pylori gastritis, and Sjogren’s syndrome increase
pIgR synthesis likely under the influence of inflammatory mediators including TNFα and IFN-γ (49). Murthy et al. demonstrated an important role for pIgR / sIgA in
controlling colonic inflammation during dextran sulphate sodium (DSS) induced colitis in
pIgR knockout mice. PIgR knockout mice displayed greater mucosal ulceration,
inflammation, edema and necrosis compared to wild type suggesting an
immunoregulatory role for pIgR and / or FSC at mucosal surfaces in controlling
inflammation and maintaining integrity of epithelial barrier (Murthy et al., Journal of
Gastroenterology and Hepatology, 2006, In Press).

Interestingly, pIgR can play a dual role in host defense as well as pathogen entry. In vitro
studies by Zhang et al. have confirmed that pIgR can translocate Streptococcus
pneumoniae across human nasopharyngeal epithelial cells. Human pIgR can bind to a
major pneumococcal adhesin, choline binding protein A (CbpA) and the whole complex
can then be endocytosed and transcytosed in a retrograde fashion, suggesting that
mucosal pathogens like pneumococci may co-opt the pIgR transcytosis machinery to
breach the epithelial barrier (410). It has been demonstrated that human pIgR via
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domains 3 and 4 bind to hexapeptide motif in the choline-binding protein SpsA of S.
pneumoniae (95,227). The SpsA-pIgR interaction mediates adherence and internalization
of the human pathogen into epithelial cells (95,133,134,227). Whether a similar
mechanism of retrograde transcytosis of pIgR is utilized by reovirus to enter IECs from
apical surface is an important question that can be addressed in future studies. It will be
very intriguing to determine if pIgR is the ‘defender of the fort’ or it may present itself as
a ‘Trojan horse’ for reovirus to hitch a ride from intestinal lumen in the mucosal
epithelium. The fact that pIgR can also facilitate pathogen entry, raises the question of
whether pIgR is a host virulence factor, rather than an innate defense molecule. The
apical-to-basolateral transcytosis of pIgR is rather inefficient and presence of FSC and
sIgA in secretions should limit binding and retrograde transport of pathogens in IECs.
However, an imbalance in any of these factors, or an overwhelming infection might favor
pIgR-mediated retrograde transcytosis and invasion of IECs. So, in reality, whether pIgR
is exclusively a component of innate immunity or might function as a host virulence
factor in reovirus infection of IECs is an open question. Considering, the unconventional
role of pIgR as a virulence factor, the findings of reovirus-mediated pIgR upregulation in
IECs might rather promote viral pathogenesis than reinforcing host defense.

Expression of PIGR gene is a significant developmental response by epithelial cells that
appears to be under the control of multiple environmental factors including infection. We
have demonstrated that infection with an enteric pathogen, reovirus enhances PIGR gene
transcription leading to upregulation of pIgR expression by IECs. It can be speculated
that manipulation of pIgR expression early in life could provide means to improve innate
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resistance to mucosal infection, improve the efficacy of mucosal vaccines administered
early in life, or improve the ability of the developing mucosal immune system to regulate
itself properly. In the long term, one could propose innovative therapies using reovirus,
either active or inactive, which ‘mature’ the mucosal immune system, particularly in
infants. The outcomes of such therapy could result in improvement of the efficacy of
mucosal vaccines or stimulate mucosal immune responses in infants. A ‘mature’ immune
system in infants helps to combat the development of immunologic abnormalities such as
dysregulated responses that could lead to allergies and / or autoimmune diseases that
result from a lack of antigenic exposure early in life. Overall, this research will influence
approaches to designing novel vaccines and therapeutics targeted against enteric virusmediated diseases including diarrhea that will greatly impact and improve public health,
will deepen the understanding of IEC biology, host-virus interactions and ensuing innate
and adaptive immune responses particularly in the intestinal tract.

159

GENERAL REFERENCES

1. Ackermann, L. W., L. A. Wollenweber, and G. M. Denning. 1999. IL-4 and
IFN-gamma increase steady state levels of polymeric Ig receptor mRNA in
human airway and intestinal epithelial cells. J Immunol 162:5112-5118.
2. Acs, G., H. Klett, M. Schonberg, J. Christman, D. H. Levin, and S. C.
Silverstein. 1971. Mechanism of reovirus double-stranded ribonucleic acid
synthesis in vivo and in vitro. J Virol. 8:684-689.
3. Alain, T., K. Hirasawa, K. J. Pon, S. G. Nishikawa, S. J. Urbanski, Y. Auer,
J. Luider, A. Martin, R. N. Johnston, A. Janowska-Wieczorek, P. W. Lee,
and A. E. Kossakowska. 2002. Reovirus therapy of lymphoid malignancies.
Blood 100:4146-4153.
4. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001.
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like
receptor 3. Nature 413:732-738.
5. Amerongen, H. M., G. A. Wilson, B. N. Fields, and M. R. Neutra. 1994.
Proteolytic processing of reovirus is required for adherence to intestinal M cells. J
Virol. 68:8428-8432.
6. Andrejeva, J., K. S. Childs, D. F. Young, T. S. Carlos, N. Stock, S.
Goodbourn, and R. E. Randall. 2004. The V proteins of paramyxoviruses bind
the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta
promoter. Proc. Natl. Acad. Sci. U. S. A 101:17264-17269.
7. Apodaca, G., L. A. Katz, and K. E. Mostov. 1994. Receptor-mediated
transcytosis of IgA in MDCK cells is via apical recycling endosomes. J. Cell Biol.
125:67-86.
8. Armitage, R. J., W. C. Fanslow, L. Strockbine, T. A. Sato, K. N. Clifford, B.
M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R.
160

Maliszewski, and . 1992. Molecular and biological characterization of a murine
ligand for CD40. Nature 357:80-82.
9. Armitage, R. J., C. R. Maliszewski, M. R. Alderson, K. H. Grabstein, M. K.
Spriggs, and W. C. Fanslow. 1993. CD40L: a multi-functional ligand. Semin.
Immunol 5:401-412.
10. Aroeti, B. and K. E. Mostov. 1994. Polarized sorting of the polymeric
immunoglobulin receptor in the exocytotic and endocytotic pathways is controlled
by the same amino acids. EMBO J. 13:2297-2304.
11. Asahi, Y., T. Yoshikawa, I. Watanabe, T. Iwasaki, H. Hasegawa, Y. Sato, S.
Shimada, M. Nanno, Y. Matsuoka, M. Ohwaki, Y. Iwakura, Y. Suzuki, C.
Aizawa, T. Sata, T. Kurata, and S. Tamura. 2002. Protection against influenza
virus infection in polymeric Ig receptor knockout mice immunized intranasally
with adjuvant-combined vaccines. J Immunol 168:2930-2938.
12. Asahi-Ozaki, Y., T. Yoshikawa, Y. Iwakura, Y. Suzuki, S. Tamura, T.
Kurata, and T. Sata. 2004. Secretory IgA antibodies provide cross-protection
against infection with different strains of influenza B virus. J Med. Virol. 74:328335.
13. Ashbolt, N. J. 2004. Microbial contamination of drinking water and disease
outcomes in developing regions. Toxicology 198:229-238.
14. Bach, S. P., A. G. Renehan, and C. S. Potten. 2000. Stem cells: the intestinal
stem cell as a paradigm. Carcinogenesis 21:469-476.
15. Bakos, M. A., A. Kurosky, and R. M. Goldblum. 1991. Characterization of a
critical binding site for human polymeric Ig on secretory component. J Immunol
147:3419-3426.
16. Bakos, M. A., S. G. Widen, and R. M. Goldblum. 1994. Expression and
purification of biologically active domain I of the human polymeric
immunoglobulin receptor. Mol. Immunol 31:165-168.
17. Bals, R., X. Wang, Z. Wu, T. Freeman, V. Bafna, M. Zasloff, and J. M.
Wilson. 1998. Human beta-defensin 2 is a salt-sensitive peptide antibiotic
expressed in human lung. J Clin Invest 102:874-880.
161

18. Barkon, M. L., B. L. Haller, and H. W. Virgin. 1996. Circulating
immunoglobulin G can play a critical role in clearance of intestinal reovirus
infection. J Virol. 70:1109-1116.
19. Barton, E. S., J. D. Chappell, J. L. Connolly, J. C. Forrest, and T. S.
Dermody. 2001. Reovirus receptors and apoptosis. Virology 290:173-180.
20. Barton, E. S., J. L. Connolly, J. C. Forrest, J. D. Chappell, and T. S.
Dermody. 2001. Utilization of sialic acid as a coreceptor enhances reovirus
attachment by multistep adhesion strengthening. J Biol. Chem. 276:2200-2211.
21. Barton, E. S., J. C. Forrest, J. L. Connolly, J. D. Chappell, Y. Liu, F. J.
Schnell, A. Nusrat, C. A. Parkos, and T. S. Dermody. 2001. Junction adhesion
molecule is a receptor for reovirus. Cell 104:441-451.
22. Barton, E. S., B. E. Youree, D. H. Ebert, J. C. Forrest, J. L. Connolly, T.
Valyi-Nagy, K. Washington, J. D. Wetzel, and T. S. Dermody. 2003.
Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary
disease. J Clin. Invest 111:1823-1833.
23. Barton, G. M. and R. Medzhitov. 2003. Toll-like receptor signaling pathways.
Science 300:1524-1525.
24. Bass, D. M., D. Bodkin, R. Dambrauskas, J. S. Trier, B. N. Fields, and J. L.
Wolf. 1990. Intraluminal proteolytic activation plays an important role in
replication of type 1 reovirus in the intestines of neonatal mice. J Virol. 64:18301833.
25. Beaulieu, J. F., P. H. Vachon, and S. Chartrand. 1991. Immunolocalization of
extracellular matrix components during organogenesis in the human small
intestine. Anat. Embryol. (Berl) 183:363-369.
26. Beg, A. A. and D. Baltimore. 1996. An essential role for NF-kappaB in
preventing TNF-alpha-induced cell death. Science 274:782-784.
27. Bell, J. K., I. Botos, P. R. Hall, J. Askins, J. Shiloach, D. M. Segal, and D. R.
Davies. 2005. The molecular structure of the Toll-like receptor 3 ligand-binding
domain. Proc. Natl. Acad. Sci. U. S. A 102:10976-10980.

162

28. Bell, J. K., G. E. Mullen, C. A. Leifer, A. Mazzoni, D. R. Davies, and D. M.
Segal. 2003. Leucine-rich repeats and pathogen recognition in Toll-like receptors.
Trends Immunol 24:528-533.
29. Berin, M. C., M. B. Dwinell, L. Eckmann, and M. F. Kagnoff. 2001.
Production of MDC/CCL22 by human intestinal epithelial cells. Am. J Physiol
Gastrointest. Liver Physiol 280:G1217-G1226.
30. Berneman, A., L. Belec, V. A. Fischetti, and J. P. Bouvet. 1998. The specificity
patterns of human immunoglobulin G antibodies in serum differ from those in
autologous secretions. Infect. Immun. 66:4163-4168.
31. Bjercke, S. and P. Brandtzaeg. 1993. Glandular distribution of
immunoglobulins, J chain, secretory component, and HLA-DR in the human
endometrium throughout the menstrual cycle. Hum. Reprod. 8:1420-1425.
32. Bjerknes, M. and H. Cheng. 1981. The stem-cell zone of the small intestinal
epithelium. I. Evidence from Paneth cells in the adult mouse. Am. J Anat. 160:5163.
33. Bjerknes, M. and H. Cheng. 1981. The stem-cell zone of the small intestinal
epithelium. II. Evidence from paneth cells in the newborn mouse. Am. J Anat.
160:65-75.
34. Blanch, V. J., J. F. Piskurich, and C. S. Kaetzel. 1999. Cutting edge: coordinate
regulation of IFN regulatory factor-1 and the polymeric Ig receptor by
proinflammatory cytokines. J. Immunol. 162:1232-1235.
35. Bodkin, D. K., M. L. Nibert, and B. N. Fields. 1989. Proteolytic digestion of
reovirus in the intestinal lumens of neonatal mice. J Virol. 63:4676-4681.
36. Bomsel, M., M. Heyman, H. Hocini, S. Lagaye, L. Belec, C. Dupont, and C.
Desgranges. 1998. Intracellular neutralization of HIV transcytosis across tight
epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity. 9:277287.
37. Bomsel, M. and K. E. Mostov. 1994. Both the Gs alpha and beta gamma
subunits of the heterotrimeric G protein, Gs, control the sorting of the polymeric
immunoglobulin receptor into transcytotic vesicles. Biochem. Soc. Trans. 22:463468.
163

38. Bonizzi, G. and M. Karin. 2004. The two NF-kappaB activation pathways and
their role in innate and adaptive immunity. Trends Immunol 25:280-288.
39. Borsutzky, S., B. B. Cazac, J. Roes, and C. A. Guzman. 2004. TGF-beta
receptor signaling is critical for mucosal IgA responses. J Immunol 173:33053309.
40. Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49:46824689.
41. Bouvet, J. P. and V. A. Fischetti. 1999. Diversity of antibody-mediated
immunity at the mucosal barrier. Infect. Immun. 67:2687-2691.
42. Brandtzaeg, P. 1971. Human secretory immunoglobulins. II. Salivary secretions
from individuals with selectively excessive or defective synthesis of serum
immunoglobulins. Clin Exp. Immunol 8:69-85.
43. Brandtzaeg, P. 1973. Structure, synthesis and external transfer of mucosal
immunoglobulins. Ann. Immunol (Paris) 124:417-438.
44. Brandtzaeg, P. 1978. Polymeric IgA is complexed with secretory component
(SC) on the surface of human intestinal epithelial cells. Scand. J Immunol 8:3952.
45. Brandtzaeg, P. 1985. Role of J chain and secretory component in receptormediated glandular and hepatic transport of immunoglobulins in man. Scand. J
Immunol 22:111-146.
46. Brandtzaeg, P., A. E. Berstad, I. N. Farstad, G. Haraldsen, L. Helgeland, F.
L. Jahnsen, F. E. Johansen, I. B. Natvig, E. M. Nilsen, and J. Rugtveit. 1997.
Mucosal immunity--a major adaptive defence mechanism. Behring Inst. Mitt.123.
47. Brandtzaeg, P., I. N. Farstad, F. E. Johansen, H. C. Morton, I. N.
Norderhaug, and T. Yamanaka. 1999. The B-cell system of human mucosae
and exocrine glands. Immunol Rev. 171:45-87.

164

48. Brandtzaeg, P., I. Fjellanger, and S. T. Gjeruldsen. 1970. Human secretory
immunoglobulins. I. Salivary secretions from individuals with normal or low
levels of serum immunoglobulins. Scand. J Haematol. Suppl 12:3-83.
49. Brandtzaeg, P., T. S. Halstensen, H. S. Huitfeldt, P. Krajci, D. Kvale, H.
Scott, and P. S. Thrane. 1992. Epithelial expression of HLA, secretory
component (poly-Ig receptor), and adhesion molecules in the human alimentary
tract. Ann. N. Y. Acad. Sci. 664:157-179.
50. Branski, D., E. Lebenthal, H. Faden, T. F. Hatch, and J. Krasner. 1980. Small
intestinal epithelial brush border enzymatic changes in suckling mice infected
with reovirus type 3. Pediatr. Res. 14:803-805.
51. Bruno, M. E. and C. S. Kaetzel. 2005. Long-term exposure of the HT-29 human
intestinal epithelial cell line to TNF causes sustained up-regulation of the
polymeric Ig receptor and proinflammatory genes through transcriptional and
posttranscriptional mechanisms. J Immunol 174:7278-7284.
52. Bruno, M. E., R. B. West, T. A. Schneeman, E. H. Bresnick, and C. S.
Kaetzel. 2004. Upstream stimulatory factor but not c-Myc enhances transcription
of the human polymeric immunoglobulin receptor gene. Mol. Immunol 40:695708.
53. Cario, E., D. Brown, M. McKee, K. Lynch-Devaney, G. Gerken, and D. K.
Podolsky. 2002. Commensal-associated molecular patterns induce selective tolllike receptor-trafficking from apical membrane to cytoplasmic compartments in
polarized intestinal epithelium. Am. J Pathol. 160:165-173.
54. Cario, E., G. Gerken, and D. K. Podolsky. 2002. "For whom the bell tolls!" -innate defense mechanisms and survival strategies of the intestinal epithelium
against lumenal pathogens. Z. Gastroenterol. 40:983-990.
55. Cario, E. and D. K. Podolsky. 2000. Differential alteration in intestinal epithelial
cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel
disease. Infect. Immun. 68:7010-7017.
56. Cario, E., I. M. Rosenberg, S. L. Brandwein, P. L. Beck, H. C. Reinecker,
and D. K. Podolsky. 2000. Lipopolysaccharide activates distinct signaling
pathways in intestinal epithelial cell lines expressing Toll-like receptors. J
Immunol 164:966-972.
165

57. Casanova, J. E., G. Apodaca, and K. E. Mostov. 1991. An autonomous signal
for basolateral sorting in the cytoplasmic domain of the polymeric
immunoglobulin receptor. Cell 66:65-75.
58. Casanova, J. E., P. P. Breitfeld, S. A. Ross, and K. E. Mostov. 1990.
Phosphorylation of the polymeric immunoglobulin receptor required for its
efficient transcytosis. Science 248:742-745.
59. Casola, A., R. P. Garofalo, S. E. Crawford, M. K. Estes, F. Mercurio, S. E.
Crowe, and A. R. Brasier. 2002. Interleukin-8 gene regulation in intestinal
epithelial cells infected with rotavirus: role of viral-induced IkappaB kinase
activation. Virology 298:8-19.
60. Cazac, B. B. and J. Roes. 2000. TGF-beta receptor controls B cell
responsiveness and induction of IgA in vivo. Immunity. 13:443-451.
61. Chadee, K., W. A. Petri, Jr., D. J. Innes, and J. I. Ravdin. 1987. Rat and
human colonic mucins bind to and inhibit adherence lectin of Entamoeba
histolytica. J Clin Invest 80:1245-1254.
62. Chapman, R. S., E. K. Duff, P. C. Lourenco, E. Tonner, D. J. Flint, A. R.
Clarke, and C. J. Watson. 2000. A novel role for IRF-1 as a suppressor of
apoptosis. Oncogene 19:6386-6391.
63. Chapuis, R. M. and M. E. Koshland. 1975. Linkage and assembly of polymeric
IgA immunoglobulins. Biochemistry 14:1320-1326.
64. Chen, D., F. Lee, J. J. Cebra, and D. H. Rubin. 1997. Predominant T-cell
receptor Vbeta usage of intraepithelial lymphocytes during the immune response
to enteric reovirus infection. J Virol. 71:3431-3436.
65. Chinery, R., J. Williamson, and R. Poulsom. 1996. The gene encoding human
intestinal trefoil factor (TFF3) is located on chromosome 21q22.3 clustered with
other members of the trefoil peptide family. Genomics 32:281-284.
66. Chintalacharuvu, K. R. and S. L. Morrison. 1997. Production of secretory
immunoglobulin A by a single mammalian cell. Proc. Natl. Acad. Sci. U. S. A
94:6364-6368.

166

67. Claessens, F., G. Verrijdt, E. Schoenmakers, A. Haelens, B. Peeters, G.
Verhoeven, and W. Rombauts. 2001. Selective DNA binding by the androgen
receptor as a mechanism for hormone-specific gene regulation. J Steroid
Biochem. Mol. Biol. 76:23-30.
68. Clarke, P., R. L. Debiasi, S. M. Meintzer, B. A. Robinson, and K. L. Tyler.
2005. Inhibition of NF-kappa B activity and cFLIP expression contribute to viralinduced apoptosis. Apoptosis. 10:513-524.
69. Clarke, P., S. M. Meintzer, L. A. Moffitt, and K. L. Tyler. 2003. Two distinct
phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis
factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected
cells. J Biol. Chem. 278:18092-18100.
70. Clarke, P., S. M. Meintzer, C. Widmann, G. L. Johnson, and K. L. Tyler.
2001. Reovirus infection activates JNK and the JNK-dependent transcription
factor c-Jun. J Virol. 75:11275-11283.
71. Coffey, M. C., J. E. Strong, P. A. Forsyth, and P. W. Lee. 1998. Reovirus
therapy of tumors with activated Ras pathway. Science 282:1332-1334.
72. Cohen, P. S. and D. C. Laux. 1995. Bacterial adhesion to and penetration of
intestinal mucus in vitro. Methods Enzymol. 253:309-314.
73. Connolly, J. L., S. E. Rodgers, P. Clarke, D. W. Ballard, L. D. Kerr, K. L.
Tyler, and T. S. Dermody. 2000. Reovirus-induced apoptosis requires activation
of transcription factor NF-kappaB. J. Virol. 74:2981-2989.
74. Coyne, R. S., M. Siebrecht, M. C. Peitsch, and J. E. Casanova. 1994.
Mutational analysis of polymeric immunoglobulin receptor/ligand interactions.
Evidence for the involvement of multiple complementarity determining region
(CDR)-like loops in receptor domain I. J Biol. Chem. 269:31620-31625.
75. Craig, S. W. and J. J. Cebra. 1971. Peyer's patches: an enriched source of
precursors for IgA-producing immunocytes in the rabbit. J Exp. Med. 134:188200.
76. Crottet, P. and B. Corthesy. 1998. Secretory component delays the conversion
of secretory IgA into antigen-binding competent F(ab')2: a possible implication
for mucosal defense. J Immunol 161:5445-5453.
167

77. Cuff, C. F., C. K. Cebra, D. H. Rubin, and J. J. Cebra. 1993. Developmental
relationship between cytotoxic alpha/beta T cell receptor-positive intraepithelial
lymphocytes and Peyer's patch lymphocytes. Eur. J Immunol 23:1333-1339.
78. Cuff, C. F., E. Lavi, C. K. Cebra, J. J. Cebra, and D. H. Rubin. 1990. Passive
immunity to fatal reovirus serotype 3-induced meningoencephalitis mediated by
both secretory and transplacental factors in neonatal mice. J Virol. 64:1256-1263.
79. Dallas, S. D. and R. D. Rolfe. 1998. Binding of Clostridium difficile toxin A to
human milk secretory component. J Med. Microbiol 47:879-888.
80. Darmoul, D., D. Brown, M. E. Selsted, and A. J. Ouellette. 1997. Cryptdin
gene expression in developing mouse small intestine. Am. J Physiol 272:G197G206.
81. de Araujo, A. N. and L. G. Giugliano. 2001. Lactoferrin and free secretory
component of human milk inhibit the adhesion of enteropathogenic Escherichia
coli to HeLa cells. BMC. Microbiol 1:25.
82. de Oliveira, I. R., A. N. de Araujo, S. N. Bao, and L. G. Giugliano. 2001.
Binding of lactoferrin and free secretory component to enterotoxigenic
Escherichia coli. FEMS Microbiol Lett. 203:29-33.
83. Debiasi, R. L., C. L. Edelstein, B. Sherry, and K. L. Tyler. 2001. Calpain
inhibition protects against virus-induced apoptotic myocardial injury. J. Virol.
75:351-361.
84. Debiasi, R. L., M. K. Squier, B. Pike, M. Wynes, T. S. Dermody, J. J. Cohen,
and K. L. Tyler. 1999. Reovirus-induced apoptosis is preceded by increased
cellular calpain activity and is blocked by calpain inhibitors. J. Virol. 73:695-701.
85. Deitcher, D. L. and K. E. Mostov. 1986. Alternate splicing of rabbit polymeric
immunoglobulin receptor. Mol. Cell Biol. 6:2712-2715.
86. Delacroix, D. L., C. Dive, J. C. Rambaud, and J. P. Vaerman. 1982. IgA
subclasses in various secretions and in serum. Immunology 47:383-385.

168

87. Delhase, M. and M. Karin. 1999. The I kappa B kinase: a master regulator of
NF-kappa B, innate immunity, and epidermal differentiation. Cold Spring Harb.
Symp. Quant. Biol. 64:491-503.
88. Diamond, G., D. E. Jones, and C. L. Bevins. 1993. Airway epithelial cells are
the site of expression of a mammalian antimicrobial peptide gene. Proc. Natl.
Acad. Sci. U. S. A 90:4596-4600.
89. Diamond, G., J. P. Russell, and C. L. Bevins. 1996. Inducible expression of an
antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells.
Proc. Natl. Acad. Sci. U. S. A 93:5156-5160.
90. Diamond, G., M. Zasloff, H. Eck, M. Brasseur, W. L. Maloy, and C. L.
Bevins. 1991. Tracheal antimicrobial peptide, a cysteine-rich peptide from
mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc. Natl.
Acad. Sci. U. S. A 88:3952-3956.
91. Diebold, S. S., T. Kaisho, H. Hemmi, S. Akira, and Reis e Sousa. 2004. Innate
antiviral responses by means of TLR7-mediated recognition of single-stranded
RNA. Science 303:1529-1531.
92. Eisenhauer, P. B., S. S. Harwig, and R. I. Lehrer. 1992. Cryptdins:
antimicrobial defensins of the murine small intestine. Infect. Immun. 60:35563565.
93. Elewaut, D., J. A. DiDonato, J. M. Kim, F. Truong, L. Eckmann, and M. F.
Kagnoff. 1999. NF-kappa B is a central regulator of the intestinal epithelial cell
innate immune response induced by infection with enteroinvasive bacteria. J
Immunol 163:1457-1466.
94. Elkins, K. L., R. M. Buller, P. W. Stashak, and P. J. Baker. 1991. CD4+ T
cells regulate the magnitude of the antibody response to several helper T cell
independent antigens. Immunobiology 183:69-78.
95. Elm, C., R. Braathen, S. Bergmann, R. Frank, J. P. Vaerman, C. S. Kaetzel,
G. S. Chhatwal, F. E. Johansen, and S. Hammerschmidt. 2004. Ectodomains 3
and 4 of human polymericiImmunoglobulin receptor (hpIgR) mediate invasion of
Streptococcus pneumoniae into the epithelium. J Biol. Chem. 279:6296-6304.

169

96. Fallgreen-Gebauer, E., W. Gebauer, A. Bastian, H. D. Kratzin, H. Eiffert, B.
Zimmermann, M. Karas, and N. Hilschmann. 1993. The covalent linkage of
secretory component to IgA. Structure of sIgA. Biol. Chem. Hoppe Seyler
374:1023-1028.
97. Fan, J. Y., C. S. Boyce, and C. F. Cuff. 1998. T-helper 1 and T-helper 2
cytokine responses in gut-associated lymphoid tissue following enteric reovirus
infection. Cell Immunol 188:55-63.
98. Fang, G. D., A. A. Lima, C. V. Martins, J. P. Nataro, and R. L. Guerrant.
1995. Etiology and epidemiology of persistent diarrhea in northeastern Brazil: a
hospital-based, prospective, case-control study. J Pediatr. Gastroenterol. Nutr
21:137-144.
99. Farone, A. L., P. C. O'Brien, and D. C. Cox. 1993. Tumor necrosis factor-alpha
induction by reovirus serotype 3. J Leukoc. Biol. 53:133-137.
100. Farrell, J. J., D. Taupin, T. J. Koh, D. Chen, C. M. Zhao, D. K. Podolsky, and
T. C. Wang. 2002. TFF2/SP-deficient mice show decreased gastric proliferation,
increased acid secretion, and increased susceptibility to NSAID injury. J Clin
Invest 109:193-204.
101. Fawaz, L. M., E. Sharif-Askari, and J. Menezes. 1999. Up-regulation of NK
cytotoxic activity via IL-15 induction by different viruses: a comparative study. J
Immunol 163:4473-4480.
102. Fernandez, M. I., T. Pedron, R. Tournebize, J. C. Olivo-Marin, P. J.
Sansonetti, and A. Phalipon. 2003. Anti-inflammatory role for intracellular
dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial
cells. Immunity. 18:739-749.
103. Fleeton, M. N., N. Contractor, F. Leon, J. D. Wetzel, T. S. Dermody, and B.
L. Kelsall. 2004. Peyer's patch dendritic cells process viral antigen from apoptotic
epithelial cells in the intestine of reovirus-infected mice. J Exp. Med. 200:235245.
104. Forstner, J. F. 1978. Intestinal mucins in health and disease. Digestion 17:234263.

170

105. Forstner, J. F., N. W. Roomi, R. E. Fahim, and G. G. Forstner. 1981. Cholera
toxin stimulates secretion of immunoreactive intestinal mucin. Am. J Physiol
240:G10-G16.
106. Frey, A., K. T. Giannasca, R. Weltzin, P. J. Giannasca, H. Reggio, W. I.
Lencer, and M. R. Neutra. 1996. Role of the glycocalyx in regulating access of
microparticles to apical plasma membranes of intestinal epithelial cells:
implications for microbial attachment and oral vaccine targeting. J Exp. Med.
184:1045-1059.
107. Fujita, Y., A. T. Cheung, and T. J. Kieffer. 2004. Harnessing the gut to treat
diabetes. Pediatr. Diabetes 5 Suppl 2:57-69.
108. Fulton, J. R., J. Smith, C. Cunningham, and C. F. Cuff. 2004. Influence of the
route of infection on development of T-cell receptor beta-chain repertoires of
reovirus-specific cytotoxic T lymphocytes. J Virol. 78:1582-1590.
109. Funami, K., M. Matsumoto, H. Oshiumi, T. Akazawa, A. Yamamoto, and T.
Seya. 2004. The cytoplasmic 'linker region' in Toll-like receptor 3 controls
receptor localization and signaling. Int. Immunol 16:1143-1154.
110. Funda, D. P., L. Tuckova, M. A. Farre, T. Iwase, I. Moro, and H. TlaskalovaHogenova. 2001. CD14 is expressed and released as soluble CD14 by human
intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells
revisited. Infect. Immun. 69:3772-3781.
111. Ganz, T. and R. I. Lehrer. 1995. Defensins. Pharmacol. Ther. 66:191-205.
112. Gebhard, A. and A. Gebert. 1999. Brush cells of the mouse intestine possess a
specialized glycocalyx as revealed by quantitative lectin histochemistry. Further
evidence for a sensory function. J Histochem. Cytochem. 47:799-808.
113. George, A., S. I. Kost, C. L. Witzleben, J. J. Cebra, and D. H. Rubin. 1990.
Reovirus-induced liver disease in severe combined immunodeficient (SCID)
mice. A model for the study of viral infection, pathogenesis, and clearance. J Exp.
Med. 171:929-934.

171

114. Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara.
2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to
induce epithelial proinflammatory gene expression. J Immunol 167:1882-1885.
115. Giancotti, F. G. 2003. A structural view of integrin activation and signaling. Dev.
Cell 4:149-151.
116. Giancotti, F. G. and E. Ruoslahti. 1999. Integrin signaling. Science 285:10281032.
117. Girardin, S. E., R. Tournebize, M. Mavris, A. L. Page, X. Li, G. R. Stark, J.
Bertin, P. S. DiStefano, M. Yaniv, P. J. Sansonetti, and D. J. Philpott. 2001.
CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella
flexneri. EMBO Rep. 2:736-742.
118. Giugliano, L. G., S. T. Ribeiro, M. H. Vainstein, and C. J. Ulhoa. 1995. Free
secretory component and lactoferrin of human milk inhibit the adhesion of
enterotoxigenic Escherichia coli. J Med. Microbiol 42:3-9.
119. Gordon, J. I. 1989. Intestinal epithelial differentiation: new insights from
chimeric and transgenic mice. J Cell Biol. 108:1187-1194.
120. Gordon, J. I. and M. L. Hermiston. 1994. Differentiation and self-renewal in
the mouse gastrointestinal epithelium. Curr. Opin. Cell Biol. 6:795-803.
121. Grand, R. J., J. B. Watkins, and F. M. Torti. 1976. Development of the human
gastrointestinal tract. A review. Gastroenterology 70:790-810.
122. Grey, H. M., C. A. Abel, W. J. Yount, and H. G. Kunkel. 1968. A subclass of
human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking
heavy and light chains. J Exp. Med. 128:1223-1236.
123. Griffiss, J. M. 1983. Biologic function of the serum IgA system: modulation of
complement-mediated effector mechanisms and conservation of antigenic mass.
Ann. N. Y. Acad. Sci. 409:697-707.
124. Guerrant, R. L. 1994. Lessons from diarrheal diseases: demography to molecular
pharmacology. J Infect. Dis. 169:1206-1218.

172

125. Guerrant, R. L., B. A. Carneiro-Filho, and R. A. Dillingham. 2003. Cholera,
diarrhea, and oral rehydration therapy: triumph and indictment. Clin Infect. Dis.
37:398-405.
126. Guerrant, R. L., J. M. Hughes, N. L. Lima, and J. Crane. 1990. Diarrhea in
developed and developing countries: magnitude, special settings, and etiologies.
Rev. Infect. Dis. 12 Suppl 1:S41-S50.
127. Guerrant, R. L., A. A. Lima, M. Barboza, S. Young, T. Silva, L. Barrett, Y.
Bao, J. Fox, and S. Moore. 1999. Mechanisms and impact of enteric infections.
Adv. Exp. Med. Biol. 473:103-112.
128. Haelens, A., G. Verrijdt, E. Schoenmakers, P. Alen, B. Peeters, W.
Rombauts, and F. Claessens. 1999. The first exon of the human sc gene contains
an androgen responsive unit and an interferon regulatory factor element. Mol.
Cell Endocrinol. 153:91-102.
129. Haller, B. L., M. L. Barkon, G. P. Vogler, and H. W. Virgin. 1995. Genetic
mapping of reovirus virulence and organ tropism in severe combined
immunodeficient mice: organ-specific virulence genes. J Virol. 69:357-364.
130. Halpern, M. S. and M. E. Koshland. 1973. The stoichiometry of J chain in
human secretory IgA. J Immunol 111:1653-1660.
131. Hamamdzic, D., T. Phillips-Dorsett, S. Altman-Hamamdzic, S. D. London,
and L. London. 2001. Reovirus triggers cell type-specific proinflammatory
responses dependent on the autocrine action of IFN-beta. Am. J Physiol Lung Cell
Mol. Physiol 280:L18-L29.
132. Hamburger, A. E., A. P. West, Jr., and P. J. Bjorkman. 2004. Crystal structure
of a polymeric immunoglobulin binding fragment of the human polymeric
immunoglobulin receptor. Structure. 12:1925-1935.
133. Hammerschmidt, S., S. R. Talay, P. Brandtzaeg, and G. S. Chhatwal. 1997.
SpsA, a novel pneumococcal surface protein with specific binding to secretory
immunoglobulin A and secretory component. Mol. Microbiol 25:1113-1124.
134. Hammerschmidt, S., M. P. Tillig, S. Wolff, J. P. Vaerman, and G. S.
Chhatwal. 2000. Species-specific binding of human secretory component to
173

SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol.
Microbiol 36:726-736.
135. Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J.
K. Eng, S. Akira, D. M. Underhill, and A. Aderem. 2001. The innate immune
response to bacterial flagellin is mediated by Toll-like receptor 5. Nature
410:1099-1103.
136. Hayashi, T., M. Morimoto, H. Iwata, and T. Onodera. 1998. Interferon-gamma
plays a role in pancreatic islet-cell destruction of reovirus type 2-induced
diabetes-like syndrome in DBA/1 suckling mice. Int. J Exp. Pathol. 79:313-320.
137. Hayashi, T., M. Morimoto, H. Iwata, and T. Onodera. 2001. Possible
involvement of IL-12 in reovirus type-2-induced diabetes in newborn DBA/1
mice. Scand. J Immunol 53:572-578.
138. Hayashi, T., Y. Yasutomi, K. Hasegawa, Y. Sasaki, and T. Onodera. 2003.
Interleukin-4-expressing plasmid DNA inhibits reovirus type-2-triggered
autoimmune insulitis in DBA/1 J suckling mice. Int. J Exp. Pathol. 84:101-106.
139. Hecht, G. 1999. Innate mechanisms of epithelial host defense: spotlight on
intestine. Am. J Physiol 277:C351-C358.
140. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira,
G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of
single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529.
141. Helander, A., K. J. Silvey, N. J. Mantis, A. B. Hutchings, K. Chandran, W. T.
Lucas, M. L. Nibert, and M. R. Neutra. 2003. The viral sigma1 protein and
glycoconjugates containing alpha2-3-linked sialic acid are involved in type 1
reovirus adherence to M cell apical surfaces. J Virol. 77:7964-7977.
142. Hempen, P. M., K. M. Phillips, P. S. Conway, K. H. Sandoval, T. A.
Schneeman, H. J. Wu, and C. S. Kaetzel. 2002. Transcriptional regulation of
the human polymeric Ig receptor gene: analysis of basal promoter elements. J.
Immunol. 169:1912-1921.
143. Hendrickson, B. A., D. A. Conner, D. J. Ladd, D. Kendall, J. E. Casanova, B.
Corthesy, E. E. Max, M. R. Neutra, C. E. Seidman, and J. G. Seidman. 1995.
174

Altered hepatic transport of immunoglobulin A in mice lacking the J chain. J Exp.
Med. 182:1905-1911.
144. Hendrickson, B. A., L. Rindisbacher, B. Corthesy, D. Kendall, D. A. Waltz,
M. R. Neutra, and J. G. Seidman. 1996. Lack of association of secretory
component with IgA in J chain-deficient mice. J Immunol 157:750-754.
145. Hermos, J. A., M. Mathan, and J. S. Trier. 1971. DNA synthesis and
proliferation by villous epithelial cells in fetal rats. J Cell Biol. 50:255-258.
146. Hexham, J. M., K. D. White, L. N. Carayannopoulos, W. Mandecki, R.
Brisette, Y. S. Yang, and J. D. Capra. 1999. A human immunoglobulin (Ig)A
calpha3 domain motif directs polymeric Ig receptor-mediated secretion. J Exp.
Med. 189:747-752.
147. Hiemstra, P. S., A. Gorter, M. E. Stuurman, L. A. van Es, and M. R. Daha.
1987. Activation of the alternative pathway of complement by human serum IgA.
Eur. J Immunol 17:321-326.
148. Hirasawa, K., S. G. Nishikawa, K. L. Norman, T. Alain, A. Kossakowska,
and P. W. Lee. 2002. Oncolytic reovirus against ovarian and colon cancer.
Cancer Res. 62:1696-1701.
149. Hirt, R. P., G. J. Hughes, S. Frutiger, P. Michetti, C. Perregaux, O. PoulainGodefroy, N. Jeanguenat, M. R. Neutra, and J. P. Kraehenbuhl. 1993.
Transcytosis of the polymeric Ig receptor requires phosphorylation of serine 664
in the absence but not the presence of dimeric IgA. Cell 74:245-255.
150. Hooper, L. V., M. H. Wong, A. Thelin, L. Hansson, P. G. Falk, and J. I.
Gordon. 2001. Molecular analysis of commensal host-microbial relationships in
the intestine. Science 291:881-884.
151. Horiuchi, K., I. Naito, K. Nakano, S. Nakatani, K. Nishida, T. Taguchi, and
A. Ohtsuka. 2005. Three-dimensional ultrastructure of the brush border
glycocalyx in the mouse small intestine: a high resolution scanning electron
microscopic study. Arch. Histol. Cytol. 68:51-56.
152. Hornef, M. W., T. Frisan, A. Vandewalle, S. Normark, and A. RichterDahlfors. 2002. Toll-like receptor 4 resides in the Golgi apparatus and
175

colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J
Exp. Med. 195:559-570.
153. Hornef, M. W., B. H. Normark, A. Vandewalle, and S. Normark. 2003.
Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal
epithelial cells. J Exp. Med. 198:1225-1235.
154. Hutchings, A. B., A. Helander, K. J. Silvey, K. Chandran, W. T. Lucas, M. L.
Nibert, and M. R. Neutra. 2004. Secretory immunoglobulin A antibodies against
the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of
mouse Peyer's patches. J Virol. 78:947-957.
155. Inman, F. P. and J. Mestecky. 1974. The J chain of polymeric
immunoglobulins. Contemp. Top. Mol. Immunol 3:111-141.
156. Inohara, N. and G. Nunez. 2001. The NOD: a signaling module that regulates
apoptosis and host defense against pathogens. Oncogene 20:6473-6481.
157. Inohara, N. and G. Nunez. 2003. NODs: intracellular proteins involved in
inflammation and apoptosis. Nat. Rev. Immunol 3:371-382.
158. Inohara, N., Y. Ogura, and G. Nunez. 2002. Nods: a family of cytosolic
proteins that regulate the host response to pathogens. Curr. Opin. Microbiol 5:7680.
159. Iwaki, D., H. Mitsuzawa, S. Murakami, H. Sano, M. Konishi, T. Akino, and
Y. Kuroki. 2002. The extracellular toll-like receptor 2 domain directly binds
peptidoglycan derived from Staphylococcus aureus. J Biol. Chem. 277:2431524320.
160. Izadpanah, A., M. B. Dwinell, L. Eckmann, N. M. Varki, and M. F. Kagnoff.
2001. Regulated MIP-3alpha/CCL20 production by human intestinal epithelium:
mechanism for modulating mucosal immunity. Am. J Physiol Gastrointest. Liver
Physiol 280:G710-G719.
161. Jan, J. T., B. H. Chen, S. H. Ma, C. I. Liu, H. P. Tsai, H. C. Wu, S. Y. Jiang,
K. D. Yang, and M. F. Shaio. 2000. Potential dengue virus-triggered apoptotic
pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and
NF-kappaB are sequentially involved. J Virol. 74:8680-8691.
176

162. Janoff, E. N., C. Fasching, J. M. Orenstein, J. B. Rubins, N. L. Opstad, and
A. P. Dalmasso. 1999. Killing of Streptococcus pneumoniae by capsular
polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin
Invest 104:1139-1147.
163. Jenkins, S. L., J. Wang, M. Vazir, J. Vela, O. Sahagun, P. Gabbay, L. Hoang,
R. L. Diaz, R. Aranda, and M. G. Martin. 2003. Role of passive and adaptive
immunity in influencing enterocyte-specific gene expression. Am. J Physiol
Gastrointest. Liver Physiol 285:G714-G725.
164. Johansen, F. E., B. A. Bosloven, P. Krajci, and P. Brandtzaeg. 1998. A
composite DNA element in the promoter of the polymeric immunoglobulin
receptor regulates its constitutive expression. Eur. J. Immunol. 28:1161-1171.
165. Johansen, F. E., R. Braathen, and P. Brandtzaeg. 2000. Role of J chain in
secretory immunoglobulin formation. Scand. J Immunol 52:240-248.
166. Johansen, F. E., R. Braathen, and P. Brandtzaeg. 2001. The J chain is essential
for polymeric Ig receptor-mediated epithelial transport of IgA. J Immunol
167:5185-5192.
167. Johansen, F. E., M. Pekna, I. N. Norderhaug, B. Haneberg, M. A. Hietala, P.
Krajci, C. Betsholtz, and P. Brandtzaeg. 1999. Absence of epithelial
immunoglobulin A transport, with increased mucosal leakiness, in polymeric
immunoglobulin receptor/secretory component-deficient mice. J. Exp. Med.
190:915-922.
168. Joklik, W. K. and M. R. Roner. 1996. Molecular recognition in the assembly of
the segmented reovirus genome. Prog. Nucleic Acid Res. Mol. Biol. 53:249-281.
169. Kaetzel, C. S. 2005. The polymeric immunoglobulin receptor: bridging innate
and adaptive immune responses at mucosal surfaces. Immunol Rev. 206:83-99.
170. Kaetzel, C. S., V. J. Blanch, P. M. Hempen, K. M. Phillips, J. F. Piskurich,
and K. R. Youngman. 1997. The polymeric immunoglobulin receptor: structure
and synthesis. Biochem. Soc. Trans. 25:475-480.
171. Kaetzel, C. S., J. K. Robinson, K. R. Chintalacharuvu, J. P. Vaerman, and
M. E. Lamm. 1991. The polymeric immunoglobulin receptor (secretory
177

component) mediates transport of immune complexes across epithelial cells: a
local defense function for IgA. Proc. Natl. Acad. Sci. U. S. A 88:8796-8800.
172. Kagan, B. L., T. Ganz, and R. I. Lehrer. 1994. Defensins: a family of
antimicrobial and cytotoxic peptides. Toxicology 87:131-149.
173. Kahn, E. 2004. Biliary atresia revisited. Pediatr. Dev. Pathol. 7:109-124.
174. Kang, D. C., R. V. Gopalkrishnan, Q. Wu, E. Jankowsky, A. M. Pyle, and P.
B. Fisher. 2002. mda-5: An interferon-inducible putative RNA helicase with
double-stranded RNA-dependent ATPase activity and melanoma growthsuppressive properties. Proc. Natl. Acad. Sci. U. S. A 99:637-642.
175. Kantele, A. 1992. Mucosa--the first specific immune defense system in the body.
Duodecim 108:2088-2096.
176. Karam, S. M. 1995. New insights into the stem cells and the precursors of the
gastric epithelium. Nutrition 11:607-613.
177. Karin, M. and M. Delhase. 2000. The I kappa B kinase (IKK) and NF-kappa B:
key elements of proinflammatory signalling. Semin. Immunol 12:85-98.
178. Karin, M. and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat.
Immunol 3:221-227.
179. Kato, H., R. Kato, K. Fujihashi, and J. R. McGhee. 2001. Role of mucosal
antibodies in viral infections. Curr. Top. Microbiol Immunol 260:201-228.
180. Kauffman, R. S., J. L. Wolf, R. Finberg, J. S. Trier, and B. N. Fields. 1983.
The sigma 1 protein determines the extent of spread of reovirus from the
gastrointestinal tract of mice. Virology 124:403-410.
181. Kaushic, C., J. M. Richardson, and C. R. Wira. 1995. Regulation of polymeric
immunoglobulin A receptor messenger ribonucleic acid expression in rodent
uteri: effect of sex hormones. Endocrinology 136:2836-2844.
182. Kawanishi, H., L. Saltzman, and W. Strober. 1983. Mechanisms regulating
IgA class-specific immunoglobulin production in murine gut-associated lymphoid
178

tissues. II. Terminal differentiation of postswitch sIgA-bearing Peyer's patch B
cells. J Exp. Med. 158:649-669.
183. Kawanishi, H., L. E. Saltzman, and W. Strober. 1983. Mechanisms regulating
IgA class-specific immunoglobulin production in murine gut-associated lymphoid
tissues. I. T cells derived from Peyer's patches that switch sIgM B cells to sIgA B
cells in vitro. J Exp. Med. 157:433-450.
184. Kelly, D., S. Conway, and R. Aminov. 2005. Commensal gut bacteria:
mechanisms of immune modulation. Trends Immunol 26:326-333.
185. Kiermaier, A., J. M. Gawn, L. Desbarats, R. Saffrich, W. Ansorge, P. J.
Farrell, M. Eilers, and G. Packham. 1999. DNA binding of USF is required for
specific E-box dependent gene activation in vivo. Oncogene 18:7200-7211.
186. Kilian, M. and K. Holmgren. 1981. Ecology and nature of immunoglobulin A1
protease-producing streptococci in the human oral cavity and pharynx. Infect.
Immun. 31:868-873.
187. Kilian, M., J. Mestecky, R. Kulhavy, M. Tomana, and W. T. Butler. 1980.
IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae,
Neisseria meningitidis, and Streptococcus sanguis: comparative immunochemical
studies. J Immunol 124:2596-2600.
188. Kilian, M., J. Mestecky, and M. W. Russell. 1988. Defense mechanisms
involving Fc-dependent functions of immunoglobulin A and their subversion by
bacterial immunoglobulin A proteases. Microbiol Rev. 52:296-303.
189. Kilian, M., J. Mestecky, and R. E. Schrohenloher. 1979. Pathogenic species of
the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin
A1 protease. Infect. Immun. 26:143-149.
190. Kilian, M., J. Reinholdt, H. Lomholt, K. Poulsen, and E. V. Frandsen. 1996.
Biological significance of IgA1 proteases in bacterial colonization and
pathogenesis: critical evaluation of experimental evidence. APMIS 104:321-338.
191. Kilian, M., B. Thomsen, T. E. Petersen, and H. S. Bleeg. 1983. Occurrence and
nature of bacterial IgA proteases. Ann. N. Y. Acad. Sci. 409:612-624.

179

192. Kindon, H., C. Pothoulakis, L. Thim, K. Lynch-Devaney, and D. K.
Podolsky. 1995. Trefoil peptide protection of intestinal epithelial barrier function:
cooperative interaction with mucin glycoprotein. Gastroenterology 109:516-523.
193. Kopp, E. B. and R. Medzhitov. 1999. The Toll-receptor family and control of
innate immunity. Curr. Opin. Immunol 11:13-18.
194. Koshland, M. E. 1975. Structure and function of the J chain. Adv. Immunol
20:41-69.
195. Koshland, M. E. 1985. The coming of age of the immunoglobulin J chain. Annu.
Rev. Immunol 3:425-453.
196. Krajci, P., D. Kvale, K. Tasken, and P. Brandtzaeg. 1992. Molecular cloning
and exon-intron mapping of the gene encoding human transmembrane secretory
component (the poly-Ig receptor). Eur. J Immunol 22:2309-2315.
197. Kramer, D. R. and J. J. Cebra. 1995. Role of maternal antibody in the induction
of virus specific and bystander IgA responses in Peyer's patches of suckling mice.
Int. Immunol 7:911-918.
198. Kvale, D. and P. Brandtzaeg. 1995. Butyrate differentially affects constitutive
and cytokine-induced expression of HLA molecules, secretory component (SC),
and ICAM-1 in a colonic epithelial cell line (HT-29, clone m3). Adv. Exp. Med.
Biol. 371A:183-188.
199. Kvale, D. and P. Brandtzaeg. 1995. Constitutive and cytokine induced
expression of HLA molecules, secretory component, and intercellular adhesion
molecule-1 is modulated by butyrate in the colonic epithelial cell line HT-29. Gut
36:737-742.
200. Lamm, M. E. 1997. Interaction of antigens and antibodies at mucosal surfaces.
Annu. Rev. Microbiol 51:311-340.
201. Lamm, M. E., M. B. Mazaneca, J. G. Nedrud, and C. S. Kaetzel. 1995. New
functions for mucosal IgA. Adv. Exp. Med. Biol. 371A:647-650.
202. Lamm, M. E., J. G. Nedrud, C. S. Kaetzel, and M. B. Mazanec. 1995. IgA and
mucosal defense. APMIS 103:241-246.
180

203. Lamm, M. E. and J. M. Phillips-Quagliata. 2002. Origin and homing of
intestinal IgA antibody-secreting cells. J Exp. Med. 195:F5-F8.
204. Lamm, M. E., J. K. Robinson, and C. S. Kaetzel. 1992. Transport of IgA
immune complexes across epithelial membranes: new concepts in mucosal
immunity. Adv. Exp. Med. Biol. 327:91-94.
205. Lamping, N., R. Dettmer, N. W. Schroder, D. Pfeil, W. Hallatschek, R.
Burger, and R. R. Schumann. 1998. LPS-binding protein protects mice from
septic shock caused by LPS or gram-negative bacteria. J Clin Invest 101:20652071.
206. Lang, D. R. and R. L. Guerrant. 1995. Summary of the 29th United StatesJapan joint Conference on Cholera and Related Diarrheal Diseases. J Infect. Dis.
171:8-12.
207. Le Roy, D., F. Di Padova, Y. Adachi, M. P. Glauser, T. Calandra, and D.
Heumann. 2001. Critical role of lipopolysaccharide-binding protein and CD14 in
immune responses against gram-negative bacteria. J Immunol 167:2759-2765.
208. Le Roy, D., F. Di Padova, R. Tees, S. Lengacher, R. Landmann, M. P.
Glauser, T. Calandra, and D. Heumann. 1999. Monoclonal antibodies to
murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal
endotoxemia by blocking either the binding of LPS to LBP or the presentation of
LPS/LBP complexes to CD14. J Immunol 162:7454-7460.
209. Lee, P. W., E. C. Hayes, and W. K. Joklik. 1981. Protein sigma 1 is the reovirus
cell attachment protein. Virology 108:156-163.
210. Lehrer, R. I., A. Barton, K. A. Daher, S. S. Harwig, T. Ganz, and M. E.
Selsted. 1989. Interaction of human defensins with Escherichia coli. Mechanism
of bactericidal activity. J Clin Invest 84:553-561.
211. Lehrer, R. I. and T. Ganz. 2002. Defensins of vertebrate animals. Curr. Opin.
Immunol 14:96-102.
212. Lehrer, R. I., A. K. Lichtenstein, and T. Ganz. 1993. Defensins: antimicrobial
and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol 11:105-128.

181

213. Lemay, G. 1988. Transcriptional and translational events during reovirus
infection. Biochem. Cell Biol. 66:803-812.
214. Lerner, A. M., J. D. Cherry, J. O. Klein, And M. Finland. 1962. Infections
With Reoviruses. N. Engl. J Med. 267:947-952.
215. Letvin, N. L., R. S. Kauffman, and R. Finberg. 1981. T lymphocyte immunity
to reovirus: cellular requirements for generation and role in clearance of primary
infections. J Immunol 127:2334-2339.
216. Li, K., Z. Chen, N. Kato, M. Gale, Jr., and S. M. Lemon. 2005. Distinct poly-I:
C and virus-activated signaling pathways leading to interferon-beta production in
hepatocytes. J Biol. Chem.
217. Li, Z. W., W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, R. Johnson,
and M. Karin. 1999. The IKKbeta subunit of IkappaB kinase (IKK) is essential
for nuclear factor kappaB activation and prevention of apoptosis. J Exp. Med.
189:1839-1845.
218. Lima, A. A., G. Fang, J. B. Schorling, L. De Albuquerque, J. F. McAuliffe, S.
Mota, R. Leite, and R. L. Guerrant. 1992. Persistent diarrhea in Northeast
Brazil: etiologies and interactions with malnutrition. Acta Paediatr. 81 Suppl
381:39-44.
219. Lima, A. A., S. R. Moore, M. S. Barboza, Jr., A. M. Soares, M. A.
Schleupner, R. D. Newman, C. L. Sears, J. P. Nataro, D. P. Fedorko, T.
Wuhib, J. B. Schorling, and R. L. Guerrant. 2000. Persistent diarrhea signals a
critical period of increased diarrhea burdens and nutritional shortfalls: a
prospective cohort study among children in northeastern Brazil. J Infect. Dis.
181:1643-1651.
220. Lin, K. I., S. H. Lee, R. Narayanan, J. M. Baraban, J. M. Hardwick, and R.
R. Ratan. 1995. Thiol agents and Bcl-2 identify an alphavirus-induced apoptotic
pathway that requires activation of the transcription factor NF-kappa B. J Cell
Biol. 131:1149-1161.
221. Lindh, E. 1975. Increased risistance of immunoglobulin A dimers to proteolytic
degradation after binding of secretory component. J Immunol 114:284-286.

182

222. Liu, Z. G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF
receptor 1 effector functions: JNK activation is not linked to apoptosis while NFkappaB activation prevents cell death. Cell 87:565-576.
223. Loeffler, M., A. Birke, D. Winton, and C. Potten. 1993. Somatic mutation,
monoclonality and stochastic models of stem cell organization in the intestinal
crypt. J Theor. Biol. 160:471-491.
224. London, S. D., J. J. Cebra, and D. H. Rubin. 1989. Intraepithelial lymphocytes
contain virus-specific, MHC-restricted cytotoxic cell precursors after gut mucosal
immunization with reovirus serotype 1/Lang. Reg Immunol 2:98-102.
225. London, S. D., J. A. Cebra-Thomas, D. H. Rubin, and J. J. Cebra. 1990. CD8
lymphocyte subpopulations in Peyer's patches induced by reovirus serotype 1
infection. J Immunol 144:3187-3194.
226. London, S. D., D. H. Rubin, and J. J. Cebra. 1987. Gut mucosal immunization
with reovirus serotype 1/L stimulates virus-specific cytotoxic T cell precursors as
well as IgA memory cells in Peyer's patches. J Exp. Med. 165:830-847.
227. Lu, L., M. E. Lamm, H. Li, B. Corthesy, and J. R. Zhang. 2003. The human
polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via
domains 3 and 4. J Biol. Chem. 278:48178-48187.
228. Lundgren, O. and L. Svensson. 2001. Pathogenesis of rotavirus diarrhea.
Microbes. Infect. 3:1145-1156.
229. Luscher, B. and L. G. Larsson. 1999. The basic region/helix-loop-helix/leucine
zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene
18:2955-2966.
230. Lycke, N., L. Erlandsson, L. Ekman, K. Schon, and T. Leanderson. 1999.
Lack of J chain inhibits the transport of gut IgA and abrogates the development of
intestinal antitoxic protection. J Immunol 163:913-919.
231. Maaser, C., M. P. Housley, M. Iimura, J. R. Smith, B. A. Vallance, B. B.
Finlay, J. R. Schreiber, N. M. Varki, M. F. Kagnoff, and L. Eckmann. 2004.
Clearance of Citrobacter rodentium requires B cells but not secretory
immunoglobulin A (IgA) or IgM antibodies. Infect. Immun. 72:3315-3324.

183

232. Mack, D. R. and P. M. Sherman. 1991. Mucin isolated from rabbit colon
inhibits in vitro binding of Escherichia coli RDEC-1. Infect. Immun. 59:10151023.
233. Macpherson, A. J., A. Lamarre, K. McCoy, G. R. Harriman, B. Odermatt, G.
Dougan, H. Hengartner, and R. M. Zinkernagel. 2001. IgA production without
mu or delta chain expression in developing B cells. Nat. Immunol 2:625-631.
234. Major, A. S. and C. F. Cuff. 1996. Effects of the route of infection on
immunoglobulin G subclasses and specificity of the reovirus-specific humoral
immune response. J Virol. 70:5968-5974.
235. Major, A. S., D. H. Rubin, and C. F. Cuff. 1998. Mucosal immunity to reovirus
infection. Curr. Top. Microbiol Immunol 233 Reovir.ii:163-177.
236. Mantle, M., L. Basaraba, S. C. Peacock, and D. G. Gall. 1989. Binding of
Yersinia enterocolitica to rabbit intestinal brush border membranes, mucus, and
mucin. Infect. Immun. 57:3292-3299.
237. Mantle, M., G. G. Forstner, and J. F. Forstner. 1984. Antigenic and structural
features of goblet-cell mucin of human small intestine. Biochem. J 217:159-167.
238. Martin, K., T. B. Kirkwood, and C. S. Potten. 1998. Age changes in stem cells
of murine small intestinal crypts. Exp. Cell Res. 241:316-323.
239. Martin, M. G., J. Wang, T. W. Li, J. T. Lam, E. M. Gutierrez, R. S.
Solorzano-Vargas, and A. H. Tsai. 1998. Characterization of the 5'-flanking
region of the murine polymeric IgA receptor gene. Am. J Physiol 275:G778G788.
240. Mashimo, H., D. C. Wu, D. K. Podolsky, and M. C. Fishman. 1996. Impaired
defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science
274:262-265.
241. Mathers, A. R. and C. F. Cuff. 2004. Role of interleukin-4 (IL-4) and IL-10 in
serum immunoglobulin G antibody responses following mucosal or systemic
reovirus infection. J Virol. 78:3352-3360.

184

242. Matsumoto, M., K. Funami, H. Oshiumi, and T. Seya. 2004. Toll-like receptor
3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol
48:147-154.
243. Matsumoto, M., K. Funami, M. Tanabe, H. Oshiumi, M. Shingai, Y. Seto, A.
Yamamoto, and T. Seya. 2003. Subcellular localization of Toll-like receptor 3 in
human dendritic cells. J Immunol 171:3154-3162.
244. Matsumoto, M., K. Funami, M. Tanabe, H. Oshiumi, M. Shingai, Y. Seto, A.
Yamamoto, and T. Seya. 2003. Subcellular Localization of Toll-Like Receptor 3
in Human Dendritic Cells. J Immunol 171:3154-3162.
245. Mattei, F., G. Schiavoni, F. Belardelli, and D. F. Tough. 2001. IL-15 is
expressed by dendritic cells in response to type I IFN, double-stranded RNA, or
lipopolysaccharide and promotes dendritic cell activation. J Immunol 167:11791187.
246. Mazanec, M. B., C. S. Kaetzel, M. E. Lamm, D. Fletcher, and J. G. Nedrud.
1992. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc.
Natl. Acad. Sci. U. S. A 89:6901-6905.
247. Mazanec, M. B., C. S. Kaetzel, M. E. Lamm, D. Fletcher, J. Peterra, and J.
G. Nedrud. 1995. Intracellular neutralization of Sendai and influenza viruses by
IgA monoclonal antibodies. Adv. Exp. Med. Biol. 371A:651-654.
248. Mazanec, M. B., J. G. Nedrud, C. S. Kaetzel, and M. E. Lamm. 1993. A threetiered view of the role of IgA in mucosal defense. Immunol. Today 14:430-435.
249. Mbawuike, I. N., S. Pacheco, C. L. Acuna, K. C. Switzer, Y. Zhang, and G. R.
Harriman. 1999. Mucosal immunity to influenza without IgA: an IgA knockout
mouse model. J Immunol 162:2530-2537.
250. McCole, D. F., L. Eckmann, F. Laurent, and M. F. Kagnoff. 2000. Intestinal
epithelial cell apoptosis following Cryptosporidium parvum infection. Infect.
Immun. 68:1710-1713.
251. McGhee, J. R., K. Fujihashi, J. Xu-Amano, R. J. Jackson, C. O. Elson, K. W.
Beagley, and H. Kiyono. 1993. New perspectives in mucosal immunity with
emphasis on vaccine development. Semin. Hematol. 30:3-12.
185

252. Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol
1:135-145.
253. Medzhitov, R. and C. Janeway, Jr. 2000. Innate immunity. N. Engl. J Med.
343:338-344.
254. Mestecky, J. and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular and
cellular interactions involved in IgA biosynthesis and immune response. Adv.
Immunol 40:153-245.
255. Mestecky, J., M. W. Russell, S. Jackson, and T. A. Brown. 1986. The human
IgA system: a reassessment. Clin Immunol Immunopathol. 40:105-114.
256. Meusel, T. R. and F. Imani. 2003. Viral induction of inflammatory cytokines in
human epithelial cells follows a p38 mitogen-activated protein kinase-dependent
but NF-kappa B-independent pathway. J Immunol 171:3768-3774.
257. Mizel, S. B., A. P. West, and R. R. Hantgan. 2003. Identification of a sequence
in human toll-like receptor 5 required for the binding of Gram-negative flagellin.
J Biol. Chem. 278:23624-23629.
258. Monteiro, R. C. and J. G. van De Winkel. 2003. IgA Fc receptors. Annu. Rev.
Immunol 21:177-204.
259. Montgomery, R. K., A. E. Mulberg, and R. J. Grand. 1999. Development of
the human gastrointestinal tract: twenty years of progress. Gastroenterology
116:702-731.
260. Moreno-Espinosa, S., T. Farkas, and X. Jiang. 2004. Human caliciviruses and
pediatric gastroenteritis. Semin. Pediatr. Infect. Dis. 15:237-245.
261. Morrison, S. L. and M. E. Koshland. 1972. Characterization of the J chain from
polymeric immunoglobulins (IgA-IgM-immunological specificity-primary
structure). Proc. Natl. Acad. Sci. U. S. A 69:124-128.
262. Morton, H. C. and P. Brandtzaeg. 2001. CD89: the human myeloid IgA Fc
receptor. Arch. Immunol Ther. Exp. (Warsz. ) 49:217-229.

186

263. Morton, H. C., M. van Egmond, and J. G. van De Winkel. 1996. Structure and
function of human IgA Fc receptors (Fc alpha R). Crit Rev. Immunol 16:423-440.
264. Mostov, K. E. 1994. Transepithelial transport of immunoglobulins. Annu. Rev.
Immunol. 12:63-84.
265. Mostov, K. E., Y. Altschuler, S. J. Chapin, C. Enrich, S. H. Low, F. Luton, J.
Richman-Eisenstat, K. L. Singer, K. Tang, and T. Weimbs. 1995. Regulation
of protein traffic in polarized epithelial cells: the polymeric immunoglobulin
receptor model. Cold Spring Harb. Symp. Quant. Biol. 60:775-781.
266. Mostov, K. E., K. A. de Bruyn, and D. L. Deitcher. 1986. Deletion of the
cytoplasmic domain of the polymeric immunoglobulin receptor prevents
basolateral localization and endocytosis. Cell 47:359-364.
267. Mostov, K. E. and D. L. Deitcher. 1986. Polymeric immunoglobulin receptor
expressed in MDCK cells transcytoses IgA. Cell 46:613-621.
268. Musil, L. S. and J. U. Baenziger. 1987. Cleavage of membrane secretory
component to soluble secretory component occurs on the cell surface of rat
hepatocyte monolayers. J Cell Biol. 104:1725-1733.
269. Negrao-Correa, D. 2001. Importance of immunoglobulin E (IgE) in the
protective mechanism against gastrointestinal nematode infection: looking at the
intestinal mucosae. Rev. Inst. Med. Trop. Sao Paulo 43:291-299.
270. Negrao-Correa, D. and M. M. Teixeira. 2006. The mutual influence of
nematode infection and allergy. Chem. Immunol Allergy 90:14-28.
271. Neutra, M. R., N. J. Mantis, A. Frey, and P. J. Giannasca. 1999. The
composition and function of M cell apical membranes: implications for microbial
pathogenesis. Semin. Immunol 11:171-181.
272. Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, and
A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and
transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. U. S.
A 89:6550-6554.

187

273. Norderhaug, I. N., F. E. Johansen, H. Schjerven, and P. Brandtzaeg. 1999.
Regulation of the formation and external transport of secretory immunoglobulins.
Crit Rev. Immunol 19:481-508.
274. Norman, K. L., M. C. Coffey, K. Hirasawa, D. J. Demetrick, S. G. Nishikawa,
L. M. DiFrancesco, J. E. Strong, and P. W. Lee. 2002. Reovirus oncolysis of
human breast cancer. Hum. Gene Ther. 13:641-652.
275. O'Donnell, S. M., G. H. Holm, J. M. Pierce, B. Tian, M. J. Watson, R. S.
Chari, D. W. Ballard, A. R. Brasier, and T. S. Dermody. 2006. Identification
of an NF-{kappa}B-Dependent Gene Network in Cells Infected by Mammalian
Reovirus. J. Virol. 80:1077-1086.
276. O'Neil, D. A., E. M. Porter, D. Elewaut, G. M. Anderson, L. Eckmann, T.
Ganz, and M. F. Kagnoff. 1999. Expression and regulation of the human betadefensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 163:6718-6724.
277. O'Neill, L. A., K. A. Fitzgerald, and A. G. Bowie. 2003. The Toll-IL-1 receptor
adaptor family grows to five members. Trends Immunol 24:286-290.
278. Offit, P. A. and D. H. Rubin. 1982. Viral diseases: infections of the
gastrointestinal tract. Compr. Ther. 8:21-26.
279. Ohteki, T., K. Suzue, C. Maki, T. Ota, and S. Koyasu. 2001. Critical role of
IL-15-IL-15R for antigen-presenting cell functions in the innate immune
response. Nat. Immunol 2:1138-1143.
280. Okamoto, C. T., S. P. Shia, C. Bird, K. E. Mostov, and M. G. Roth. 1992. The
cytoplasmic domain of the polymeric immunoglobulin receptor contains two
internalization signals that are distinct from its basolateral sorting signal. J. Biol.
Chem. 267:9925-9932.
281. Okamoto, C. T., W. Song, M. Bomsel, and K. E. Mostov. 1994. Rapid
internalization of the polymeric immunoglobulin receptor requires phosphorylated
serine 726. J. Biol. Chem. 269:15676-15682.
282. Oliveira, C. S. and A. C. Linhares. 1999. [Rotavirus: clinical features and
prevention]. J Pediatr. (Rio J) 75 Suppl 1:S91-S102.

188

283. Onodera, T., A. B. Jenson, J. W. Yoon, and A. L. Notkins. 1978. Virusinduced diabetes mellitus: reovirus infection of pancreatic beta cells in mice.
Science 201:529-531.
284. Organ, E. L. and D. H. Rubin. 1998. Pathogenesis of reovirus gastrointestinal
and hepatobiliary disease. Curr. Top. Microbiol Immunol 233 Reovir.ii:67-83.
285. Ortega-Cava, C. F., S. Ishihara, M. A. Rumi, K. Kawashima, N. Ishimura, H.
Kazumori, J. Udagawa, Y. Kadowaki, and Y. Kinoshita. 2003. Strategic
compartmentalization of Toll-like receptor 4 in the mouse gut. J Immunol
170:3977-3985.
286. Otte, J. M., E. Cario, and D. K. Podolsky. 2004. Mechanisms of cross
hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial
cells. Gastroenterology 126:1054-1070.
287. Ouellette, A. J. 1997. Paneth cells and innate immunity in the crypt
microenvironment. Gastroenterology 113:1779-1784.
288. Ouellette, A. J. 2005. Paneth cell alpha-defensins: peptide mediators of innate
immunity in the small intestine. Springer Semin. Immunopathol. 27:133-146.
289. Ouellette, A. J., R. M. Greco, M. James, D. Frederick, J. Naftilan, and J. T.
Fallon. 1989. Developmental regulation of cryptdin, a corticostatin/defensin
precursor mRNA in mouse small intestinal crypt epithelium. J Cell Biol.
108:1687-1695.
290. Ouellette, A. J. and M. E. Selsted. 1996. Paneth cell defensins: endogenous
peptide components of intestinal host defense. FASEB J 10:1280-1289.
291. Pahl, H. L. and P. A. Baeuerle. 1995. Expression of influenza virus
hemagglutinin activates transcription factor NF-kappa B. J Virol. 69:1480-1484.
292. Pahl, H. L. and P. A. Baeuerle. 1997. The ER-overload response: activation of
NF-kappa B. Trends Biochem. Sci. 22:63-67.
293. Palladino, G., K. Mozdzanowska, G. Washko, and W. Gerhard. 1995. Virusneutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA

189

isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 69:20752081.
294. Paulsson, M. 1992. Basement membrane proteins: structure, assembly, and
cellular interactions. Crit Rev. Biochem. Mol. Biol. 27:93-127.
295. Paulsson, M., S. Fujiwara, M. Dziadek, R. Timpl, G. Pejler, G. Backstrom, U.
Lindahl, and J. Engel. 1986. Structure and function of basement membrane
proteoglycans. Ciba Found. Symp. 124:189-203.
296. Phillips, T. E., T. H. Phillips, and M. R. Neutra. 1984. Regulation of intestinal
goblet cell secretion. III. Isolated intestinal epithelium. Am. J Physiol 247:G674G681.
297. Phillips-Quagliata, J. M., M. E. Roux, M. Arny, P. Kelly-Hatfield, M.
McWilliams, and M. E. Lamm. 1983. Migration and regulation of B-cells in the
mucosal immune system. Ann. N. Y. Acad. Sci. 409:194-203.
298. Philpott, D. J. and S. E. Girardin. 2004. The role of Toll-like receptors and Nod
proteins in bacterial infection. Mol. Immunol 41:1099-1108.
299. Philpott, D. J., S. E. Girardin, and P. J. Sansonetti. 2001. Innate immune
responses of epithelial cells following infection with bacterial pathogens. Curr.
Opin. Immunol 13:410-416.
300. Pine, R. 1997. Convergence of TNFalpha and IFNgamma signalling pathways
through synergistic induction of IRF-1/ISGF-2 is mediated by a composite
GAS/kappaB promoter element. Nucleic Acids Res. 25:4346-4354.
301. Piskurich, J. F., J. A. France, C. M. Tamer, C. A. Willmer, C. S. Kaetzel, and
D. M. Kaetzel. 1993. Interferon-gamma induces polymeric immunoglobulin
receptor mRNA in human intestinal epithelial cells by a protein synthesis
dependent mechanism. Mol. Immunol. 30:413-421.
302. Piskurich, J. F., K. R. Youngman, K. M. Phillips, P. M. Hempen, M. H.
Blanchard, J. A. France, and C. S. Kaetzel. 1997. Transcriptional regulation of
the human polymeric immunoglobulin receptor gene by interferon-gamma. Mol.
Immunol. 34:75-91.

190

303. Plaut, A. G. 1997. Trefoil peptides in the defense of the gastrointestinal tract. N.
Engl. J Med. 336:506-507.
304. Podolsky, D. K. 1999. Mucosal immunity and inflammation. V. Innate
mechanisms of mucosal defense and repair: the best offense is a good defense.
Am. J Physiol 277:G495-G499.
305. Podolsky, D. K. 2000. Mechanisms of regulatory peptide action in the
gastrointestinal tract: trefoil peptides. J Gastroenterol. 35 Suppl 12:69-74.
306. Podolsky, D. K., K. Lynch-Devaney, J. L. Stow, P. Oates, B. Murgue, M. De
Beaumont, B. E. Sands, and Y. R. Mahida. 1993. Identification of human
intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for
apical secretion. J Biol. Chem. 268:12230.
307. Porter, E. M., L. Liu, A. Oren, P. A. Anton, and T. Ganz. 1997. Localization
of human intestinal defensin 5 in Paneth cell granules. Infect. Immun. 65:23892395.
308. Porter, E. M., E. van Dam, E. V. Valore, and T. Ganz. 1997. Broad-spectrum
antimicrobial activity of human intestinal defensin 5. Infect. Immun. 65:23962401.
309. Potoka, D. A., E. P. Nadler, X. Zhou, X. R. Zhang, J. S. Upperman, and H. R.
Ford. 2000. Inhibition of NF-kappaB by IkappaB prevents cytokine-induced NO
production and promotes enterocyte apoptosis in vitro. Shock 14:366-373.
310. Potten, C. S. 1974. The epidermal proliferative unit: the possible role of the
central basal cell. Cell Tissue Kinet. 7:77-88.
311. Potten, C. S. 1998. Stem cells in gastrointestinal epithelium: numbers,
characteristics and death. Philos. Trans. R. Soc. Lond B Biol. Sci. 353:821-830.
312. Potten, C. S. and R. J. Morris. 1988. Epithelial stem cells in vivo. J Cell Sci.
Suppl 10:45-62.
313. Prescott, S. L. 2003. Allergy: the price we pay for cleaner living? Ann. Allergy
Asthma Immunol 90:64-70.

191

314. Prioult, G. and C. Nagler-Anderson. 2005. Mucosal immunity and allergic
responses: lack of regulation and/or lack of microbial stimulation? Immunol Rev.
206:204-218.
315. Quan, C. P., E. Ruffet, K. Arihiro, R. Pires, and J. P. Bouvet. 1996. High
affinity serum-derived Fab fragments as another source of antibodies in the gut
lumen of both neonates and adults. Scand. J Immunol 44:108-114.
316. Quan, C. P., S. Watanabe, F. Forestier, and J. P. Bouvet. 1998. Human
amniotic IgA inhibits natural IgG autoantibodies of maternal or unrelated origin.
Eur. J Immunol 28:4001-4009.
317. Quondamatteo, F. 2002. Assembly, stability and integrity of basement
membranes in vivo. Histochem. J 34:369-381.
318. Renegar, K. B., G. D. Jackson, and J. Mestecky. 1998. In vitro comparison of
the biologic activities of monoclonal monomeric IgA, polymeric IgA, and
secretory IgA. J Immunol 160:1219-1223.
319. Rincheval-Arnold, A., L. Belair, A. Cencic, and J. Djiane. 2002. Up-regulation
of polymeric immunoglobulin receptor mRNA in mammary epithelial cells by
IFN-gamma. Mol. Cell Endocrinol. 194:95-105.
320. Rincheval-Arnold, A., L. Belair, and J. Djiane. 2002. Developmental
expression of pIgR gene in sheep mammary gland and hormonal regulation. J
Dairy Res. 69:13-26.
321. Roos, A., L. H. Bouwman, D. J. Gijlswijk-Janssen, M. C. Faber-Krol, G. L.
Stahl, and M. R. Daha. 2001. Human IgA activates the complement system via
the mannan-binding lectin pathway. J Immunol 167:2861-2868.
322. Rosen, L. 1960. Serologic grouping of reoviruses by hemagglutination-inhibition.
Am. J Hyg. 71:242-249.
323. Rosen, L. 1962. Reoviruses in animals other than man. Ann. N. Y. Acad. Sci.
101:461-465.
324. Roulston, A., R. Lin, P. Beauparlant, M. A. Wainberg, and J. Hiscott. 1995.
Regulation of human immunodeficiency virus type 1 and cytokine gene
192

expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol
Rev. 59:481-505.
325. Rubin, D. H., M. A. Eaton, and A. O. Anderson. 1986. Reovirus infection in
adult mice: the virus hemagglutinin determines the site of intestinal disease.
Microb. Pathog. 1:79-87.
326. Rubin, D. H., M. J. Kornstein, and A. O. Anderson. 1985. Reovirus serotype 1
intestinal infection: a novel replicative cycle with ileal disease. J Virol. 53:391398.
327. Russell, M. W., J. Reinholdt, and M. Kilian. 1989. Anti-inflammatory activity
of human IgA antibodies and their Fab alpha fragments: inhibition of IgGmediated complement activation. Eur. J Immunol 19:2243-2249.
328. Sajjan, S. U. and J. F. Forstner. 1990. Role of the putative "link" glycopeptide
of intestinal mucin in binding of piliated Escherichia coli serotype O157:H7 strain
CL-49. Infect. Immun. 58:868-873.
329. Sakuma, S. and Y. Watanabe. 1971. Unilateral synthesis of reovirus doublestranded ribonucleic acid by a cell-free replicase system. J Virol. 8:190-196.
330. Sakuma, S. and Y. Watanabe. 1972. Reovirus replicase-directed synthesis of
double-stranded ribonucleic acid. J Virol. 10:628-638.
331. Sanderson, I. R. and W. A. Walker. 1993. Uptake and transport of
macromolecules by the intestine: possible role in clinical disorders (an update).
Gastroenterology 104:622-639.
332. Sands, B. E. and D. K. Podolsky. 1996. The trefoil peptide family. Annu. Rev.
Physiol 58:253-273.
333. Sansonetti, P. J. 2004. War and peace at mucosal surfaces. Nat. Rev. Immunol
4:953-964.
334. Schjerven, H., P. Brandtzaeg, and F. E. Johansen. 2000. Mechanism of IL-4mediated up-regulation of the polymeric Ig receptor: role of STAT6 in cell typespecific delayed transcriptional response. J Immunol 165:3898-3906.

193

335. Schjerven, H., P. Brandtzaeg, and F. E. Johansen. 2001. A novel NF-kappa
B/Rel site in intron 1 cooperates with proximal promoter elements to mediate
TNF-alpha-induced transcription of the human polymeric Ig receptor. J Immunol
167:6412-6420.
336. Schjerven, H., T. N. Tran, P. Brandtzaeg, and F. E. Johansen. 2004. De novo
synthesized RelB mediates TNF-induced up-regulation of the human polymeric Ig
receptor. J Immunol 173:1849-1857.
337. Schnare, M., G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R.
Medzhitov. 2001. Toll-like receptors control activation of adaptive immune
responses. Nat. Immunol 2:947-950.
338. Schneeman, T. A., M. E. Bruno, H. Schjerven, F. E. Johansen, L. Chady, and
C. S. Kaetzel. 2005. Regulation of the polymeric Ig receptor by signaling through
TLRs 3 and 4: linking innate and adaptive immune response. J Immunol 175:376384.
339. Schonberg, M., S. C. Silverstein, D. H. Levin, and G. Acs. 1971. Asynchronous
synthesis of the complementary strands of the reovirus genome. Proc. Natl. Acad.
Sci. U. S. A 68:505-508.
340. Schonwetter, B. S., E. D. Stolzenberg, and M. A. Zasloff. 1995. Epithelial
antibiotics induced at sites of inflammation. Science 267:1645-1648.
341. Schumann, R. R. and J. Zweigner. 1999. A novel acute-phase marker:
lipopolysaccharide binding protein (LBP). Clin Chem. Lab Med. 37:271-274.
342. Seidel, B. M., S. Schubert, B. Schulze, and M. Borte. 2001. Secretory IgA, free
secretory component and IgD in saliva of newborn infants. Early Hum. Dev.
62:159-164.
343. Selb, B. and B. Weber. 1994. A study of human reovirus IgG and IgA antibodies
by ELISA and western blot. J Virol. Methods 47:15-25.
344. Shatkin, A. J., J. D. Sipe, and P. Loh. 1968. Separation of ten reovirus genome
segments by polyacrylamide gel electrophoresis. J Virol. 2:986-991.

194

345. Sherman, P., N. Fleming, J. Forstner, N. Roomi, and G. Forstner. 1987.
Bacteria and the mucus blanket in experimental small bowel bacterial overgrowth.
Am. J Pathol. 126:527-534.
346. Sherry, B. 1998. Pathogenesis of reovirus myocarditis. Curr. Top. Microbiol
Immunol 233:51-66.
347. Sherry, B. 2002. The role of interferon regulatory factors in the cardiac response
to viral infection. Viral Immunol 15:17-28.
348. Shimada, S., M. Kawaguchi-Miyashita, A. Kushiro, T. Sato, M. Nanno, T.
Sako, Y. Matsuoka, K. Sudo, Y. Tagawa, Y. Iwakura, and M. Ohwaki. 1999.
Generation of polymeric immunoglobulin receptor-deficient mouse with marked
reduction of secretory IgA. J Immunol 163:5367-5373.
349. Silvey, K. J., A. B. Hutchings, M. Vajdy, M. M. Petzke, and M. R. Neutra.
2001. Role of immunoglobulin A in protection against reovirus entry into Murine
Peyer's patches. J Virol. 75:10870-10879.
350. Singh, P. K., H. P. Jia, K. Wiles, J. Hesselberth, L. Liu, B. A. Conway, E. P.
Greenberg, E. V. Valore, M. J. Welsh, T. Ganz, B. F. Tack, and P. B.
McCray, Jr. 1998. Production of beta-defensins by human airway epithelia. Proc.
Natl. Acad. Sci. U. S. A 95:14961-14966.
351. Singh, P. K., B. F. Tack, P. B. McCray, Jr., and M. J. Welsh. 2000.
Synergistic and additive killing by antimicrobial factors found in human airway
surface liquid. Am. J Physiol Lung Cell Mol. Physiol 279:L799-L805.
352. Sirito, M., Q. Lin, J. M. Deng, R. R. Behringer, and M. Sawadogo. 1998.
Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice.
Proc. Natl. Acad. Sci. U. S. A 95:3758-3763.
353. Solorzano-Vargas, R. S., J. Wang, L. Jiang, H. V. Tsai, L. O. Ontiveros, M.
A. Vazir, R. J. Aguilera, and M. G. Martin. 2002. Multiple transcription factors
in 5'-flanking region of human polymeric Ig receptor control its basal expression.
Am. J Physiol Gastrointest. Liver Physiol 283:G415-G425.
354. Song, W., M. Bomsel, J. Casanova, J. P. Vaerman, and K. Mostov. 1994.
Stimulation of transcytosis of the polymeric immunoglobulin receptor by dimeric
IgA. Proc. Natl. Acad. Sci. U. S. A 91:163-166.
195

355. Spiekermann, G. M., P. W. Finn, E. S. Ward, J. Dumont, B. L. Dickinson, R.
S. Blumberg, and W. I. Lencer. 2002. Receptor-mediated immunoglobulin G
transport across mucosal barriers in adult life: functional expression of FcRn in
the mammalian lung. J Exp. Med. 196:303-310.
356. Stewart, M. J., M. A. Blum, and B. Sherry. 2003. PKR's protective role in viral
myocarditis. Virology 314:92-100.
357. Stolzenberg, E. D., G. M. Anderson, M. R. Ackermann, R. H. Whitlock, and
M. Zasloff. 1997. Epithelial antibiotic induced in states of disease. Proc. Natl.
Acad. Sci. U. S. A 94:8686-8690.
358. Strong, J. E., M. C. Coffey, D. Tang, P. Sabinin, and P. W. Lee. 1998. The
molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by
reovirus. EMBO J 17:3351-3362.
359. Sumpter, R., Jr., Y. M. Loo, E. Foy, K. Li, M. Yoneyama, T. Fujita, S. M.
Lemon, and M. Gale, Jr. 2005. Regulating intracellular antiviral defense and
permissiveness to hepatitis C virus RNA replication through a cellular RNA
helicase, RIG-I. J Virol. 79:2689-2699.
360. Sun, K., F. E. Johansen, L. Eckmann, and D. W. Metzger. 2004. An important
role for polymeric Ig receptor-mediated transport of IgA in protection against
Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173:4576-4581.
361. Sun, S. C. and D. W. Ballard. 1999. Persistent activation of NF-kappaB by the
tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases.
Oncogene 18:6948-6958.
362. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L.
Shamel, S. Sovath, J. Goode, L. Alexopoulou, R. A. Flavell, and B. Beutler.
2004. Toll-like receptors 9 and 3 as essential components of innate immune
defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A
101:3516-3521.
363. Tai, D. I. and S. L. Tsai. 2001. Apoptosis in viral hepatitis B and C. Chang
Gung. Med. J 24:285-293.
364. Tai, D. I., S. L. Tsai, Y. M. Chen, Y. L. Chuang, C. Y. Peng, I. S. Sheen, C. T.
Yeh, K. S. Chang, S. N. Huang, G. C. Kuo, and Y. F. Liaw. 2000. Activation
196

of nuclear factor kappaB in hepatitis C virus infection: implications for
pathogenesis and hepatocarcinogenesis. Hepatology 31:656-664.
365. Takeda, K. and S. Akira. 2003. Toll receptors and pathogen resistance. Cellular
Microbiology 5:143-153.
366. Takenouchi-Ohkubo, N., T. Takahashi, M. Tsuchiya, J. Mestecky, Z.
Moldoveanu, and I. Moro. 2000. Role of nuclear factor-kappaB in the
expression by tumor necrosis factor-alpha of the human polymeric
immunoglobulin receptor (plgR) gene. Immunogenetics 51:289-295.
367. Tamer, C. M., M. E. Lamm, J. K. Robinson, J. F. Piskurich, and C. S.
Kaetzel. 1995. Comparative studies of transcytosis and assembly of secretory IgA
in Madin-Darby canine kidney cells expressing human polymeric Ig receptor. J.
Immunol. 155:707-714.
368. Tangye, S. G., D. T. Avery, and P. D. Hodgkin. 2003. A division-linked
mechanism for the rapid generation of Ig-secreting cells from human memory B
cells. J Immunol 170:261-269.
369. Tarkowski, A., C. Lue, Z. Moldoveanu, H. Kiyono, J. R. McGhee, and J.
Mestecky. 1990. Immunization of humans with polysaccharide vaccines induces
systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol
144:3770-3778.
370. Taterka, J., J. J. Cebra, and D. H. Rubin. 1995. Characterization of cytotoxic
cells from reovirus-infected SCID mice: activated cells express natural killer- and
lymphokine-activated killer-like activity but fail to clear infection. J Virol.
69:3910-3914.
371. Taupin, D. and D. K. Podolsky. 2003. Trefoil factors: initiators of mucosal
healing. Nat. Rev. Mol. Cell Biol. 4:721-732.
372. Teller, I. C. and J. F. Beaulieu. 2001. Interactions between laminin and
epithelial cells in intestinal health and disease. Expert. Rev. Mol. Med. 2001:1-18.
373. Thompson, A. H., L. London, and S. D. London. 1999. Heterogeneous cytokine
production by acutely stimulated bronchoalveolar T lymphocytes in reovirus
1/Lang-infected mice. Cell Immunol 198:120-130.
197

374. Thompson, A. H., J. G. McRoberts, S. R. Crowe, L. London, and S. D.
London. 1999. Optimal induction of upper respiratory tract immunity to reovirus
1/L by combined upper and lower respiratory tract inoculation. Vaccine 17:14041415.
375. Timpl, R. 1994. Proteoglycans of basement membranes. EXS 70:123-144.
376. Timpl, R. 1996. Macromolecular organization of basement membranes. Curr.
Opin. Cell Biol. 8:618-624.
377. Timpl, R. and J. C. Brown. 1996. Supramolecular assembly of basement
membranes. Bioessays 18:123-132.
378. Timpl, R., M. Paulsson, M. Dziadek, and S. Fujiwara. 1987. Basement
membranes. Methods Enzymol. 145:363-391.
379. Tomasetto, C., N. Rockel, M. G. Mattei, R. Fujita, and M. C. Rio. 1992. The
gene encoding the human spasmolytic protein (SML1/hSP) is in 21q 22.3,
physically linked to the homologous breast cancer marker gene BCEI/pS2.
Genomics 13:1328-1330.
380. Tomasi, T. B., Jr., E. M. Tan, A. Solomon, And R. A. Prendergast. 1965.
Characteristics Of An Immune System Common To Certain External Secretions. J
Exp. Med. 121:101-124.
381. Tyler, K. L., R. T. Bronson, K. B. Byers, and B. Fields. 1985. Molecular basis
of viral neurotropism: experimental reovirus infection. Neurology 35:88-92.
382. Tyler, K. L., R. J. Sokol, S. M. Oberhaus, M. Le, F. M. Karrer, M. R.
Narkewicz, R. W. Tyson, J. R. Murphy, R. Low, and W. R. Brown. 1998.
Detection of reovirus RNA in hepatobiliary tissues from patients with
extrahepatic biliary atresia and choledochal cysts. Hepatology 27:1475-1482.
383. Tyler, K. L., M. K. Squier, S. E. Rodgers, B. E. Schneider, S. M. Oberhaus,
T. A. Grdina, J. J. Cohen, and T. S. Dermody. 1995. Differences in the
capacity of reovirus strains to induce apoptosis are determined by the viral
attachment protein sigma 1. J. Virol. 69:6972-6979.

198

384. Tyler, K. L., H. W. Virgin, R. Bassel-Duby, and B. N. Fields. 1989. Antibody
inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the
central nervous system. J Exp. Med. 170:887-900.
385. Uren, T. K., F. E. Johansen, O. L. Wijburg, F. Koentgen, P. Brandtzaeg, and
R. A. Strugnell. 2003. Role of the polymeric Ig receptor in mucosal B cell
homeostasis. J Immunol 170:2531-2539.
386. Uren, T. K., O. L. Wijburg, C. Simmons, F. E. Johansen, P. Brandtzaeg, and
R. A. Strugnell. 2005. Vaccine-induced protection against gastrointestinal
bacterial infections in the absence of secretory antibodies. Eur. J Immunol
35:180-188.
387. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma.
1996. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science
274:787-789.
388. van Loghem, E. and J. Biewenga. 1983. Allotypic and isotypic aspects of
human immunoglobulin A. Mol. Immunol 20:1001-1007.
389. Veeravigrom, M., A. Theamboonlers, and Y. Poovorawan. 2004.
Epidemiology and clinical manifestation of rotavirus and norwalk-like viruses in
Thai children. J Med. Assoc. Thai. 87 Suppl 2:S50-S54.
390. Virgin, H. W., T. S. Dermody, and K. L. Tyler. 1998. Cellular and humoral
immunity to reovirus infection. Curr. Top. Microbiol Immunol 233:147-161.
391. Virgin, H. W. and K. L. Tyler. 1991. Role of immune cells in protection against
and control of reovirus infection in neonatal mice. J Virol. 65:5157-5164.
392. Walker, W. A. and I. R. Sanderson. 1992. Epithelial barrier function to
antigens. An overview. Ann. N. Y. Acad. Sci. 664:10-17.
393. Wang, A. C. and H. H. Fudenberg. 1974. Genetics and evolution of human
immunoglobulin A. Adv. Exp. Med. Biol. 45:161-165.
394. Watanabe, Y. and A. F. Graham. 1967. Structural units of reovirus ribonucleic
acid and their possible functional significance. J Virol. 1:665-677.

199

395. Watanabe, Y., L. Prevec, and A. F. Graham. 1967. Specificity in transcription
of the reovirus genome. Proc. Natl. Acad. Sci. U. S. A 58:1040-1046.
396. Weiner, D. B., K. Girard, W. V. Williams, T. McPhillips, and D. H. Rubin.
1988. Reovirus type 1 and type 3 differ in their binding to isolated intestinal
epithelial cells. Microb. Pathog. 5:29-40.
397. Weiner, H. L., D. Drayna, D. R. Averill, Jr., and B. N. Fields. 1977. Molecular
basis of reovirus virulence: role of the S1 gene. Proc. Natl. Acad. Sci. U. S. A
74:5744-5748.
398. Weinstein, P. D. and J. J. Cebra. 1991. The preference for switching to IgA
expression by Peyer's patch germinal center B cells is likely due to the intrinsic
influence of their microenvironment. J Immunol 147:4126-4135.
399. Wolf, J. L., R. Dambrauskas, A. H. Sharpe, and J. S. Trier. 1987. Adherence
to and penetration of the intestinal epithelium by reovirus type 1 in neonatal mice.
Gastroenterology 92:82-91.
400. Wolf, J. L., R. S. Kauffman, R. Finberg, R. Dambrauskas, B. N. Fields, and
J. S. Trier. 1983. Determinants of reovirus interaction with the intestinal M cells
and absorptive cells of murine intestine. Gastroenterology 85:291-300.
401. Wolf, J. L., D. H. Rubin, R. Finberg, R. S. Kauffman, A. H. Sharpe, J. S.
Trier, and B. N. Fields. 1981. Intestinal M cells: a pathway for entry of reovirus
into the host. Science 212:471-472.
402. Wright, N. A. and M. Irwin. 1982. The kinetics of villus cell populations in the
mouse small intestine. I. Normal villi: the steady state requirement. Cell Tissue
Kinet. 15:595-609.
403. Wright, N. A., A. R. Morley, D. R. Appleton, J. M. Marks, A. P. Douglas, and
A. J. Watson. 1973. Measurement of cell production rate in the human small
bowel. Pathol. Microbiol (Basel) 39:251-253.
404. Yamamoto, M. and S. Akira. 2004. [TIR domain--containing adaptors regulate
TLR-mediated signaling pathways]. Nippon Rinsho 62:2197-2203.

200

405. Yamamoto, M., S. Sato, H. Hemmi, S. Uematsu, K. Hoshino, T. Kaisho, O.
Takeuchi, K. Takeda, and S. Akira. 2003. TRAM is specifically involved in the
Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat.
Immunol 4:1144-1150.
406. Yamamoto, M., S. Sato, K. Mori, K. Hoshino, O. Takeuchi, K. Takeda, and
S. Akira. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing
adapter that preferentially activates the IFN-beta promoter in the Toll-like
receptor signaling. J Immunol 169:6668-6672.
407. Yamamoto, M., K. Takeda, and S. Akira. 2004. TIR domain-containing
adaptors define the specificity of TLR signaling. Mol. Immunol 40:861-868.
408. You, L. R., C. M. Chen, and Y. H. Lee. 1999. Hepatitis C virus core protein
enhances NF-kappaB signal pathway triggering by lymphotoxin-beta receptor
ligand and tumor necrosis factor alpha. J Virol. 73:1672-1681.
409. Yu-Lee, L. 2001. Stimulation of interferon regulatory factor-1 by prolactin.
Lupus 10:691-699.
410. Zhang, J. R., K. E. Mostov, M. E. Lamm, M. Nanno, S. Shimida, M. Ohwaki,
and E. Tuomanen. 2000. The polymeric immunoglobulin receptor translocates
pneumococci across human nasopharyngeal epithelial cells. Cell 102:827-837.
411. Zhao, C., I. Wang, and R. I. Lehrer. 1996. Widespread expression of betadefensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett.
396:319-322.
412. Zuercher, A. W., S. E. Coffin, M. C. Thurnheer, P. Fundova, and J. J. Cebra.
2002. Nasal-associated lymphoid tissue is a mucosal inductive site for virusspecific humoral and cellular immune responses. J Immunol 168:1796-1803.
413. Zuercher, A. W., H. Q. Jiang, M. C. Thurnheer, C. F. Cuff, and J. J. Cebra.
2002. Distinct mechanisms for cross-protection of the upper versus lower
respiratory tract through intestinal priming. J Immunol 169:3920-3925.
414. Zweigner, J., H. J. Gramm, O. C. Singer, K. Wegscheider, and R. R.
Schumann. 2001. High concentrations of lipopolysaccharide-binding protein in
serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide
response in human monocytes. Blood 98:3800-3808.
201

415. Zamanian-Daryoush, M., T. H. Mogensen, J.A. DiDonato, and B.R.
Williams.2000. NF-kappaB activation by double-stranded-RNA-activated protein
kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB
kinase. Mol Cell Biol 20:1278-1290.

202

